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Body fluid and sex determination at the crime scene are important forensic questions 
where information can be obtained using various approaches. The standard techniques 
involved are well established and often utilise cheap, rapid tests to presumptively detect 
the presence of characteristic proteins and chemicals. However, the relatively poor 
accuracies of these tests compared to laboratory-based techniques that analyse nucleic 
acids limits their effectiveness and can lead to inefficient sample triage. This presents a 
need for novel field-based biomarker detection techniques that are both sensitive and 
specific.  
Toehold switches are de novo designed RNA/DNA sequences that contain the genetic 
motifs necessary for coupled transcription-translation of a reporter gene. Gene 
expression is repressed in the absence of a specific complementary target “trigger” 
sequence due to switch hairpin formation. Hybridisation of the trigger to the switch 
initiates hairpin unwinding and enables downstream gene expression. This specific and 
sensitive approach has led to toehold switches becoming an emerging platform for bio-
detection, primarily in the field of viral RNA detection. This thesis identifies a lack of such 
applications to forensic science alongside a need for novel field-based DNA detection 
tools amongst forensic end-users with a market research study. To address these issues, a 
set of toehold switches were designed in-house for the detection of mRNA sequences 
specific to blood, saliva, semen, and the sex marker amelogenin. A contemporary qPCR 




To facilitate in vitro expression of toehold switches without expensive commercial cell-
free protein synthesis systems, an Escherichia coli cell lysate was developed and 
optimised in-house. Gene expression from control plasmids was comparable to a 
commercial equivalent at 37°C and exceeded it at 29°C, with a shelf-life of approximately 
6 – 8 months at -80°C.  Toehold switches circuit function was unsuccessful with either 
system, which suggested an issue with toehold switch design. A screening framework 
utilising a combined melting curve and in silico thermodynamic analysis approach was 
devised to highlight high-performance toehold switches. This framework was able to 
predict the performances of six novel toehold switch designs and recommended designs 
to be discarded or studied further, but further characterisation is required to assess 
prediction accuracy.  
Results throughout are discussed in relation to the needs of forensic scientists and the 
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The advancement of molecular biology techniques has led to the characterisation of 
complete cellular networks made up of individual, interconnecting genetic parts which act 
upon one another in response to stimuli to carry out a specific function. Isolated genetic 
parts can be assembled de novo to produce novel networks or reconfigure existing ones 
with alternative pathways or outputs. This synthetic approach to biology has within the 
past two decades been used to construct biological devices encompassing myriad 
functions, including biosensors which can detect the presence of a desired molecule.  
It was thought that a synthetic strategy could be applied to biosensing of body fluids and 
sex-specific DNA deposited at a crime scene for use in forensic investigation. To aid in this 
objective, a review of the literature regarding synthetic biosensors was performed. The 
aims of the review were to determine if this was a novel concept or one that had already 
been achieved by another laboratory; and to develop an understanding of the methods 
utilised in synthetic network construction to aid design of an in-house forensic biosensor. 
Furthermore, the review assesses the practicality of applying synthetic biosensing 
strategies in the field, using viral RNA detection in healthcare as an example. Lastly, the 
enabling technologies that have allowed synthetic biology to proliferate are detailed, 
along with the hurdles to implementing synthetic biosensing into detection workflows.




1.2. Introduction  
 
Synthetic biology is an interdisciplinary field, applying engineering logic to biological 
systems to construct novel biological devices, or to alter existing systems with new 
functions that do not exist in nature [1]. This approach has produced wide-ranging 
applications, including bioremediation [2], the introduction of new metabolic pathways to 
micro-organisms [3], and bio-computing [4]. The diversity of these applications is due 
primarily to the inherent programmability of genetic modules derived from living 
organisms [5, 6]. Following the advent of molecular biology techniques in the latter half of 
the 20th Century, cells could be analysed as a product of individual parts that connect and 
interact with one another in order to carry out specific functions on the level of both 
single cells and multicellular systems such as tissues and organs [7]. This holistic approach 
to biology – known as systems biology – is closely linked to synthetic biology as it 
encompasses study of the complex interactions that comprise cellular networks, with 
metabolic and genetic networks modelled. An analogy commonly used to describe 
synthetic biological parts and devices is that of electrical engineering, wherein individual 
parts constitute increasingly complex systems and networks to perform useful functions 
[8]. This is not a one-to-one comparison however as these biological components can only 
function inside a complex surrounding such as a living cell, where the vast amounts of 
transient signals and interactions can have unpredictable impacts on device function [9]. 
Synthetic biologists engage in the field by conceptualising a desired device/network 
function, identifying the key genetic components involved, assembling and configuring 
those parts into a biological host or chassis, then iteratively testing network performance 
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until a biological device of suitable performance has been generated. However, it is not 
merely a case of extracting natural parts from an existing system and placing them in 
combination as might be expected. Networks consisting of natural parts often fail as the 
behaviour of the parts in conjunction with one another are unpredictable [10]. To 
circumvent this and develop useful frameworks for circuit design and construction, 
synthetic networks are comprised of standardised biological parts. A standardised 
biological part is defined as a genetically-encoded object responsible for performing a 
biological function and that has been engineered within specified design or performance 
parameters [11]. This requirement of standardisation requires that parts be refined in 
order to suit requirements for synthetic devices. For instance, the spatial composition of 
parts i.e. the physical connection between components is standardised by expressing 
each DNA part in a plasmid vector flanked both up- and downstream by a specific 
sequence of restriction enzymes, at least two of which will generate identical overhangs 
(isocaudomers) [12]. These “BioBricks” can be chained together simply by cleaving at 
these restriction sites, which connects the two parts via joining of overhangs. This also 
means that the restriction enzymes can be used again without breaking apart the BioBrick 
chain as there is now a mixed restriction site between them. This does however place 
certain sequence constraints on standardised parts as it prevents them including certain 
restriction sites within the sequence itself. Functional composition i.e. ensuring that parts 
work within a system and to defined parameters is more difficult. This requires 
knowledge, often expert level, of how the intended system will operate and the metrics 
being measured. This knowledge requirement of both the biological systems in use and 
the underlying circuitry increases likelihood of poorly optimised networks and the need 
for iterative assembly and testing. As the genetic sequences of more organisms become 
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available due to advancements in DNA sequencing, more parts become available for 
researchers to standardise and document. Over time, this has led to the creation of part 
catalogues and user-submitted documentation to enable laboratories to engage with 
synthetic biology and further contribute to the field [13]. The wide range of identified 
parts has enabled biological devices to be synthetically produced for a variety of 
applications. A selection of these applications is outlined below (Table 1.1).
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Table 1.1: Description of described synthetic biological devices by their functions. Categories are not strict as devices may have traits in multiple 
categories.  
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Of these devices, biosensing has emerged as a useful tool for detection of specific target 
analytes in the field away from the equipped laboratory [14]. Biosensors are analytical 
devices consisting of a biological sensor element that interacts with a defined target 
molecule to provide a user with information on the presence/absence of that molecule in 
a complex biological substrate. Conventional biosensing with chemicals and proteins have 
been in use for at least the past century, exploiting the visual change in antibody-antigen 
interactions with blood to determine its species origin [15]. With the advent of more 
sophisticated laboratory-based detection techniques, these simple biosensors are 
typically now only utilised as simple presumptive tests for sample triaging. However, gold-
standard laboratory techniques such as qPCR, while effective, face drawbacks such as 
labour-intensive sample handling, high per-test and instrumentation costs, higher 
personnel training requirements and the need for a fully equipped laboratory. A 
significant portion of the literature surrounding synthetic biology has been in the 
development and testing of synthetic biosensors which aim to detect a range of target 
analytes in a manner that is rapid, cheap, easy to handle, and can be performed away 
from the laboratory without sacrificing the performance of existing standard techniques.  
Synthetic biosensors have been a point of research interest primarily for healthcare, 
where rapid testing is necessary to inform patient treatment or facilitates healthcare 
access to remote areas or monitoring of patients with chronic illnesses. Concurrently, 
advances in instrumentation, workflow, nanotechnology, and storage further enable their 
use in the field [16, 17]. Forensic investigation would be particularly well suited to 
adoption of synthetic biosensors given the issues with confirmatory DNA testing outlined 
above. A synthetic biosensor that is capable of rapidly detecting the presence of human 
DNA at a crime scene would be a valuable tool for forensic investigators, reducing the 
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likelihood of processing samples downstream that would not yield useful information 
such as complete STR profiles. This would greatly benefit cost effectiveness in a field that 
has in the past several years been subject to increased budget constraints [18]. Synthetic 
biosensing devices have been described with the capability for high sensitivity and 
specificity, as well as low production cost. This makes them a potential alternative for 
existing presumptive sex identification tests, which often lack in these areas [14]. 
This chapter acts as an introduction to synthetic biology with particular focus on synthetic 
biosensing and its practical applications. Design strategies are discussed in relation to 
development of an in-house synthetic biosensor design for forensic body fluid and sex 
identification. The enabling factors to synthetic biology are discussed, as are the number 
of hurdles faced by the field to become accepted as bio-detection tools.  
 
1.3. Emergence of Synthetic Biosensors 
 
Synthetic biology is a field that has experienced a number of paradigm shifts since its 
inception, referred to as distinct “waves”. The first such wave came shortly after the 
isolation of the first restriction enzymes in the early 1970s [19]. Identification of these 
enzymes and improvements to DNA sequencing allowed scientists to cut bacterial 
plasmids at specific sites and insert foreign DNA, creating the first chimeric organisms 
[20]. If this wave is primarily defined by the appearance of modules, or single 
components, then the second wave is characterised by the assemblage of these modules 
into functional, interconnected systems, first described in the research journal Nature in 
2000 [21, 22]. Although the functions performed by these systems (feedback loops and 
genetic toggling) have previously been well-studied [23-27], they are the first examples 
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of synthetic networks utilising regulatory components that were not part of a naturally 
occurring specialised cell behaviour (Figure 1.1).  
 
Figure 1.1: Generalised representations of synthetically produced genetic feedback loops (A) 
and a genetic toggling system (B) as described by Elotwiz and Leibler and Gardner et al. 
respectively. In the genetic feedback loop, 3 genes are associated with individual promoters. 
The product of gene 1 inhibits transcription of promoter 2, the product of gene 2 inhibits 
transcription of promoter 3, and the product of gene 3 inhibits transcription from promoter 1, 
closing the negative feedback loop. In the genetic toggling system, repressor 1 inhibits 
transcription from promoter 1 and is itself repressed by inducer 1, with the same function in 
regulatory network 2. This enables bi-stable gene regulation depending on the presence of 
suitable inducers such as IPTG. 
 
The third, emergent wave of synthetic biology looks to improve upon the complexity of 
the synthetic systems used for novel purposes such as biocomputing [28]. This 
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demonstrates the potentially broad utility of synthetic biology for constructing gene 
networks to output a desired function. This wave, with its more sophisticated circuits 
and novel functions, is where synthetic biology is beginning to be practically applied 




Figure 1.2: Timeline of advancements and enabling events in the field of synthetic biology. 
Complexity of systems and devices increases over time as more information becomes available. 
Delineation of waves is not to a precise date; it is instead a general approximation of when the 
described wave first appeared.   
 
A factor of the third wave of synthetic biology that has allowed for this expansion of 
functions that is not directly related to advancements in technology is the establishment 
of institutions and appearance of publications specifically focused on bringing synthetic 
biology to a wider user base. The iGEM Foundation is a non-profit organisation for the 
advancement of synthetic biology through transparent development and co-operation in 
this field between laboratories globally [29]. While the foundation was launched in 2012, 
it had been operating as an annual team-based synthetic biology competition since 2004. 
This competition has since expanded to include more than 350 teams across over 40 
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countries by 2019 [30]. With the projects and results of each year being publicly available, 
and any novel parts and systems being uploaded to BioBricks repositories, this 
significantly aids the knowledge surrounding synthetic biology design, allowing 
engagement by even more laboratories not involved with the competition. Within 
roughly the past decade, frameworks for design of synthetic biological devices have 
appeared in the literature. Whilst some of these are focussed on detailing strategies for 
bottom-up network design in various hosts [31-33], automation of network design has 
become a popular topic in order to address issues of poor network predictability and long 
hands-on characterisation periods in the laboratory [34-36].  
 
1.4. Strategies for Biosensor Design 
 
1.4.1. Biosensor Construction Strategies 
 
The first consideration when developing a synthetic biosensor is in the structure of the 
sensor itself, as this will determine both the type of target that it can interact with, as well 
as the nature of interaction. When looking to regulatory networks that exist in nature, 
there are a number of “moving parts” involved that govern gene expression cascades 
such as DNA/RNA, proteins/polypeptides, etc. which can all form the basis for a 
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Table 1.2: Summary of common synthetic biological sensor elements, targets, and the potential benefits and hurdles associated with their use. 
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Nucleic acids are a popular basis for creating biosensors given their ease of synthesis, 
strong Watson-Crick base-pairing, specificity and sensitivity. Additionally, structural 
features of DNA as influenced by its base composition [37] allows a variety of 
conformations in three-dimensional space, and can be exploited to produce biosensors 
that can self-regulate their activity [38]. There are several ways that nucleic acids can be 
incorporated into biosensing elements. In the vast majority of cases, the NA sensor 
element is a single-stranded oligonucleotide which hybridises with a complementary 
target sequence [39]. Typically, DNA/RNA-based biosensors are employed in the 
detection of viruses [40, 41], gene biomarkers [42, 43], and micro-organisms [44], making 
them particularly useful in the fields of healthcare, environmental monitoring, and food 
safety. However, detection targets being limited to other oligonucleotides presents its 
own drawbacks. For instance, if the detection target is a gene sequence expressed by a 
pathogenic bacterium, the sequence must be isolated from the host to become 
bioavailable. This requires cell lysis, adding additional cost, processes, and reagents into 
the detection workflow, which is undesirable. This can impact the range of situations in 
which synthetic biosensors are applicable, and can lessen the benefits offered by this 
method, namely rapid detection of biomolecules on-site.  
Aptamers are a class of nucleic acid oligonucleotides that are generated through in vitro 
selection and evolution of random sequences to bind to a specific ligand with high affinity 
[45, 46]. This test tube-based approach to biosensor design allows for relatively simple 
functionalisation of oligonucleotides, allowing aptamer-based biosensors (aptasensors) to 
have perhaps the greatest breadth of target recognition, having been demonstrated to 
function in the detection of large biomolecules [47], pathogens [48], illicit drugs [49], and 
genetic biomarkers [50, 51]. Another class of synthetically generated functionalised 
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nucleic acids – DNAzymes – behave similarly to aptamers in their specificity to a desired 
ligand, but are capable of catalysing chemical reactions (most commonly single-stranded 
RNA cleavage) in the presence of cofactors such as metal ions and amplifying the signal 
for transduction [52, 53].  
Much like nucleic acid oligonucleotides, proteins can also recognise and bind biologically 
significant ligands with high affinity/specificity, and are also involved in many vital cellular 
regulatory processes. Often, natural proteins are used as the basis for the biosensor 
platform as they already exhibit the desired recognition and binding traits for the target 
being sensed. For this recognition event to be detected by the end user however, the 
protein must be functionalised in some manner to provide readout. These 
functionalisation methods encompass both genetic and chemical modifications to the 
protein, and generally involve the incorporation of transduction elements (e.g. 
fluorophores) to some position in the protein. Commons methods of achieving this are by 
utilising site-directed mutagenesis and/or chemical modifications to covalently attach a 
transducer molecule [54].   
With the construction of part repositories that allow synthetic biologists to combine 
individual biological components, end users have compiled whole-cell biosensors by 
assembling network parts inside a cellular chassis. These have the obvious advantages 
associated with whole cells, namely cheap, rapid production and deployment. Whole-cell 
biosensors are widely used in environmental analysis, as the sensors are submitted to the 
same environmental conditions, pollutants, and stresses as natural cells. They are also 
more accurate in estimating concentrations of bioavailable compounds than conventional 
chemical detection platforms i.e. chromatography as they are capable of detecting 
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molecules that may have been solubilised in the microbial environment [55]. Some of 
these whole-cell sensors have been successfully commercialised [56], highlighting their 
potential for widespread adoption compared to more traditional nucleic acid and protein 
biosensors. 
 
1.4.2. Biosensor Target Detection Strategies 
 
For a biosensor to initiate a recognition event, it must enter contact with its target 
analyte. Much like synthetic biosensor construction, there are numerous methods for 
accomplishing this and are usually dependent on the type of biosensor in use. A summary 
of common biosensing detection strategies is included below (Table 1.3). 
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Table 1.3: Summary of common detection strategies employed by synthetic biosensors. 
Design Description of function Pros Cons
Strong base-pairing enables detection using complex mixture as 
input
Requires bioavailability of sequence of interest
Immobilisation strategies are well-documented and simple to set 
up
Range of immobilisation chemistries requires 
knowledge of the system for optimal performance
Easily paired with microfluidics
Highly specific (up to single base-pair resolution)
Construction strategies for toehold switches are still 
in their infancy
Components can be freeze dried onto paper for long-term use at 
room temperature
Few sequence constraints allows for a wider variety of genetic 
targets to be sensed
Functionalised nucleic acids
Various functions but most commonly involve 
structure alteration that is target-dependent
Allosteric regulation prevents leaky transduction of signal
Repeatability concerns due to mode of construction 
(directed evolution)
Range of possible detection events increases applications
Protein-protein detection "Lock-and-key" recognition with protein ligand Easily sourced from biological material
Sensitivity often weaker than nucleic acid 
approaches
Amenable to various signal transduction strategies
Sensor is housed within a protective cell chassis
Handling and storage concerns to maintain cell 
viability
Can be utilised in environments otherwise unsuitable to other 
forms of detection i.e. soils, tissues
Use of synthetic circuits subject to various hurdles 
such as poor predictability, reliability, etc.
Can utilise existing cellular operons
Toehold switch nucleic acids
Sensor element nucleic acid self-binds to form a 
hairpin which sequesters the ribosome binding site but 
leaves a ~12nt 5' overhang. Binding of a 
complementary target to this overhang unwinds the 
hairpin and enables downstream reporter gene 
translation
Whole-Cell Biosensing
Detection event coupled with genetic activity to 
transduce signal downstream
Immobilisation of Nucleic Acids to Inert Surface
Immbolised nucleic acids function as probes for 
complementary sequences, binding initiates signal 
transduction
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Nucleic acid-based biosensors use hybridisation of the oligonucleotide biosensing 
element to the complementary target sequence to initiate detection. In order to ensure 
that contact between both sequences occur, biosensor elements are typically 
immobilised onto an inert solid-phase surface such as glass, nitrocellulose, metal oxides, 
carbon, etc.  [57, 58]. This creates a probe that can hybridise with single-stranded 
oligonucleotides. Detection tests that employ immobilised nucleic acids immerse the 
sensor in a solution that contains the target sequence of interest [59], then washed to 
remove any non-specific molecules. The Watson-Crick base pairs formed during this 
hybridisation step are strong enough to be maintained after washing. There are various 
immobilisation chemistries in use to allow reliable binding of nucleic acids to their 
substrate material whilst still allowing for the biosensing recognition event to take place 
and reducing likelihood of probe desorption from the surface. These can include basic 
adsorption, stronger covalent attachment [59-61], or self-assembly of chemical linkers 
[62]. The best choice for immobilisation will depend on the material used [57]. Proper 
immobilisation of the sensing element can enhance selectivity and hybridisation 
efficiency against the target sequence by ensuring that the “capture region” of the probe 
(i.e. the sequence of nucleotides that are specific to the complementary target sequence) 
are correctly aligned outwardly from the immobilised surface [63]. The secondary 
structure of nucleic acid chains can be exploited to impose self-regulation on nucleic acid 
biosensors. By engineering in a region of self-complementarity, important genetic 
regulators such as ribosome binding sites can be sequestered in hairpins, preventing 
circuit activity. Only in the presence of a complementary target sequence can this sensor 
element bind and initiate unwinding of the hairpin, enabling downstream gene 
expression. These “toehold switch” networks are a popular emerging tool for nucleic acid 
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detection and have already been deployed in viral RNA detection [17] (Figure 1.3). The 
high specificity offered by this approach would be useful for combating the poor 
performance of existing field-based body fluid and sex identification techniques in 








Figure 1.3: Diagram of immobilised nucleic acid (A) and toehold switch (B) detection methods. The first 
~30 nucleotides of the de novo designed toehold switch are the reverse complement of a region of a 
desired target RNA sequence to be detected (the “trigger” sequence). This is immediately followed by a 
ribosome binding site, start codon (AUG) mismatch and reporter gene to be expressed. The toehold 
switch under ambient conditions self-binds to form a hairpin, rendering the RBS in an inaccessible loop 
region repressing gene expression and leaving a short (~15 nt length) single-stranded overhang at the 
5’ end of the sequence. This “toehold” is free to hybridise with the appropriate region of the trigger 
RNA, causing unwinding of the hairpin due to greater complementarity with the RNA than the hairpin 
stem due to the AUG mismatch. This linearisation allows formation of the ribosomal complex around 
the RBS and initiation of reporter gene expression, which can be measured as indicative of a successful 
detection event.  




Functionalised nucleic acids (FNAs - i.e. aptamers and DNAzymes) retain the benefits of 
NA testing (flexibility, ease of modification or immobilisation, etc.) but are also suitable 
for use when sensing molecules such as toxins for which other sensing strategies would 
be difficult to implement or costly [64]. Functionalised nucleic acids are well represented 
in the literature as research tools, with a variety of detection strategies being employed. 
Aptamers have been demonstrated to initiate recognition events via target-dependent 
secondary structure alteration [65], ligand-induced structural switching of biomolecules 
[66], excimer formation [67], amongst others. DNAzyme-based biosensors typically 
engage in allosteric regulation due to their catalytic properties; this enables them to 
activate and begin signal transduction only in the presence of the appropriate 
biomolecular target [68, 69].  Nucleic acid biosensors have high potential to be deployed 
as robust detection platforms in situations that require a sensitive and specific test with 
high throughput that can be developed quickly, such as in response to infectious disease 
outbreaks. Synthetic protein biosensors are typically based on receptor or intracellular 
signalling proteins, due to their high specificity for their cognate proteins involved in 
cellular pathways. In healthcare, antigens and antibodies created by the body in response 
to infection by a disease are common targets for detection [70]. The detection event is 
therefore the typical “lock-and-key” binding mechanism associated with protein-protein 
interactions. The detection event can be transduced in a number of manners, such as 
conjugating the biosensing protein with a fluorescent reporter gene to enable 
visualisation of detection [71]. Similarly, synthetic whole cell biosensors function in much 
the same way as their natural counterparts do, by coupling a detection event to genetic 
activity, using existing operons or synthetically constructed networks [72, 73]. Whole cell 
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biosensors, with the housing of the cell chassis, are protected from environmental 
conditions and as such are more easily applied to sensing in areas where exposed nucleic 
acids or proteins would be rendered unusable, such as environmental soil/water samples, 
or transplanted into animal tissues [74]. 
 
1.4.3. Biosensor Readout and Signal Transduction Strategies  
 
The detection event initiated after interaction of the biosensor with its molecular target 
causes a change in the chemical energy of the network. This change in energy can be 
transduced into a form that is measurable by the end user. Much like the other stages of 
biosensing, there are a variety of strategies that can be used for test readout, where the 
most preferable option will depend on the type of biosensor used, the target analyte, and 
the equipment available to end users. All types of biosensors are amenable to the 
different forms of readout strategies. Optical detection readout is a very common 
strategy for both research and commercial purposes as interpretation is simple and can 
be configured to not require labelling of biosensors which may impact function [75]. Of 
these optical approaches, fluorescent signal transduction has been widely adopted due to 
factors that make it both more convenient and efficient for synthetic biology applications 
. Firstly, there are multiple methods to modify nucleic acids and proteins with 
fluorophores without disrupting their existing function or structure [76-79]. Due to the 
high sensitivity and strong cell penetration of fluorescent molecules, fluorescence 
resulting from oligonucleotide hybridisation of biosensors can be easily visualised in living 
cells with fluorescence microscopy [80], making them strongly compatible with standard 
molecular beacon approaches. This has the added benefit of not requiring cell disruption 
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or any other pre-treatment of sample for the target to be detected. The rapid production 
of fluorescence when excited with light of the correct wavelength enables multiple 
detection strategies such as time-resolved fluorescence and fluorescence energy transfer 
[81, 82]. Additionally, many fluorophores are commercially available as dyes at a range of 
colours and wavelengths, allowing for fluorescence detection to be quantitative when 
compared against a control of known fluorescence (Table 1.4). 
 
Table 1.4: Common fluorophore dyes used as reporters with wavelengths and colours listed. 
  Wavelength (nm)   
Fluorophore Excitation Emission Colour 
Hydroxycoumarin 325 386 Blue 
Alexa Fluor 345 442 Blue 
FAM 495 516 Dark green 
Alexa Fluor 488 494 517 Light green 
Fluorescein 495 518 Light green 
Cy3 550 570 Yellow 
TRITC 547 572 Yellow 
Rhodamine Red-X 560 580 Orange 
Alexa Fluor 568 578 603 Orange 
Texas Red 615 615 Red 
Alexa Fluor 594 590 617 Red 
 
By employing multiple synthetic biosensors in an assay at once with unique fluorophore 
attachments, simple multiplex detection is enabled and can be useful in situations where 
a complex biological substrate may include several targets of interest [64].  
In a similar vein to fluorescence, colorimetry is a useful readout function as results can be 
observed with the naked eye or quantified by use of a spectrophotometer measuring 
absorbance. Colorimetric approaches have been applied to the detection of microbes [83, 
84], DNA [85], and organic compounds [86], highlighting the ease of use and integration 
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of this method. These features and applications outlined above suggest that an optical 
detection strategy (either fluorescent or colourimetric) would be preferable for a novel 
forensic biosensor design from both a developer and end-user perspective. 
 Electrochemical detection is another popular readout technique for synthetic biosensors 
as it does not require labelling of the components involved the sensing interaction. In 
these instances, an electrode acts as the transducer element. Binding of the target 
biomolecule to the sensor element induces a change in overall charge, which is picked up 
and transmitted by the electrode. Blood glucose monitors, perhaps the single most well-
known commercial point-of-care biosensing devices, typically utilise the interaction of 
blood with a test strip to convert the signal to an electrical charge which is read by a 
handheld device [87]. Electrochemical readout strategies have also been implemented 
into whole cell detection platforms via immobilisation of cells onto electrodes [88].  
While other readout strategies have been described, including surface plasmon resonancy 
[89, 90], surface-enhanced Raman spectroscopy [91], and gravimetric detection [92, 93], 
their application to field-based bio-detection has been limited by high costs and training 
requirements. Furthermore, the miniaturisation necessary for successful 
commercialisation of synthetic biosensors has not been sufficiently met by these 
techniques [94]. It does however highlight the scale of customisation possible with 
synthetic biosensors. A summary of readout strategies is detailed below (Table 1.5). 
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Table 1.5: Summary of common readout methods used with synthetic biosensor devices.  
 
 
Strategy Definition Pros Cons
Non-expert use possible Difficult to quantify without side-by-side control test
High range of readouts Results open to user interpretation in edge cases
Enables detection in the field Sensor element must be labelled to be detected
Result can be viewed even within live cells Sample pre-treatment may be required
Multiplex capability
Quantification of result is simple Requires instrumentation to detect output
Label-free detection Higher potential for interference from background noise
Capability for miniaturisation
Rapid Output is qualitative rather than quantitative
Portable Sample pre-treatment may be required





Signal is transduced in a manner that can be confirmed visually 
(i.e. fluorescence or colorimetry)
Signal is transduced to a measurable change in electrical charge
Signal is detected by immunochromatography 
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1.5. Synthetic Biosensors as Practical Tools for Field-Based Bio-detection 
 
Throughout the literature search to describe the range of synthetic biosensors that have 
been developed and their construction strategies, no examples of synthetic biosensors 
specifically designed for forensic purposes were identified. While this does imply the 
existence of a niche in both the literature and market for a novel biosensor, it makes 
assessment of the choice to develop a synthetic biosensor for forensic use difficult as 
there are no direct comparisons to be made amongst existing tests. To justify 
development of a synthetic biosensor for forensic body fluid and sex identification, it 
must be determined if existing field-based synthetic biosensors can perform to the 
standards required for forensic investigation and if they can be adapted to detect forensic 
biomarkers of interest.  
The Zika virus (ZIKV) outbreak of 2015-2016 in the north-eastern states of Brazil and other 
parts of the Americas [95] acts as a useful case study for this purpose, where in response 
to the need for a rapid, sensitive, and specific test that could be performed in low-
resource environments, several Zika detection tests were created with different methods, 
synthetic biosensors amongst them. Using a synthetic toehold switch network (see Table 
1.3, panel B) where the sensor oligonucleotide had been embedded onto paper via 
freeze-drying, Pardee et al. were able to demonstrate sensitive, rapid, isothermal, and 
high-fidelity detection of Zika virus (ZIKV) RNA [16]. A major benefit of this biosensing 
approach is in the low instrumentation requirement compared with standard benchtop 
nucleic acid detection. In comparison to other diagnostic tests that were developed for 
ZIKV around this time, synthetic biosensing had the edge in terms of cost, specificity, and 
sensitivity (Table 1.6). Whilst the workflow length for the synthetic approach is closer to 
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RT-PCR or ELISA assays, the developers of the synthetic gene network specifically 
highlight the drastically shortened design, synthesis, and screening steps of developing 
the assay [16]. This allows for rapid rollout of a detection platform in situations such as 
disease outbreak that require quick and robust monitoring. Similar nucleic acid tests using 
isothermal amplification are currently in development for biosensing of COVID-19 strains, 
highlighting this point [96]. Taken together, this suggests that synthetic biosensors for 
nucleic acids can be practically applied to field-based biodetection.    








ELISA Immunoassay Synthetic Biosensor RT-LAMP RT-RPA 
Per-test cost (Approximate) $5-20 $4-5 $0.1-$1 <$1  $2-3  
Instrumentation Required 
Thermal cycler, centrifuge, 
reagents for RNA 
extraction 






Sensitivity ~15 copies RNA/µL 92.50% 
Femtomolar (fM) 
concentrations of 
viral RNA trigger 
1-20 copies RNA/µL ~50 copies 
RNA/µL 











Length of workflow (Approximate) 4-6 hours 3 hours 3 hours <60 minutes 30 minutes 
Readout Method 
Amplification data to be 
manually interpreted 
Appearance of band 












References [97, 98]  [99-101]  [16, 17]  [102, 103]  [104, 105] 
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The benefits of the toehold switch system over other field-based methods and its 
capability to detect specific DNA sequences would make it well-suited to forensic science 
which routinely encounters DNA evidence deposited at crime scenes. This is further 
enabled by the reported lack of sequence constraints in the design of toehold switches, 
which suggests the method could be adapted for genetic markers relating to body fluids 
and/or sex.  
 
1.6. Enabling Technologies 
 
A portion of the recent successes of synthetic biosensors can be attributed to 
advancements in related fields that enable their use. Sensor elements made of nucleic 
acids have been supported as a research tool via reductions in the cost of DNA/RNA 
synthesis, as well as DNA sequencing. Construction and verification of oligonucleotide 
sequences can now be performed rapidly, and for low cost, even for relatively long  
sequences [106]. Advancements in microfluidics and miniaturisation of other components 
has enabled the development of microfluidic biosensors that can perform the entire 
detection workflow in the field [101, 107]. The emergence of cell-free synthetic biology 
has presented numerous benefits, primarily the removal of constraints necessitated for in 
vivo cellular work [108], which are known to affect performance of synthetic biosensors in 
an unpredictable manner [109]. As with most applications that concern the detection of 
nucleic acids, PCR or nucleic acid sequence-based amplification (NASBA) are necessary 
pre-treatments for the generation of sufficient DNA or RNA material, respectively. As one 
of the most widely performed techniques in molecular biology, developmental trends in 
recent years have aimed to support the convenience of its use, microfluidic platforms 
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have integrated nucleic acid amplification steps into their standard workflows [110, 111].  
An issue with some nucleic acid-based networks is their need for the sensor 
oligonucleotide to contain specific bases that are vital for transducer function e.g. a 
ribosome binding site (RBS) for protein production. Given the limited size of sensor 
oligonucleotides, the inclusion of these sequence constraints reduces the number of 
bases that are available to engage in hybridisation with a target sequence. As a result, 
these sensors can display poor orthogonality, which has implications for biosensor 
specificity and reliability. Some work has been done on addressing this issue by exploiting 
the secondary structure of oligonucleotide probes to sequester these critical sequence 
elements into inaccessible loop regions which do not take part target recognition, but 
become available to transcription/translation machinery via conformational “unwinding” 
following hybridisation of the sensor element and the target oligonucleotide. This allows 
all of the bases that are directly engaged in target hybridisation to be complementary, 
greatly increasing specificity and orthogonality, without compromising on performance.  
One factor that will provide smaller laboratories with the confidence to engage with 
synthetic biology is the availability of standardised frameworks and protocols in the 
literature. Using standardised BioBrick parts, third parties have developed “toolboxes” for 
parts that have been optimised for use in different cellular hosts [112-114]. The 
availability of such toolboxes, and data generated with them, provides low-resource or 
inexperienced laboratories an avenue to branch into synthetic biology using reliable, 
documented protocols. Accelerationism is likely to drive the field of synthetic biology in 
the coming years, as various concepts regarding gene networks are elucidated, and 
biosensors become more widespread in their usage, or commercialised. A review from 
Oldham et al. in 2012 [115], using the Web of Science database [116] identified a total of 
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1,255 publications related to synthetic biology and synthetic genomics (underestimated 
due to lag times in publication) up to the end of December 2011. Using the same search 
criteria, an up to date search (to the end of May 2020) found a total of 17,076 
publications (Figure 1.4).  
 
Figure 1.4: Number of publications regarding synthetic biology or genomics retrieved on a per-year 
basis by the Web of Science search engine, refined by publication type. Total number of 
publications is 17,076. Red asterisk at 2011 data point denotes end point of Oldham et al. review 
of the same search criteria. Search terms: “synthetic biology” OR “synthetic genomics” 
 
This upwards trend that Oldham et al. identified in their literature search has continued 
for the 9 years following publication, with the value for the incomplete year 2020 as the 
only outlier. It is thought that this trend is due to the availability of literature and 
published protocols allowing other laboratories to engage with synthetic biology for their 
own research purposes. Of all publication types, journal articles were the most common 
in each year, but reviews and book chapters became more represented in the late 2000’s 
and early 2010’s as more information was needed to be consolidated. Much like Oldham 
et al.’s study, it is anticipate that these figures are still an underestimate, due to both 
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publication lag, and the expansion of synthetic biology in to several sub-categories which 
may not have fallen under the search terms used with the Web of Science database.  
 
1.7. Technical Hurdles to Synthetic Biosensor Adoption 
 
Despite the variety and reported success of synthetic biosensors in the literature, there 
are comparatively few commercialised examples. This is due to multiple factors that have 
acted as hurdles to widespread adoption. One of the biggest criticisms of the field that is 
preventing adoption is the lack of common methodology and reproducibility in synthetic 
biology [10, 117, 118]. 
While there is an effort to make these protocols available (see iGEM and BioBrick), this 
only represents a small portion of the field. Without access to existing protocols, it 
becomes much more difficult for synthetic biologists to leave the early development and 
prototyping stages of biosensor construction. Synthetic biology projects that run into 
significant developmental issues are more likely to be abandoned and the results 
collected unsuitable for publication in a research journal. This lack of published 
experimental data makes it difficult for other laboratories to avoid pitfalls in synthetic 
biosensor design, it turn making performance optimisation and reproducibility harder to 
achieve. This can only be addressed by scaling up inter-laboratory co-operation of those 
engaging with synthetic biology.  
Many of the biosensors that have been detailed in this chapter sense only a single target 
biomolecule. While this is certainly useful for specific research purposes, the lack of assay 
flexibility is a concern when trying to commercialise these techniques as it reduces the 
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potential market scope for an assay. The use of biomolecules as a sensor element 
presents concerns about their handling and storage. Nucleic acids and whole cells require 
sub-zero freezing temperatures to maintain performance, potentially prohibiting their use 
in resource-poor environments. While there have been advances in room temperature 
biosensing paper-based synthetic biosensors [17], this method is still undergoing 
development and iteration. Despite the often remarked upon comparison of synthetic 
gene networks to electrical networks, a review by Teo et al. [119] found this to be an 
inaccurate comparison and identified 5 key issues that prevent their widespread 
adoption. These are: oversimplified designs, non-modular behaviour, molecular toxicity, 
resource consumption, and noise, all of which must be addressed to reliably produce 
robust synthetic biosensors (Table 1.7).  
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The analogy of genetic regulatory components as electrical circuits is inaccurate, as cells do not reliably provide binary 
outputs like computers do. This makes interconnecting gene regulatory networks far leakier than would be expected. 
Design frameworks must accommodate for this difference to reliably produce circuits of predictable performance. 
Non-modular behaviour 
Cells are subject to a variety of biological processes that are not present in digital systems. These processes may deplete 
resources used by genetic circuits at various points both up- and down-stream in the network. This has the impact of 
increasing performance variation, but the extent varies depending on the complexity of the network. 
Molecular toxicity 
Cells have finite energy that can be applied to metabolic processes. This not only limits the rate at which metabolites 
can be produced, but also introduces components that are toxic to cells such as reactive oxygen species which will 
affect cell function if accumulated. This issue prevents scaling up of synthetic biology. 
Resource consumption 
There is a finite number of cellular machinery components (e.g. polymerases, ribosomes, etc.) which are shared for 
critical network functions such as transcription and translation of genes. 
Noise 
Cellular signals are a function of molecule copy number and as such are subject to random noise in output signal. This 
variation is difficult to model in silico which impacts repeatability of results. 
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Although there is a wealth of experimental data published regarding the activity of 
synthetic biosensors, some of these data sets were only achieved after a high number of 
rounds of sensor development and optimisation. For example, published data from Green 
et al. reported on the performances of 168 different sequences for a fluorescence-based 
synthetic gene network [38]. Whilst the design of these networks was automated using 
an in silico design algorithm, and the mode of action was relatively simple 
(complementary base hybridisation to initiate reporter gene expression), the 
performance of each network varied over a massive range. The lack of performance 
predictability from the design to wet lab testing stages is compounded further by the 
length of time needed to characterise each network in vivo. Determining the causes of 
poor performance can be multi-factorial and require significant manpower or expert 
knowledge to achieve. This issue of poor concurrence between in silico predictions and in 
vivo/vitro testing is pervasive and unlikely to be solved by a single process or piece of 
software. Instead, these tools are likely to arise following the continued co-operation and 
collaboration of laboratories around the world in publishing data, participating in meta-
analyses, and preparing standardised frameworks and protocols for working with 
synthetic gene networks. There have been other efforts to automate SGN design with an 
in silico approach away from standard “brute-force” applications currently in use, to 
rational engineering approaches that utilise desired input-output functions to generate 
and rank putative network designs [120]. While the strength of these methods will 
depend on initial input data obtained from experimental in vivo work, and similarly 
require in vivo testing to confirm their results; the potential to remove much of the trial-
and-error of network design would be hugely beneficial to synthetic biologists. Biosensors 
based on whole cells brings forward concerns regarding biosafety and how these micro-
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organisms will be utilised, requiring robust testing and validation prior to introduction. 
Cells used to express synthetically constructed genetic regulatory networks are classed as 
genetically modified organisms (GMOs) and as such are subject to legislation surrounding 
the contained use of GMOs enforced by the Health & Safety Executive branch of the UK 
Government [121]. Any synthetic cell-based biosensor would be subject to risk 
assessment as outlined by the guidance from the Scientific Advisory Committee on 
Genetic Modification (SACGM) [122]. Any synthetic biosensor developed for the detection 
of non-hazardous target molecules would most likely fit to the lowest class of GMOs 
outlined by the HSE (class 1) with the accompanying lowest containment level (level 1) 
where physical barriers to GMO containment suffice as products such as fluorescent 
reporters are also non-hazardous to both human health and the environment. Despite 
the very low risks associated with this method of biodetection, risk assessment would 
need to form a section of any validation work with the sensor to ensure it complies with 
any relevant legislation in this area.   
 
1.8. Summary and Aims 
 
This chapter has covered the various strategies employed by synthetic biologists in the 
construction, activity, and readouts of synthetic biosensors. Synthetic biosensors have 
been applied in multiple fields given their highly customisable nature; but have been 
most successful in the fields of healthcare and environmental monitoring. This exposes a 
potential niche for underrepresented fields that still require the rapid, portable, and 
reliable detection offered by synthetic biosensors, namely forensic science. Modern 
forensic science typically deals with DNA as a target analyte [123], so it would make sense 
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to apply nucleic acid based biosensing strategies to this field. Comparing the detection 
strategies outlined above, the use of toehold switches as a basis for a synthetic gene 
network is attractive, given the properties of self-regulation, high specificity/sensitivity, 
and high customisability. Additionally, toehold switches have been demonstrated in a 
practical setting to have greater performance and faster time-to-result than 
contemporary field-based detection tests with the same target analyte (Zika virus). Taken 
together, this provides a clear developmental goal moving forward, which is to develop a 
synthetic toehold switch biosensor in-house which is capable of detecting nucleic acid 
sequences of forensic importance, such as those upregulated in body fluids or sex-specific 
genes for sex identification at the crime scene. 




Surveying End-User Requirements for a Novel Field-Based Bio-Detection 
Assay 
2.1. Abstract 
A literature scan revealed that toehold switch synthetic gene networks are potentially 
useful tools for the rapid field-based biosensing of genetic markers, and that there is 
currently a dearth of synthetic detection techniques being developed with forensic 
practitioners in mind. This would suggest that development of a toehold switch sensor for 
forensic targets would be worthwhile and fulfil the research needs of end-users. A market 
research questionnaire was devised to determine if there was any need for a novel field-
based biosensing assay amongst forensic, healthcare, and environmental monitoring end-
users, and if so, how such an assay should function and which biomarkers it should target.  
The questionnaire, distributed to professionals and postgraduate/final-year 
undergraduate students in the above fields, assessed multiple factors regarding the 
current state of field-based bio-detection amongst potential end-users. These were: 1) 
the types of detection techniques already in use and the frequency with which they are 
applied; 2) awareness of existing techniques outside of the scope of standard practice; 3) 
perceived issues in the adoption of novel tests to standard procedure; and 4) the ideal 
features and functions of a novel field-based detection assay. In total, 154 participants 
took part in the questionnaire (54 professionals, 100 students). Overall, participants from 
both groups identified low costs, high accuracy, and results within 30 minutes of sample 
input as key features in an ideal field-based test, with human body fluids and DNA as the 
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most requested target analytes. Results are discussed in the context of toehold switch 
synthetic gene circuit function and whether it is a suitable assay to achieve these goals.  
 
2.2. Introduction 
Over the past several decades, bio-detection techniques have broadly fallen into two 
categories: laboratory-based (i.e. tests performed within the confines of the controlled 
laboratory environment) and field-based. When compared to laboratory-based 
techniques, field-based tests are often cheaper and more rapid but typically sacrifice 
sensitivity and/or specificity for the convenience of performing the test in a greater range 
of environments with a shorter workflow [14]. Given their limited performance, these 
tests are often qualitative and presumptive in nature, in that they cannot conclusively 
confirm the presence/absence of a molecule and necessitate further processing in the 
laboratory [124]. Thus, many field-based tests act to inform further decision making in 
the detection process. Whilst field-based tests are capable of streamlining detection 
workflows, lower accuracy increases the rate of false positives and negatives which can 
lead to the incorrect processing of samples, resulting in a loss of time, reagents, and 
money. In addition, the need for further processing of field-collected samples in the 
laboratory environment opens up the risk of contamination or sample loss during 
transport [125]. This can also significantly increase the time between sample collection 
and result output, which is of concern for fields such as healthcare where quick 
turnaround time may be critical to effective patient treatment. These issues have recently 
come into focus with the emergence of COVID-19 as a global viral pandemic. Currently, 
there is a need for rapid, low-cost, instrument-free molecular detection techniques that 
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perform to the standards necessary for reliable mass testing of the disease. Even 
laboratory-based RT-PCR of a respiratory tract swab taken from a patient, considered the 
gold standard for molecular detection of SARS-CoV-2, has noted sensitivity issues [126, 
127]. Low sensitivity leads to the appearance of false-negative results where patients who 
do have the virus are not appropriately flagged by the detection technique. This has 
serious implications for accurate tracking of the virus’ progression in large populations, 
which coupled with the fairly long time-to-result of RT-PCR [96], presents a clear need for 
improved rapid molecular detection tools.  
In the past decade, improvements in instrument miniaturisation and protocol workflow 
has enabled detection techniques that were previously exclusive to the laboratory to be 
transferred into the field [14]. This in turn reduces the training required to operate and 
interpret results from these tests, increasing the potential end-user base. Efforts have 
been made to commercialise next-generation field-based tests for a range of purposes, 
e.g. the ParaDNA® Intelligence System suite of field-deployable forensic DNA detection 
tests [128], Cepheid GeneXpert viral detection platforms [129], and the AQMesh platform 
for remote multiplex monitoring of air-based pollutants [130]. However, one factor that 
these tests share is that the instrumentation requirement has not been totally reduced. 
The instrument used for STR profiling by the ParaDNA® System as the most complex of 
the above processes is roughly the size of a suitcase. While still portable, further 
reduction would increase the system’s ease of use and facilitate its transfer to more 
laboratories and end-users. The identification of synthetic gene networks as potential 
low-cost, low-equipment field-deployable biodetection platforms [17] presents an 
alternative method for DNA detection, and the inherent programmability of the network 
would allow for sensor networks to be constructed for almost any desired biomarker. This 
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open-ended approach however creates difficulty when deciding on which biomarkers to 
design a network for, and to which field it should be applied. The rapid development and 
commercialisation of field-based tests has given little time to assess their impact on the 
end user.  
To highlight this, a scan of the literature through the Google Scholar and Scopus search 
engines of a 24-month period (from January 2018 to January 2020) was performed. The 
search criteria used the AND logic rule to identify the number of publication items that 
specifically covered validation or market research in the fields of forensics and healthcare 
(e.g. “forensics” AND “validation”). To account for differences in terminology between 
forensics and healthcare, the terms used for tests performed outside of the laboratory 
environment (“field-based tests” in forensics, “point-of-care” tests in healthcare) were 
only used for searches of their respective fields. The results of the search revealed that 
validation of novel techniques outnumbered market research publications in both fields 
by factors of approximately 10 – 1000 (“validation study AND forensic” = 16900 (Google), 
1685 (Scopus); “validation study AND healthcare” = 29400 (G), 7062 (S); “market research 
AND point-of-care test” = 2190 (G), 25 (S); “market research AND field-based test” = 48 
(G), 36 (S)). Of the market research papers, many of these are reviews and meta-analyses 
of existing products. While these provide a snapshot into the state of the field at a given 
time, it does not provide much useful information for laboratories looking to develop and 
commercialise their own novel assays. Whilst the transition of laboratory-based tests to 
the field presents new research opportunities, this will have no significant positive impact 
on the scientific community if the intended end-users are not aware of their existence 
and/or they do not adequately fulfil their research needs. Conversely, from a developer’s 
perspective, a lack of market data presents obstacles to successful development and 
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commercialisation of a novel field-based assay, and risks development overlooking 
potential end-users that may have a need for a specific test that is not being heard.  
There are existing benchmarks and policies in place to help guide the development of 
novel field-based diagnostic tests. The World Health Organisation (WHO) have developed 
the “ASSURED” criteria for point-of-care testing, which contains solutions to many of the 
needs of modern disease control, but is also broadly applicable to the needs of other 
fields [131]. The criteria are Affordable, Sensitive, Specific, User-friendly, Rapid/Robust, 
Equipment-free, and Delivered to end-users. However, it is not always possible for a 
single test to meet all these criteria and does not take into account the specific needs that 
may be encountered for a given field. A further policy guide prepared by Kosack et al. 
[132] on the selection and casework implementation of diagnostic tests provides more 
detail on the obstacles to adopting novel detection platforms. The first two steps of their 
six-part policy statement provide an extremely useful guide for laboratories to focus 
development on novel assays, namely definitions of the test’s intended use, and 
reviewing the market for it. These two steps should be considered key points of 
information to obtain before beginning full development of a novel forensic assay in-
house. As mentioned previously, toehold switch networks appear applicable to forensic 
science as a tool for biosensing of genetic markers related to body fluids and sex 
determination. This provides a test definition, but market data for such an assay is not 
available which necessitates obtaining this first-hand. To obtain the market review data, a 
market research questionnaire was prepared.  
The purpose of the questionnaire was to develop an understanding of current approaches 
regarding bio-detection by researchers in various fields. In addition to this, assessment of 
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end-user awareness of the market and opinions on existing techniques would allow for 
market niches to be identified. Finally, identification of hurdles to assay adoption and 
needs in an ideal field-based assay (including preferred target analytes) provide 
developmental drivers to guide assay development in-house. It should be noted that the 
use of questionnaires targeting focus groups in product development allows for iterative 
design [133]. Obtaining broad design cues from end users which are then refined further 
after prototyping aids in product applicability as it matches end-users needs closely. It is 
important to survey end user opinions on factors not directly related to test function (e.g. 
cost, awareness of existing tests, routine operation etc.) as barriers to adoption of new 
tests are not simply limited to poor performance metrics [134]. For instance, a test that 
fulfils all end-user requirements but is more expensive or difficult to use than current 
practice is much less likely to be adopted.  
The aims of this chapter are to assess the state of the market with regards to field-based 
molecular detection in the areas of forensics, policing, healthcare, and environmental 
science, and to inform the development of a novel field-based assay based on participant 
feedback. The objectives that arise from this, which can all be achieved through the use of 
a targeted questionnaire, are to determine the current detection methods in place and 
their frequency of use, and if these tests meet all end-user research needs to an adequate 
degree. If a desire for a novel field-based molecular detection assay is present amongst 
respondents, the specific detection target, ideal performance metrics, and cost can also 
be surveyed. These expectations can then be compared against the known performance 
and target compatibility of toehold switch synthetic gene networks to determine if these 
expectations are achievable with this method.  
Chapter Two – Market Research 
62 
 
2.3. Materials and Methods 
2.3.1. Identification of Stakeholders and Questionnaire Development 
Stakeholders were defined as any parties that impact or are impacted by the market 
research. To this end, professionals working in fields that routinely use assays for the 
detection of biological molecules (forensics, policing, healthcare) were identified as the 
primary stakeholders. To supplement participant numbers, post-graduate and final year 
undergraduate students in these same fields were also included as stakeholders as it was 
thought that late-stage students would have views and knowledge similar to 
professionals at the beginning of their careers. The expected number of participants 
prevented one-to-one interviews from being a viable method to obtain responses, so an 
online questionnaire was used (see Appendix III). Gatekeepers were used to disseminate 
the questionnaire to wider groups within organisations. Gatekeepers were identified as 
individuals with authority within the organisation of interest that could consent to 
distribution e.g. lab managers, lecturers, etc. Institutions and organisations surveyed 
included the UK Environment Agency, Merseyside Police, Merseyside NHS practices and 
hospitals, LGC Forensic Group, and Liverpool John Moores University (LJMU). 
The overall aim of the study was to identify end-user requirements for a field-based 
molecular detection assay in the fields of forensic investigation or healthcare including 
preferred molecular targets and assay performance to inform later assay design in-house. 
From this aim, a series of objectives were set that could be delivered upon with market 
research. These objectives and their purpose in the market research study are listed in 
Table 2.1.  




Table 2.1: Market research objectives and their relevance to the study. 
Objective Purpose 
 
Approach relevant stakeholder groups in the fields of 
forensics, healthcare, and environmental science  
Surveying end-users from the appropriate fields ensures that the opinions obtained 
are relevant to stakeholders at large and that user requirements are relevant to use as 
developmental drivers 
 
Identify the types of detection assays already in use, their 
frequency of use, and whether these are laboratory-based or 
field-based  
Provides an understanding of current practice amongst end-users, and if there is any 
scope introduce a novel field-based assay 
Assess end-user knowledge and opinions of field-based 
testing 
Will determine if end-users are aware of recent advancements in field-based testing 
and will establish perceived drawbacks and benefits to its use 
Determine if end-user requirements are met by existing tools Highlights niche for development if end-users' research needs are not adequately met 
 
Specify key end-user requirements for field-based assay 
performance and preferred target molecules  
Provides key information to inform development of in-house field-based assay 
 
Identify any hurdles that would prevent the adoption of an 
otherwise suitable field-based molecular detection assay  
Provides developmental information that is not directly related to test function, 
factors such as per-test cost, need for instrumentation, training etc. 
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Separate questionnaires were prepared for professional and student participants. The 
questionnaire for professionals consisted of 26 questions broken into subheadings, 
whereas the student questionnaire had 10 questions. The additional questions in the 
questionnaire for professionals concerned current testing usage and opinions, as well as 
factors that student participants were deemed to not have the requisite 
knowledge/experience for e.g. laboratory funding for assay purchasing. 
Both questionnaires were granted ethical approval from LJMU’s Research Ethics 
Committee (Approval Number 17/PBS/013) prior to uploading onto SurveyMonkey® 
online survey hosting site [135]. Prior to sending questionnaire web links to individuals, 
participants were quickly briefed on the background of the research, which was also 
presented in the web link itself prior to questionnaire start. Technical terms such as 
“field-based”, “accuracy”, “sensitivity”, etc. were defined within the questionnaire to 
avoid misinterpretation of questions. Completion of the survey was voluntary, 
anonymised, and no personally identifiable information was collected. In total, 154 
individuals participated in the survey; of which 54 participants were from the professional 
sector, and 100 participants were current postgraduate or final year undergraduate 
students at LJMU. The decision to use a greater number of student participants was a 
practical choice due to poor professional response rates and time constraints.   
Survey completion rate was 68% (professionals) and 97% (students). Professional 
participants were also grouped by field forensic science/policing (n = 25), healthcare (n = 
16), environmental monitoring (n = 6), and other (n = 7, included food analytics, 
archaeology, and chemists) but also according to the primary role within their work. 
These categories, of which respondents could select more than one if their duties were 
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evenly divided, were laboratory-based personnel (n = 26; consisting of researchers and 
scientists providing analytical services), field-based personnel (n = 11; consisting of field 
researchers, crime scene investigators, SOCOs, etc.), administrative personnel (n = 3; e.g. 
project managers that oversee sample processing), and research & development 
personnel (n = 15), and other (n = 6, all self-reported as academics). Student participants 
were placed into 4 broad categories according to their area of study; forensic science (n =  
27), healthcare (n = 61), policing (n = 7), and other (n = 5, included fields that did not fit 
into any of the other categories i.e. industrial biotechnology, and industrial research and 
development). Results from professionals were discussed in terms of field, role, or both 
where appropriate. 
 
2.3.2. Data Analysis 
All tabulated questionnaire responses were exported from SurveyMonkey® into Excel for 
further analysis and preparation of graphs. When analysing responses to questions that 
used a ranking system, a weighted average was applied to tallied results. Weighted 
averages were calculated by applying a weight to each response relative to its ranking by 
the respondent. For instance, a ranking question with 11 options has a weight of 11 
applied to the option that a respondent marked as most preferable/important, a weight 
of 10 applied to their second option, and so on. The number of responses at each 
preference level (1st, 2nd, 3rd, etc.) was multiplied by its weight, summed, then divided by 
the total number of respondents for that response. The full formula for calculating 
weighted average score is as follows: 
x w + x w + x w … x w
Total Response Count
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Where X is the number of responses for that answer option, and W is the weight of that 
position.  
A Mann-Whitney U test was utilised to compare the means of test frequency of use data 
to determine if there was a significant difference in their distributions. Means were 
compared as the distributions of the two factors (presumptive and confirmatory tests) 
were non-identical. A two-tailed Mann-Whitney U test was performed using the Data 
Analysis tool in Microsoft Excel. Resulting U-values were compared to statistical tables to 
determine significance.  
 
2.4. Results and Discussion 
2.4.1. Assessment of Current Testing Approaches 
Professional participants were asked a series of questions regarding current testing 
practice to understand how existing field-based tests fit into typical working routines. 
Participants were first asked how often they used field-based tests in their routine sample 
detection and analysis work.  Of 54 total respondents, 13% answered daily; 9.3% 
answered weekly; 14.8% answered monthly; another 14.8% answered greater than 
monthly; 25.9% answered that they never used field-based tests; and the remaining 
22.2% of participants did not know how often they were used.  As expected, field-based 
respondents had the highest frequency of use of field-based tests, with 64% of 
participants from this role using field-based tests on a weekly or shorter basis. 
Conversely, only 12% of laboratory-based participants utilised field-based tests at this 
same rate, compared with 54% who used field-based testing on a monthly or greater 
basis or not at all.  In total, 51% of all participants use field-based testing to some degree 
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in their routine work, implying that a subset of targeted end-users may be interested in 
applying a novel field-based test should one be developed that suits their research needs.  
To develop an understanding of the applications of field-based tests currently in use, 
professional participants were asked to select which sample types were most commonly 
processed in their routine work from a list of “known human biological samples”, “known 
animal biological samples”, “known environmental samples”, and “samples of unknown 
origin”. This question was multiple choice and allowed participants to select multiple 
sample types or enter their own if appropriate. To aid participants in answering the 
question, examples of each sample type were given in the category description (Figure 
2.1). 
 




Figure 2.1: Representation of the sample types most commonly processed by professional 
participants, filtered by field of research (A) or role within field (B). N = 54. The singular response 
for “Other” was reported as “food and animal feed”.  
 
Except for respondents in environmental sciences, human biological samples were the 
most common sample type processed both between fields and between job roles, 
accounting for 88% of forensic/policing professionals and 94% of healthcare 
professionals. Common sample types processed generally correlated with typical testing 
measures for each field i.e. environmental scientists primarily processed environmental 
samples, healthcare professionals with human biological samples, etc. When filtered by 
job role, each role processed a range of sample types, though all but one laboratory-
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based professional identified “known human biological samples” as their most common 
sample type. Again, the high prevalence of human biological targets in the forensic and 
healthcare fields provides an indication that a novel assay in these fields should also 
target these types of molecules.  
Professional participants who responded that they used field-based testing to some 
degree (i.e. did not select “never” with regards to their frequency of use (n = 42 of 54)) 
were asked to categorise both the presumptive and confirmatory tests they use based on 
their mode of action. The three modes of action were based on whether the assay used 
chemical interaction, protein-protein binding, or DNA hybridisation to detect its target. 
After doing so, participants were asked to assign a percentage score to these tests 
regarding how often they were used in their routine work, with the requirement that 
percentage scores must add to 100% (Figure 2.2). Two of the qualifying respondents did 
not complete the questions so were not included in the results.  




Figure 2.2: Professional respondents’ self-reported usage percentages of both presumptive and confirmatory field-based assays for the detection of protein, 
chemical, and nucleic acid targets. N = 40 (presumptive tests) and 39 (confirmatory tests). 
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Assessing the overall trends for both presumptive and confirmatory field-based tests, less 
than 10% of participants responded that field-based tests of any one kind made up 100% 
of their testing routine, implying that end-users engaged with field-based testing utilise a 
variety of tests with different molecular targets and modes of action. In each category, 
“0%” is the overall mode response. Selecting this result means that the participant does 
not use this type of test at all in their routine work. Combined with the result that very 
few end-users are using any one specific type of test, it indicates that a combination of 
two of the three categories of test is the most common way end-users fulfil their testing 
needs. Confirmatory protein testing and presumptive DNA testing were the least popular 
detection methods amongst forensic scientists and police, whereas a combination of 
presumptive chemical/protein detection and confirmatory chemical/DNA testing was 
common. This finding links with the known common testing practices of the field with 
regards to known human biological sample testing, the most common sample type 
encountered as reported by participants (Figure 2.1). Common field-based presumptive 
test in forensic investigation utilise chemical reactions [136-138] or antigen binding [139, 
140] to detect the presence of samples such as human body fluids. Presumptive testing is 
typically followed by downstream confirmatory testing, of which DNA profiling is a key 
technique, and has been expanded from a laboratory-based process to a field-based one 
[128].  
Amongst healthcare professionals, all types of presumptive and confirmatory test were 
employed. Presumptive protein detection tests were the most common type of test used, 
with 10 non-zero responses from participants. Serological testing against antibodies is a 
common presumptive diagnosis tool in healthcare for the support of molecular diagnosis 
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techniques [141].  A range of confirmatory tools were used by healthcare professionals, 
with chemical and DNA testing more popular.  
Respondents working in environmental monitoring did not use presumptive protein 
testing but a 90/10 split of presumptive DNA/chemical testing, and roughly even usage of 
the three confirmatory tools. Again, this fits with known practice as DNA biosensors are 
simple and rapid tools that have applications in both centralised and on-site 
environmental monitoring of toxins, pollutants, and pathogens that are harmful to human 
health [142-144]. The remaining participants containing food analysts and chemists were 
least engaged with DNA-based testing but used a mix of all three methods for both 
presumptive and confirmatory testing needs. These participants had a mix of roles 
including laboratory-based personnel, field-based personnel, and research & 
development staff would account for this varied usage of tests. The results from each 
participant group lining up with known standard practice for their respective fields 
provides confidence that responses obtained from professionals are relevant to the wider 
field of which they are a part.   
A two-tailed Mann-Whitney U test was performed between presumptive and 
confirmatory tests of each detection target within fields to determine if distribution of 
test usage changed significantly depending on whether the test was presumptive or 
confirmatory. None of the categories within any field returned significant U-values, 
suggesting no evidence for significant difference in usage of presumptive vs. confirmatory 
tests. However, the small sample size for this question makes assessment of significance 
difficult and would be worth repeating with a larger sample.  
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By observing the number of non-zero responses, presumptive testing was used slightly 
more than confirmatory testing, with presumptive chemical testing the most popular 
form of test (presumptive protein testing n = 31, presumptive chemical testing n = 32, 
presumptive DNA testing n = 26; confirmatory protein testing n = 23, confirmatory 
chemical testing n = 27, confirmatory DNA testing n = 26). The usage of both presumptive 
and confirmatory field-based tests by end-users implies that a novel field-based test may 
be attractive for end-users to adopt irrespective of whether its function is presumptive or 
confirmatory.  In terms of informing synthetic gene network assay design, field-based 
tests targeting DNA that function either as presumptive or confirmatory detection tools 
are in use in all fields surveyed. This implies that a novel field-based toehold switch assay 
may face hurdles in being adopted in these fields if it does not present significant benefits 
over existing tools and techniques. 
To follow up on these questions, participants were asked how many samples were 
processed using any field-based presumptive or confirmatory tests within the space of an 
average month, with a number of mutually exclusive options detailing the number of 
samples, ranging from <5 to ≥100 (Figure 2.3).  
 




Figure 2.3: Frequency of use by professional respondents of presumptive (A) and confirmatory (B) 
field-based tests for any detection target. Administrative personnel did not engage in any field-
based testing so were omitted from the results. N = 44 (presumptive), 42 (confirmatory). 
 
Laboratory-based personnel primarily responded with fewer than 5 tests used per month 
or that they were unaware of the number of tests used per month for both presumptive 
and confirmatory field-based tests. This contrasts with field-based personnel, where both 
presumptive and confirmatory field-based tests were used upwards of 100 times a 
month, with a minimum of 5 – 10 (presumptive) or 20 – 50 (confirmatory) per month. 
This gap in field-based test usage is expected given the differences in roles and available 
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repertoire of tests. Research and development personnel were varied in their usage of 
field-based tests, with usage rates at both extremes of the scale. Lastly, academics 
reported themselves as using 5 – 10 tests per month or 50 – 100 per month for both 
presumptive and confirmatory field-based tests. Taken together, these results indicate 
that a novel field-based test would be best suited to those already primarily working in 
the field, or to research & development personnel. 
Functional aspects of the confirmatory tests in current practice were surveyed, including 
need for sample pre-treatment, time-to-result, and method of result interpretation. By 
developing an understanding of existing test functionality, any issues in the process such 
as lengthy workflows or laborious sample pre-treatment can be identified and potentially 
addressed in the development of a synthetic gene network approach. Participants were 
first asked a simple yes/no/unsure question regarding the need for pre-treatment of 
samples prior to use with routine confirmatory tests. The majority of respondents 
indicated a need for sample pre-treatment, with 62% responding “yes” when tallied by 
field, and 57% when tallied by work role. Interestingly, all participants who identified 
themselves as field-based researchers responded that sample pre-treatment was 
necessary. This is a potentially significant issue as it increases handling and testing time, 
while introducing the potential for contamination or sample loss as a function of the test 
itself. This finding indicates that availability of a field-based test that can be performed 
without the need for sample pre-treatment would be of immediate benefit to the field-
based researchers surveyed here.  
 When asked the approximate length of time it took from sample collection to obtaining a 
confirmatory result, a large range of answers was provided (Figure 2.4).  




Figure 2.4: Approximate time between sample collection and a confirmatory result of sample 
identity being obtained. Results tallied by field (A) and primary role (B). N = 42. 
 
A key timeframe identified from the responses to this question was obtaining a 
confirmatory result within one week from sample collection. By this point, the majority of 
existing techniques have returned a confirmatory result for each field and work role 
(forensics/policing = 87%, healthcare = 100%, food analysis = 60%, laboratory-based 
personnel = 85%, field-based personnel = 86%, research & development = 54%, academia 
= 66%). Furthermore, 20% of field-based forensic detection workflows were completed 
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within a day, alongside 50% of healthcare assays. To design a novel assay in these areas, 
time-to-result should compete with these timeframes. The primary outlier in this data 
was environmental professionals who reported a minimum of 2 weeks to result, with a 
maximum of greater than two months. While this would highlight environmental science 
as a field for assay development, the low sample size prevents interpretation of this result 
as a clear need for rapid novel field-based detection assays.  
With regards to delivery of test result, participants were presented with a range of 
common methods by which confirmatory tests report results and asked to choose which 
option(s) best represented those in current practice. These options included “visual 
identifiers” such as tests that rely on a colour change or appearance of test band, 
“manually-interpreted raw data”, “automatic interpretation of data by instrumentation”, 
or “raw data exported to specialised software for interpretation”.  
With the exceptions of healthcare professionals with software interpretation and 
environmental professionals with visual identifiers, all fields reported the use of all types 
of result interpretation methods. Visual identifiers were the most popular result delivery 
method in current practice, followed by manual interpretation of raw data, automatic 
interpretation of data, and lastly export of raw data into specialised software (32%, 29%, 
21%, and 18%, respectively). As visual identification of test result is also the method that 
requires the least intensive result interpretation, the ease of handling is greater and could 
be employed by a larger number of end-users. This is a factor that should be taken into 
consideration for the development of a novel assay. Colorimetric and fluorescent 
readouts were previously identified as simple and popular amongst synthetic biologists 
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(see Chapter 1 section 1.4.3, Biosensor Readout and Signal Transduction Strategies), so 
could be applied here to great benefit. 
 
2.4.2. Stakeholder Awareness of Field-Based Testing Methods 
To assess stakeholder awareness of existing field-based molecular detection platforms, 
participants were asked how much they agreed with the following statement: “I am 
familiar with the range of both presumptive and confirmatory non-laboratory based 
detection techniques that are used in my field". Possible responses for this question were 
aligned along a 5-point Likert scale [145] from ‘strongly disagree’ to ‘strongly agree’, with 
‘neither agree nor disagree’ as a neutral answer. The collated and individual category 
responses were plotted onto a diverging stacked bar chart (Figure 2.5). A diverging 
stacked bar chart was used to represent this data as splitting results into broad positive 
(i.e. high agreement) and negative categories provides a greater visual clarity when 
processing a large amount of respondent opinion data, and is well represented as a 
method for displaying Likert scale data in the literature [146, 147]. Data was centred on 
the midpoint of neutral “neither agree nor disagree” answers so as not to bias results 
towards positive or negative responses. 




Figure 2.5: Professional respondent results when asked of their awareness of existing field-based tests, divided by field of work and role within work. N = 49. 




When looking at the totalled responses by field and role, they are strikingly similar. Both 
totals have an approximate 55%/45% split between positive and negative responses 
which indicates that overall professional respondents have some awareness of field-
based tests available to them but that knowledge gaps exist. When results are filtered by 
specific fields/roles, particular trends are noticed. Laboratory-based personnel tended 
more towards poorer awareness, accounting for more than half of all negative responses 
by role (~27% of total responses). This contrasted with field-based personnel, where 77% 
of respondents in this field expressed agreement or strong agreement. Additionally, none 
of the respondents in this field strongly disagreed or expressed uncertainty. This result 
was expected as field-based personnel were thought to routinely engage with field-based 
detection tests on a much more frequent basis than laboratory-based personnel. 
Research and development personnel were split on opinion, similar to overall results. 
Expected awareness of field-based tests in this role would be dependent on the specific 
duties carried out by the researcher and without more information it is difficult to 
interpret this result. The three respondents that selected ‘Other’ as their primary field of 
work all identified their field as ‘Academia’, two of which expressed strong agreement 
with awareness of field-based tests, with the remaining respondent uncertain. While it 
could be expected that academics would have a greater awareness of the testing 
techniques in their field due to familiarity with emerging literature including assay 
validation papers, this interpretation cannot be claimed without a much greater sample 
size. 
Professionals working in forensics or policing reported the greatest confidence in 
awareness of field-based testing, with 82.5% of participants from these fields responding 
Chapter Two – Market Research 
81 
 
in agreement, and accounting for a third of positive responses overall. This would be 
expected as forensic scientists, scene of crime officers (SOCOs) and other trained 
evidence-handling personnel are more likely to routinely work with field-based tests and 
as such would likely have an understanding of the various tests available to them. This is 
an observation that been recorded by other studies regarding field-based detection in the 
law enforcement and wildlife forensics communities [148-150]. 
Conversely, healthcare professionals expressed the lowest awareness of field-based tests 
available to them, with 83% of respondents responding negatively. This is likely a result of 
the centralised testing approach to healthcare in developed countries as the dominant 
testing arrangement, which forgoes field-based testing in favour of laboratory-based 
testing [151]. Environmental professionals generally expressed unawareness of field-
based tests but the sample size here was too low to draw reasonable conclusions from. 
Lastly, individuals in the ‘Other’ category reported themselves as working in the area of 
food analytics. The relatively even spread of responses in this group indicates there is 
some knowledge gap amongst users. This is potentially a result of food analytics 
employing a range of both laboratory-based and field-based techniques for detection, 
and a respondents’ awareness of field-based tests would be dependent on their routine 
testing use. Overall, the results indicate that those already routinely engaged in field-
based work have a greater awareness of field-based tests, and those who routinely work 
in the laboratory have a lower awareness. This provides evidence of a knowledge gap for 
field-based testing based on field and role of work.   
One drawback of this question that was realised after data collection was that the 
wording of the question did not account for any knowledge gaps that may exist in 
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laboratory-based testing. To amend this, supplementary data obtained from students 
surveyed awareness of both laboratory-based and field-based techniques (Figure 2.6). 
 




Figure 2.6: Student respondent results when asked of their awareness of existing laboratory-based and field-based tests. N = 100.
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In total, only 49% of student respondents agreed they were familiar with the field-based 
tests available to them, compared with 86% that agreed with the same statement 
regarding laboratory-based techniques. Breaking this result down by area of study, both 
forensic science and policing students agree that they have some familiarity of field-based 
techniques (67% of participants responding positively in both fields), but healthcare 
students are majority unaware of them, with 62% of participants responding negatively. 
These responses are similar to those obtained above from career professionals in the 
same fields which indicates that the knowledge gaps of the two groups are similar. The 
reason for the greater awareness of laboratory-based techniques was thought to be that 
laboratory techniques represent the gold standards of detections across fields, so an 
average end-user would be more likely to be aware of the laboratory-based techniques 
available to them over the field-based ones.  
 
2.4.3. Perceived Issues to Adoption of Novel Detection Techniques 
To identify the major pitfalls involved in introduction of novel detection techniques to 
existing workflows, professional and student participants were asked to rank issues that 
would prevent their adoption of a novel detection test from a list of eleven pre-prepared 
responses. Issues were ranked on a scale of 1 – 11, with 1 being the greatest hurdle, 11 
being the lowest. Results were tallied for each field and a weighted average score 
calculated, where a higher weight corresponds to a more significant issue. There was a 
high concordance in ranking results between professional and student participants. Both 
groups identified the same factors in the top 4 hurdles to adoption (Cost of equipment, 
cost of instrumentation, poor accuracy, time taken to obtain a result) and bottom 4 
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hurdles (no issues with current process, difficult storage of reagents, poor assay flexibility, 
and lack of quality control). This provides evidence that student and career professionals 
have similar priorities when looking to adopt novel detection assays, and that student 
awareness of the market is similar to professionals who have started their careers. These 
eleven issues were sorted into three categories (cost-related issues, performance-related 
issues, and methodological issues) which are addressed individually below in descending 
order of importance as indicated by survey results.  
 
2.4.3.1. Cost-Related Issues  
Across all fields surveyed, participants highlighted the cost of new 
equipment/instrumentation as the greatest hurdle to adopting novel detection platforms. 
Additionally, per-test cost of reagents was identified as the second and third greatest 
hurdles overall to professional and student participants, respectively (Figure 2.7).  




Figure 2.7: Weighted average responses of perceived issues relating to costs of adopting a novel 
field-based assay/technique. N = 33 (professionals) and 99 (students) 
 
Start-up and per-test cost issues being ranked higher than hurdles specifically related to 
test performance or methodology implies that economic viability of an assay is a primary 
factor in its adoption. Forensic science services have often struggled with sufficient 
funding for laboratories, exacerbated by economic downturns caused by recession [152, 
153]. With regards to healthcare, studies have consistently highlighted low cost (both on 
one-time instrumentation and per-test bases) and short workflows to achieve a result as 
essential factors when considering an ideal point-of-care test, regardless of target analyte 
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[154-157]. Taken together, economic concerns represent a clear hurdle to assay adoption, 
and cost-effectiveness should be placed highly in the list of developmental drivers for any 
novel assay.  
Professional participants were asked to identify the maximum amount of money they 
would be willing to spend when purchasing a field-based test that performed according to 
their research needs on both an instrumentation (i.e. initial cost of the device) and per-
test (i.e. individual reagents or test kits needed to run the assay) basis (Figure 2.8). 
Student respondents were not asked this question at it was thought they would not have 
the requisite knowledge of funding employed by research laboratories and NGOs to 
purchase and maintain operation of testing equipment.  




Figure 2.8. Professional participant responses concerning maximum acceptable costs for field-
based instrumentation (A) and per-test reagents (B). Number of participants for each field was 17 
(lab-based personnel), 4 (field-based personnel), 12 (research & development), and 2 (other). 
 
The results of the costing analysis show that with regards to instrumentation, an increase 
in price above £1000 is associated with a decrease in the percentage of respondents that 
would accept an instrument in those price ranges. There is equal support for the £100 - 
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<£500 and £500 - <£1000 categories, but the latter has support from all four roles of 
professional participants. This indicates that a test instrument/platform costing between 
£500 and £1000 in initial costs would be acceptable for 56% of respondents. This pricing 
could be achieved by reducing instrumentation requirements as far as possible to reduce 
production costs. It is thought that a toehold switch approach to bio-detection would only 
require a handheld heater for reaction incubation at an isothermal temperature. If 
configured with a colorimetric output, a toehold switch network could conceivably not 
require any instrumentation for result interpretation, relying on visual detection with the 
naked eye. At this early stage of development however, these represent unknown factors. 
As such, instrumentation costs cannot be totally discounted.  
In terms of the cost associated with the per-test operation of the platform, opinion was 
much more varied, with roughly even distribution of responses by work role. The reasons 
for this spread of data is multi-faceted and dependent on the end-user’s research aims 
and outcomes when using the test. Acceptable per-test cost would depend on numerous 
factors, such as the amount/quality of data received from a single test, and the number of 
tests being carried out by end-users at a given time. A higher cost could be justified if the 
amount of data obtained by the test is high with robust accuracy. As participants were 
specifically asked about the costs associated with a hypothetical confirmatory field-based 
test, it follows that the significant proportion of respondents that answered with higher 
per-test costs at least partly took this into account. Secondly, higher testing costs are 
easier to justify when end-users are carrying out a lower throughput of testing, and 
financial concerns about long-term running of the platform are reduced. Returning to 
participants’ existing routine testing regimes, field-based and research and development 
personnel process the greatest numbers of samples. With this data, it would be expected 
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that participants from these fields would prefer a lower per-test cost. Whilst this is true 
for most field-based professionals, results from research & development personnel are 
concentrated around the middle range (£5 - <£10 and £10 - <£20). Lab-based personnel 
also distributed their responses evenly across all options, with no clear preference per-
test. This contrasts with this group’s opinions regarding instrumentation costs, where 
most participants opted for a cheaper instrument. The varied response from participants 
implies that assay start-up costs (i.e. cost of acquiring any instrumentation for a novel 
technique) is more important than its per-test running costs. Additionally, without 
knowing the exact tests used by participants it may be that the most popular responses 
are in line with current testing costs. However, a brief survey of cost analysis of forensic 
tests found that many standard field-based presumptive tests for identifying body fluids 
estimate per-test cost between £1 - £25 [158-161]. In total, the data indicates that a test 
costing between £10 and £20 would be acceptable for a majority of the market research 
participants (56%). 
A common issue with emerging technologies is that costs to end-users can be high, 
impeding adoption rate. Depending on the field of work, there may be governmental 
funding bodies available to subsidise testing costs, resulting in little or no cost to the end-
user at the point of use. However, this is not a reliable solution to high testing costs as 
such bodies are not globally available and available funds are already limited [162]. The 
proposed toehold switch detection method can be expressed within cell-free protein 
synthesis (CFPS) systems. The simplest method by which this could be achieved would be 
to utilise commercial CFPS systems. Currently, there are several commercial CFPS 
formulations available, with the best cost-to-yield ratio offered by those derived from E. 
coli. However, the per-reaction cost for these kits is both fairly high and varies greatly, 
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from ~£10 [163] to~£80 [164]. When coupled with the respondent data that indicates 
some potential end-users for a hypothetical field-based assay are processing upwards of 
100 samples per month, it prohibits use of synthetic gene networks in standard liquid-
phase reactions as outlined by the manufacturers. Significant cost reduction would need 
to be achieved to enable the adoption of the test by more end-users. Efforts towards cost 
reduction have been demonstrated in the literature through freeze-drying of CFPS 
solutions and associated synthetic gene network components onto small paper discs as a 
substrate which retain their function after rehydration [165, 166]. The ability to execute 
genetic circuit function in a smaller volume (typically as low as 1.8 µL) enables a larger 
number of tests to be performed from the same volume of CFPS solution, reducing the 
per-test cost, with some demonstrations in the literature detailing <£1 per test with this 
system [16]. Costs from sub-zero storage are also eliminated as discs can be stored at 
room temperature. Several commercial CFPS solutions are derived from the PURE system 
first described by Shimizu et al. [167] where each component necessary for cell-free 
protein synthesis is purified and reconstituted into a minimal system. While the PURE 
system is widespread and robust, its cost is higher than crude systems that can be 
prepared in an equipped molecular biology laboratory while also providing a lower yield 
of transcription/translation machinery [168]. Recently, protocols have been described for 
the simple preparation of the PURE system at greatly reduced cost (approx. £0.06/µL) 
[169] which could greatly enable the use of toehold switch sensors as a detection tool. 
Nucleic acid sensor elements typically have slightly greater costs associated with them 
due to the need for synthesis and ligation into a plasmid to retain stability and sequence 
integrity necessary for test function, with a cost of ~£14.89/sensor [16]. However, large 
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quantities of sensor plasmid can be generated during the PCR-ligation process, offsetting 
this cost.  
 
2.4.3.2. Performance-Related Issues 
After cost, issues related to test performance were generally ranked the next highest by 
both professional and student respondents (Figure 2.9).  Amongst these issues, poor 
test/instrument accuracy was identified overall as the greatest hurdle.  
 
Figure 2.9: Weighted average responses of perceived issues relating to test performance of 
adopting a novel field-based assay/technique. N = 33 (professionals) and 99 (students). 
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Accuracy of a test is defined as the degree to which a measurement agrees with the true 
value of a sample. A test with poor accuracy generates a larger proportion of both false 
positive and negatives over a test with higher accuracy. End-user accuracy requirements 
and acceptable level will shift depending on the context and detection needs [170].  A 
test of lower accuracy may be acceptable if the test’s purpose is purely presumptive, 
rather than as a key process. Although the question does not specify the type of detection 
technique that is hypothetically being introduced (i.e. presumptive or confirmatory), it 
does indicate that prospective end-users have an expectation that any novel test 
introduced to routine detection workflows should perform reliably to a high standard. 
Professional participants were asked the lowest level of operational accuracy they would 
accept in a novel field-based confirmatory test, ranging from 80% accuracy (i.e. a 1 in 5 
error rate) to 100% accuracy (Figure 2.10). None of the participants selected an accuracy 
between 80 - 85%; 16% would accept a test with 90% accuracy; the majority of 
participants (57%) selected 95% accuracy as the minimum; whilst 20% and 7% of 
participants would require an accuracy of 99% or 100%, respectively. This data set 









Figure 2.10: A tally of responses from professional participants regarding the lowest acceptable 
accuracy for a novel field-based confirmatory test.  
 
Responses for acceptable accuracy being skewed towards the upper end fits with the 
above identification of poor accuracy as a major hurdle to test identification and indicates 
that 95% accuracy should be a developmental driver for novel assays. At this early stage 
of development, it is unknown if the diagnostic capability of an in-house toehold switch 
network would perform to this standard, but the high potential sensitivity and specificity 
of the system suggests that this may be possible [171].  
Time taken to achieve a result was identified as the second largest hurdle overall for 
professional participants. Within the fields of healthcare and forensic science, lengthy 
workflows can contribute to a range of issues such as inadequate patient care, sample 
loss during storage, and slow casework resolution, amongst others. These are issues that 
commercial assays developers have identified, and has contributed to rapid sample 
analysis becoming a key developmental driver [172, 173]. In DNA testing, this reduction in 
time-to-result has been achieved by shortening or combining workflow steps, such as 
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sample preparation and PCR amplification. However, it remains to be seen if the 
demonstration of short assay workflows in the literature has impacted end-user opinions 
on the general speed of novel assays. Participants were asked what they considered the 
maximum length of time should be to generate useable data from a confirmatory field-
based test starting from the point of sample input, ranging from 5 minutes to over 2 
hours. In both participant groups, over 80% would be satisfied with a confirmatory test 
that reports a result within 30 minutes. However, this drops to 19% (students) and 38% 
(professionals) satisfaction with a test that resolves within 1 hour.  With the proposed 
paper-based DNA detection assay, signal detection after reaction start can occur in as 
little as 20 minutes, which is directly in the middle of the most popular response 
timeframe (10 - <30 minutes), but generally reach maximum output expression in around 
1 - 2 hours [16, 17]. It is expected that an early forensic toehold switch prototype would 
not immediately perform at these levels. A sub-optimal toehold switch sensor taking 
approximately 60 - 90 minutes to report a result would still be considered a rapid test, but 
would only be acceptable to a smaller proportion of potential end-users. One 
consideration to be made regarding question structure when analysing these results is 
that the inclusion of options describing very short workflows (i.e. 5 minutes) may bias 
participants into choosing the shorter options. Furthermore, as the questions are 
specifically aimed at an ideal field-based test, participants may be more likely to choose 
the highest performance option regardless of feasibility.  
Assay sensitivity was ranked within the top half of potential issues by both participant 
groups. Poor sensitivity can severely impact assay function when working with low 
template input. This is often an issue in forensic investigation when little DNA can be 
extracted from a sample. When asked which level of sensitivity they thought would be 
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most appropriate in a novel field-based test (Figure 2.11), 3.5% of professional 
participants selected single target copy detection; 37.9% selected <100 target copies; 
27.6% selected <1000 target copies; 20.7% selected <10,000 target copies; and 10.3% 
selected <100,000 target copies. Together the data suggests that 69% of participants 
would accept a test that can detect down to 1000 target copies. Copy number was used 
as it allows participants from different fields to apply their own field’s standards to it, 
instead of using defined counts such as cells or molecules.  
 
Figure 2.11: Most appropriate level of sensitivity as identified by professional end users filtered by 
field (A) and role (B). N = 29 (field), 37 (role).  
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It was expected that responses to this question would bias towards the lower target copy 
detection as this would represent the highest possible performance. Contrary to this, a 
range of responses was given both by field and by role, with <100 target copies as the 
mode option. This range indicates that test sensitivity, much like accuracy, is a factor 
where requirements will depend on the end-users’ research needs. These results would 
indicate that most respondents expect that a test detecting under 100 target copies of a 
target analyte would be sufficient to fulfil confirmatory testing purposes. This level would 
be appropriate for immunoassay and DNA-based approaches [148], suggesting that a 
toehold switch sensor could fulfil this requirement. 
Ranked lowest amongst performance issues was assay flexibility. The flexibility of an 
assay is defined as the number of targets that can be detected with a single assay. Existing 
immunoassays are single-plex, meaning they are designed to detect one specific target 
protein. DNA profiling kits are multiplex in that they amplify and report on multiple 
regions of DNA at once to provide unique STR profiles [174, 175]. Professional and 
student participants were asked if a hypothetical field-based test should be designed for 
the detection of a single target analyte (single-plex) or able to detect a range of analytes 
(multiplex). Of 30 professional respondents, 80% indicated a preference for multiplexing 
assays. It was noted after data collection that there was no option in this question to 
indicate no preference either way, which may skew responses towards multiplexing as 
this is the option with more utility. A “no preference” option was included in the student 
questionnaire to address this, with the assumption made that student opinions would 
roughly align with professionals as they have previously in the questionnaire. Sixty-four 
percent of student participants preferred a multiplex design, with a near even split 
between single-plex detection or no preference (17% and 18% response, respectively). 
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The high support for a multiplex assay by both groups is expected given the extra utility of 
such a test. Due to the conflict between the intersection of end-users’ open research 
questions (what is the identity of this sample?) and the capacity of existing field-based 
detection tests to only answer closed questions (i.e. is it blood?), a multiplex design 
would allow researchers to have the most flexibility when performing their routine 
analysis work. The potential for multiple closed identification tests to be performed at a 
single time by a multiplex assay would greatly aid in the detection of unknown samples, 
such as unknown body fluids encountered in crime scene investigation. Multiplexing using 
toehold switch networks would be a case of including multiple toehold switches, each 
with a different target and reporter gene in the reaction mixture or substrate. Whether 
this is possible in the in-house system or not will remain to be seen depending on how the 
toehold switch is constructed and the targets being detected.  
 
2.4.3.3. Methodological Issues 
The methodological factors of the test i.e. how tests are used and implemented were 
generally ranked lower than either cost or performance-related issues that might be 
encountered with a novel detection technique (Figure 2.12). 
 




Figure 2.12: Weighted average responses of perceived issues relating to test methodology of 
adopting a novel field-based assay/technique. N = 33 (professionals) and 99 (students). 
 
Unlike other fields, professional and student participants in forensic science identified 
“training required to operate instrumentation/interpret results” as the second and third 
greatest hurdles to test adoption, respectively. There are a number of potential reasons 
for this result. Firstly, forensic practitioners encompass a wide spectrum of end-users 
relative to other fields. This can range from experts in DNA profiling to crime scene 
investigators (CSI) with perhaps a more limited awareness of forensic science but who are 
trained in sample collection and handling. This distinction between end-users has been 
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exacerbated by the closing of the UK Forensic Science Service in 2012 [176], which has 
necessitated forensic analysis to be contracted out to the private sector, or in-house in 
the case of police forces with sufficiently high funds. The development of an assay with 
expert-level knowledge requirements to operate and interpret, but routinely used by 
non-experts or individuals with less training would drastically reduce the practical 
applications of the test, potentially causing commercial failure. As training was identified 
as a significant hurdle for forensic practitioners, it may suggest that this group would be 
more receptive to a user-friendly assay over other fields that did not rank the issue as 
highly.  
Following the required training to operate an instrument, the size of the instrumentation 
itself was identified as the next most problematic hurdle. The ideal for a field-based test 
would be equipment-free as highlighted in the ASSURED guidelines on point-of-care 
testing. However, due to the nature of certain processes that may be involved in sample 
detection such as PCR amplification of genetic template, some equipment may be 
necessary. As mentioned previously, toehold switches can potentially be expressed with 
only a handheld heater. However, there are few examples of commercialised systems 
making use of this technology and their usage has for the most part not been validated in 
low-resource environments [177] where they would provide the most benefit. Given the 
relatively low ranking of this issue amongst participants, it implies that a test that can be 
easily transported and readily deployed in the field is unlikely to face any significant 
hurdles to workflow implementation. 
Quality control concerns ranked on the lower end of issues facing new instrumentation. A 
lack of quality control is defined as lacking a set of pre-prepared standardised 
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experiments using the assay to determine factors such as identifying false 
positives/negatives, limit of detection, cross-reactivity, etc. Although the field listed as 
‘other’ ranked this highly as an issue in both questionnaires, the very low number of 
respondents for this field (n = 3 and 4 for professional and student groups, respectively) 
skews the weighted average higher. Deployment of field-based technology carries issues 
that are not present with laboratory-based testing. Primarily, environmental conditions 
cannot be controlled in the field, and factors such as temperature, light, humidity, etc. 
may all have an impact on assay function that must be accounted for. Additionally, the 
non-sterile environment may increase the chance of sample contamination or co-
collection of contaminations during sample handling and/or transport. This said, the 
overall low concern of participants regarding this issue may imply that end-users would 
circumvent potential quality control issues during in-house validation studies prior to 
introducing the test to routine use. 
Difficult reagent storage was ranked as the second lowest hurdle to adoption of a novel 
test. The vast majority of field-based tests are designed with varied deployment locations 
in mind, and as such dispense with reagents that require specific storage needs, e.g. 
storage at freezing temperatures. Additionally, all testing equipment and reagents may be 
packaged together e.g. immunoassay strips which makes storage and transport of tests 
much easier. Storage of reagents for confirmatory tests are often not considered difficult 
as these are carried out in the laboratory which is expected to have the necessary storage 
spaces and conditions (e.g. -80°C freezers). Taken together, end-users can reasonably 
assume that storage requirements are appropriately accounted for in the development of 
both field- and laboratory-based tests, preventing storage from becoming a major issue in 
their routine use. One of the benefits of paper-based toehold switch testing is the 
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capability for long-term storage at room temperature, eliminating any problematic 
storage requirements. 
Lastly, in both questionnaires, “no issues with the current process” was identified as the 
least problematic hurdle to adoption of a novel technique. This issue was ranked as the 
single lowest issue by the majority of participants (53% in professional questionnaire, 75% 
in student questionnaire). This data implies that given access to a hypothetical novel field-
based test with favourable performance and functionality, end-users would consider it for 
use in their routine sample analysis routine. 
 
2.4.4. Stakeholder Needs in a Novel Field-Based Test 
After assessing stakeholder awareness of the market and determining which factors 
represented the greatest issue to widespread adoption of field-based tests, questionnaire 
participants were asked a series of questions regarding requirements of a hypothetical 
field-based test for use in their field. To determine if there was any market niche to 
adopt, participants were asked if they thought whether a novel field-based test would be 
of routine use to them in their field of study, again on a 5-point Likert scale (Figure 2.13). 
None of the professional participants surveyed thought such a test would be unhelpful, 
with 87.5% of respondents thinking a test would be either somewhat or very useful in 
their routine work. Of the student respondents, 68% thought that such a test would be 
extremely helpful or somewhat helpful, with only 2% thinking a test would be somewhat 
unhelpful, and the remaining thirty percent unsure. The high rate of positive responses 
across fields from both participant groups indicates that there may be a market niche for 
a novel field-based detection test to adopt. 





Figure 2.13: Bar chart displaying student (A) and career professional (B) opinions on the 
helpfulness that a hypothetical novel field-based test in their area may provide.  
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To assess if this market niche had already been filled by existing commercialised tests, 
professional participants were asked if they were aware of existing tests that fit their 
requirements that they currently do not use. Potential responses included definitive 
“yes”, “no”, and “don’t know” answers, but also included additional “no” responses, with 
the caveats “field-based tests do exist but are of inferior quality to existing laboratory-
based tests” or “field-based tests do exist but are too expensive for routine use”. No 
participants responded with a definitive “yes”, whereas 75% percent of respondents were 
unsure if any such field-based tests were available to them, which links back to the gap in 
stakeholder awareness identified earlier. Of the remaining 25% of participants that 
responded “no”, 18.75% responded that existing tests were of inferior quality to existing 
practices, so were not considered for use, while the remaining 6.25% responded with a 
definitive “no”. No participant identified a test that suited their routine testing needs but 
was prohibitively expensive for routine use. This data further evidences uncertainty 
regarding the state of the market around field-based tests amongst questionnaire 
participants, but a small subset identified low performance quality amongst existing tests 
as an issue. This implies that if a high-performance novel field-based test were available in 
the market, it may be considered for use by end-users. 
Although there is evidence from the previous questions to suggest that representative 
end-users would be interested in using a novel field-based molecular detection platform, 
the questions still remains of how the test should aim to function, and which biomarker(s) 
the test should detect. Firstly, participants were asked if they thought a novel field-based 
test should be confirmatory or presumptive in function. Whilst there is no clean 
separation between what makes a test confirmatory versus presumptive, it is generally 
accepted that confirmatory tests possess a higher test accuracy and do not require 
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additional tests for completing sample analysis. Field-based tests are often presumptive 
in nature, due to lower accuracy, sensitivity, or specificity [178, 179]. The majority of 
professional respondents (65%) indicated no preference for test function, with a greater 
proportion of those left over choosing presumptive over confirmatory (22% and 11%, 
respectively) (Figure 2.14). Student participants responded similarly, with 52% thinking a 
novel field-based test should be presumptive, with a quarter of respondents opting for a 
confirmatory test, and the remaining 21% with no preference either way. Almost two-
thirds of healthcare students thought a presumptive test would be more appropriate. This 
fits with current usage, where point-of-care tests are often presumptive and used early in 
patient diagnosis. Together, this data suggests that potential end-users would be willing 
to use a test that has lower performance metrics in exchange for the convenience offered 
by field-based detection. This would suggest that toehold switch sensor design could 
remain simplistic, with circuit function programmed to report a qualitative binary yes/no 
result on target presence.  
 
 




Figure 2.14: Professional (A) and student (B) preference for presumptive or confirmatory function 
from a novel field-based test. N = 35 (professionals), 99 (students).  
 
A key feature of the intended toehold switch detection platform is in the specific 
recognition of DNA sequences with high resolution. Given the lack of sequence 
constraints imposed on the toehold switch’s sensor region, there is a potential to develop 
this test for practically any genetic marker. With the vast array of stakeholders and 
sample types encountered within healthcare and forensic science, focussing the 
development of the assay becomes difficult without end-user feedback. Participants were 
asked which types of sample they thought a novel field-based test should detect. 
Participants were given a list of 22 common sample types (e.g. human/animal body fluids, 
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tissues, etc.) to choose from, with an additional “Other” option where a custom response 

















Figure 2.15 – Tally of participant responses to which sample types should be prioritised in the design of a novel field-based test. Number of student 
participants was 23 for forensics, 41 for healthcare, 6 for policing, and 4 for other. 17 lab-based, 5 field-based, 13 R&D, 2 for other. Responses for the 
“Other” included “drugs/narcotics”, “pathogens in processed food matrices”, compound mixtures in fingermarks”, and “hormones in animal body fluids”. 
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Broadly, sample types were separated into three categories – Human samples, non-
human animal samples, and plant/environmental samples. Across groups, there was 
roughly equal support for a test that would detect either environmental or animal 
samples, with 188 and 153 total responses for these categories, respectively. However, 
cross-field support for human sample detection by both professionals and student 
participants was much greater, with a total of 542 responses. Of these sample types, 
mixed human body fluids and human DNA received the most support, both with 85 
responses. These were followed by neat human body fluids, human tissues, pathogens in 
human body fluids, and human DNA mixtures (72, 67, 66, and 71 responses respectively). 
High support for mixed body fluids and total human DNA suggests that end-users are 
looking for a platform that can be used in the initial stages of DNA detection that may be 
encountered in forensic casework or patient diagnosis. This would fit well with the nucleic 
acid detection capabilities of a toehold switch network. During initial DNA detection, 
research questions shift from specific questions regarding identity, to more general 
diagnostic questions such as “how much DNA is present?” or “is the sample mixed-
source?”. This supports the development of a forensic sex identification test for 
presumptive use as the quantitative detection of male and autosomal markers would 
enable both questions to be answered simultaneously. This would require the output of a 
toehold switch system to directly or indirectly assess DNA quantity, which would depend 
on circuit readout.   
In addition to test function, participants were asked to select which method of result 
delivery would be most preferable in a novel field-based test. Participants were presented 
with the choice of visual detection (i.e. a qualitative visible colour change or appearance 
of a test band) or detection of target analyte by the instrumentation (i.e. quantitative 
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readouts of % sequence similarity to target sequence, etc.) followed by either manual or 
automatic interpretation of the result (Figure 2.16). Respondents could choose more than 
one option.  
  
Figure 2.16: Professional (A) and student (B) respondent opinions on the most preferable form of 
assay readout method. N = 38 (professionals) and 99 (students). 
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When separated by role, there was equal support amongst professionals for both visual 
and instrument-based detection methods. Overall, automatic interpretation of assay 
result was more popular than manual for both qualitative and quantitative assay readout 
strategies, fitting with the readout strategies of existing techniques identified in the 
assessment of current test usage. One of the primary benefits of automatic interpretation 
is that it reduces the knowledge requirement to perform the test. A visual cue for assay 
completion coupled with automatic interpretation of the result would have enable the 
widest variety of end-users to employ the assay. Although simpler to handle, calibration 
of any associated instrumentation as part of internal validation studies prior to 
implementation would be required by the end-user’s laboratory or working group to 
obtain reliable and robust results from an automated system.  
A subset of participants in both questionnaires expressed support for a system that 
utilises manual result interpretation. A possible reason for this result even when 
participants are presented with a more user-friendly approach is that the final 
interpretation of results in the fields of forensics and healthcare can have profound 
impact on casework resolution or patient diagnosis and treatment. Automating this 
process can increase the speed at which testing is performed, but manual interpretations 
allows for any potential errors to be identified and corrected prior to moving forward 
with downstream processes. Visual detection of assay result has already been 
demonstrated with paper-based toehold switches utilising LacZ metabolism of paper-
embedded substrate to elicit a colorimetric change [17]. Automatic interpretation of this 
change may be more complicated to implement, but may be possible by coupling the 
colour-change with a camera module from a miniature low-cost Raspberry Pi computer as 
an imaging sensor to obtain quantitative data [180, 181]. Such a feature would be part of 
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the late optimisation process, but colorimetric approaches to result delivery can be 
implemented early in response to this need.  
Lastly, student participants were asked a question regarding how a novel confirmatory 
field-based test should compare against existing laboratory-based confirmatory tests. The 
intent of this question was to determine if end-users would accept lower performance 
metrics e.g. sensitivity/accuracy in a field-based test given the convenience of their 
increased workflow speed and broader usage contexts. Participants were provided with 
three statements and asked to pick which one they most agreed with. These statements 
were “both tests should perform to the same standards”, “the field-based test should not 
be as sensitive/specific as the lab-based test”, and “the lab-based test should not be as 
sensitive/specific as the field-based test” (Figure 2.17).  
 
Figure 2.17: Student participant responses when asked how a novel confirmatory field-based test 
should compare to equivalent laboratory-based techniques.   
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Over three-quarters of participants thought that both the field- and lab-based should 
perform at the same standards of performance. This is likely because as both tests are 
confirmatory, end-users consider them to have high accuracy and should be as similar as 
possible in function. Of the remaining participants, 18% felt that the field-based test 
should have lower performance, with 5% thinking the lab-based test should be less 
sensitive/specific as the field-based test. This data suggests that a minority of users would 
accept lower performance in a field-based test. This is consistent with both the high 
ranking of accuracy and sensitivity as important hurdles to adoption of new techniques by 
both groups, and the answers regarding ideal test accuracy provided by professional 
participants. While this question provides insight into end-users’ expectation of 
confirmatory tests regardless of where they are deployed, the preference displayed for a 
novel field-based test to be presumptive in nature leads towards more modest accuracy 
and sensitivity metrics for in-house assay design.  
 
2.5. Summary 
The aim of the market research was to assess the state of the market surrounding field-
based bio-detection techniques, and to provide a definition of novel test function. The 
questionnaire enabled fulfilment of the research objectives outlined in Table 2.1, such as 
assessment of end-user satisfaction with existing techniques, market niche for a novel 
field-based test, and ideal features and functions of such an assay. From the market 
research, there is evidence to suggest that end-users would be interested in adopting a 
novel field-based test that meets their detection needs. Taking the survey data into 
account, it is possible to map these overall needs of end-users onto a hypothetical field-
based test, which can be utilised as developmental drivers (Table 2.2). 




Table 2.2: Ideal parameters for novel field-based detection assay function as identified by 
questionnaire participants.  
Assay Factor Ideal End-User Needs 
Functionality Presumptive 
  




Flexibility Multiplexing capability 
  
Detection target Human body fluids, human DNA (neat/mixed), pathogens in human body 
fluids 
  
Time-to-Result 10 - 30 minutes 
  
Assay Readout Visual detection, automatic interpretation 
 
There is precedent in the literature to expect that each of these needs can be met with a 
toehold switch synthetic gene network detection assay as outlined in the relevant 
sections of the above discussion. The selection of mixed human DNA and human body 
fluids as key biomarkers would suit toehold switch detection well to forensic science and 
particularly sex identification, which routinely encounter these sample types early in the 
detection workflow. It should be noted that certain aspects of ideal assay functions 
identified here (e.g. multiplex detection, time-to-result) can only be realised at later 
stages of development after test function has been demonstrated in-house using existing 
protocols. While the survey results themselves did not provide the initial idea to use 
toehold switches as this came earlier during background reading, the results align well 
with this idea and justify further study.   
Following on from this research, the most appropriate course of action would be to assess 
existing techniques for forensic human DNA detection to act as benchmarks for 
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performance before beginning development of toehold switch sensors in-house that are 
specific to human body fluids. Market research should be returned to at key stages of the 
assay development cycle with a refined set of questions, enabling iterative development 
of the assay based on end-user responses. Any future market research should include a 
larger sample size to offset any bias that may have been introduced to respondent 
answers as a result of small sample size. 




Benchmarking Existing Techniques for DNA Detection 
3.1. Abstract 
The previous chapters identified that toehold switch networks could potentially be a 
useful tool for field-based forensic identification and that there is an unfilled market niche 
for novel field-based forensic assays for human DNA from body fluids that is rapid, 
sensitive, specific, and cheap. Together, these findings justify the development of an in-
house toehold switch network for human body fluid and sex identification markers. 
Performance benchmarks from existing assays should be utilised to guide development of 
an in-house toehold switch sensor to ensure that assay performance meets all 
developmental drivers and is fit for application. For this process to be most efficient, the 
assay used for benchmarking should be relevant to the assay under development. 
Quantitative PCR approaches were deemed most suitable as they are high-performance, 
DNA-based, and act as one of the earliest indicators of sample donor sex in the forensic 
workflow.  
A series of validation studies was performed on a commercial quantitative PCR kit 
(Investigator® Quanitplex® Prog RGQ, Qiagen), in pre-release phase at the time of testing. 
The validation series consisted of a structured beta test arranged by the manufacturer and 
a series of independent studies where kit accuracy, sensitivity, and specificity for 
autosomal and male-specific DNA was validated when using neat, male:female mixed, and 
degraded DNA template. Kit performance was compared against two existing 
quantification kits, the PowerQuant® System and Plexor® HY kit.  
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Results showed that pre-prepared beta test samples were quantified accurately by the kit, 
concurring with the manufacturer’s specifications regarding their formulation. 
Independent validation studies how no significant difference in the accuracy and 
sensitivity of quantification between the Investigator® Quantiplex® Pro RGQ kit and the 
Promega PowerQuant® System, both detecting the lowest amount of DNA tested, 4 pg. 
Conversely, non-amplification was observed at lower template quantities when using the 
Plexor® HY kit. Laboratory-controlled mixture studies demonstrated male DNA 
quantification values down to a male:female DNA ratio of 1:1000 in 500 pg template. 
Analysis software appropriately flagged mixed and degraded DNA samples that were 
prepared in excess of their detection thresholds. The Quantiplex® Pro RGQ kit is 
demonstrated to be significantly more tolerant to PCR inhibition than the Plexor® HY kit, 
able to amplify DNA in the presence of up to 500 ng/µL humic acid and 2000 µM hematin. 
STR analyses of laboratory-controlled sensitivity, mixture, and degradation studies 
supports the quality metrics obtained from quantification. 
Taken together, the validation studies provide useful performance benchmarks to act as 
drivers for in-house toehold switch development, providing data related to kit 
performance within forensically relevant restrictions such as low template, inhibited, and 
degraded DNA.  
 
3.2. Introduction 
The aim of forensic investigation is to collect, analyse, and present biological evidence in 
service of resolving a crime by identifying suspects. The biological evidence in question 
takes a number of forms such as fingerprint identification or blood spatter analysis, but 
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the primary target of forensic crime scene investigation with the strongest scientific 
foundation in legal proceedings is DNA evidence [182]. DNA is present in the cells of all 
living organisms and can be extracted from body fluids through various methods to 
prepare template for quantification [183-185]. Extracted DNA can also be used for STR 
analysis, which can match biological evidence to an individual as a suspect in a crime 
[186].  
The identification of human DNA from body fluids as a primary target for a novel field-
based test by market research participants (see Chapter Two) therefore fits very well with 
development of a toehold switch assay (see Figure 1.3) for forensic detection purposes. 
While market research participants also highlighted a preference for presumptive testing 
of targets, there are few suitable comparisons to be made amongst existing presumptive 
body fluid and sex determination tests to toehold switches, as these tests are often in the 
form of immunoassays for proteins and antigens rather than DNA [140]. For toehold 
switch assay development to proceed optimally, an understanding of existing forensic 
techniques for DNA detection and their strengths and limitations must be developed so 
that a novel assay can either supplement the data obtained from these techniques or 
replace them outright.  
The primary forensic method by which the presence of DNA is confirmed in a sample is 
through quantitative PCR, which amplifies DNA and quantifies the amount via comparison 
to a standard of known DNA concentration [187, 188]. Early qPCR kits utilised DNA 
intercalating dyes as a measure of DNA quantity, however intercalating dyes will also 
fluoresce in the presence of primer-dimers and other non-target double-stranded DNA 
[189]. This can over-estimate sample DNA quantity which has implications for further 
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processing of the sample [190], and non-target amplification is particularly an issue at low 
template input concentrations [191]. In addressing this issue, molecular biologists 
developed qPCR kits that will produce fluorescence only when a specific region of DNA is 
present. This is achieved by the inclusion of short, 5’ fluorescently-labelled 
oligonucleotide probes that are complementary to a specific genomic region [192]. 
Fluorescence of these probes is not constitutive, rather they contain a quencher at the 3’ 
end of the sequence that prevents reporter fluorescence even after annealing of the 
probe to the target sequence. It is only once PCR proceeds to the extension stage and the 
DNA polymerase enzyme reaches the hybridised probe that the polymerase’s 5’ to 3’ 
exonuclease activity cleaves the fluorophore from the probe away from the quencher, 
producing fluorescence. Attaching different fluorophores to different probes allows for 
multiple regions of DNA to be amplified and individually measured in a single qPCR 
reaction. This principle has been applied to forensic science by amplifying DNA regions of 
significance to forensic investigation. For example, sex identification can achieved by 
amplification of sequences that differ between sexes such as amelogenin [193]. In qPCR, 
the differential amplification of Y-specific and autosomal markers between sexes (e.g. no 
amplification of the Y-specific target should be observed in single-source female samples) 
informs the forensic scientist on the sex of the individual(s) that deposited the sample 
[194]. This quantification step is one of the first reliable indicators of donor sex. 
Commercial manufacturers of forensic qPCR kits have made further advancements with 
the inclusion of multiple probes of different lengths for the same forensic markers in their 
proprietary reaction mixtures [195]. Longer probes more susceptible to degradation than 
short probes and so quantification reduction and dropout is observed earlier. The relative 
difference in quantification between both probes allows more information to be obtained 
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from a single sample, providing the end user with data regarding the samples quality 
alongside typical quantity data  [196-199]. This can help to prioritise samples for further 
processing or aiding in troubleshooting where DNA of sufficient quantity is incapable of 
generating a complete or partial STR profile. Quantitative PCR is a laboratory-based 
technique which as mentioned previously requires sample transport and can be time-
consuming and laborious to perform. The development of a toehold switch assay that can 
reliably detect the presence of DNA from samples at the crime scene would therefore act 
to streamline the DNA detection workflow and reduce the number of unsuitable samples 
sent for processing.  
Assay development consists of several stages such as identifying practical applications of a 
biological component, generating proof of concept data, developing prototypes, etc. 
Typically at the midway and end points of these production timelines, validation data is 
generated for both individual components and wider systems [14]. Validation data serves 
to ensure that the platform works in the way it is intended to. While in-house validation 
studies will be performed by the manufacturer of a given system during development, 
independent third-party validation studies performed by the scientific community (most 
often the end users of the system being validated) are necessary to verify any claims 
regarding performance. In addition, these independent validations may provide 
experimental data for the usage of the system in different biological contexts. The benefit 
of validating a pre-existing commercial system that is approaching full release is two-fold: 
firstly, validation of the manufacturer’s claims provides a service to the scientific 
community who will use this system; and secondly, metrics are obtained that allow for 
easy comparison in the performance of the in-house sex identification DNA detection 
assay against a leading commercial system. To this end, the QIAGEN Investigator® 
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Quantiplex® Pro RGQ kit [175] was validated, which is a qPCR kit for the detection of both 
total and Y-specific (male) DNA in a sample. This kit was chosen for its novelty as it was in 
pre-release at the time of writing, and would be expected to provide the highest 
performance of commercial qPCR kits currently available. The Quantiplex® Pro RGQ kit 
also supports the detection of mixed and degraded DNA. These metrics are important to 
benchmark as template target DNA from a body fluid is likely present as part of a mixture 
of other markers, or be degraded after deposition. With regards to mixed-source DNA in 
particular, information regarding a commercial kit’s limit of detection for male DNA 
against a majority female background is a crucial metric for the purposes of sex 
identification. Assessing the activity of the Quantiplex® Pro RGQ kit with low-quality DNA 
template (i.e. DNA that is highly degraded or contains PCR inhibitors) will give some 
indication as to how the in-house DNA detection platform will perform when using real-
world samples that are likely to be degraded or co-collected with inhibitors as is common 
in forensic casework [200]. As part of the validation process of a novel kit, it is necessary 
to perform a side-by-side comparison against existing standard practice. Two additional 
commercially available qPCR kits were included in the validation studies, Plexor® HY and 
the PowerQuant® System (Promega). Both kits quantify total autosomal and male DNA 
within a sample, and the PowerQuant® kit contains an additional autosomal target for the 
assessment of autosomal DNA quality. Metrics tested included sensitivity, accuracy, 
inhibitor tolerance, mixture detection and degradation detection using both control DNA 
samples prepared under laboratory-controlled conditions, and DNA samples extracted 
from volunteers. Results are discussed in context of other qPCR kits as well as whether a 
forensic toehold switch assay would be an appropriate alternative method for 
confirmatory DNA detection or if their function should be presumptive.   
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3.3. Materials and Methods  
Prior to the commercial release of the Quantiplex® Pro RGQ kit, Qiagen invited LJMU to 
take part in a beta testing event. As part of this event, Qiagen provided test kits and DNA 
samples intended to demonstrate the kit’s performance with a variety of DNA template 
types, including inhibited and degraded DNA.  In addition to this beta test, five key 
validation parameters of the Quantiplex® Pro RGQ kit were independently assessed in-
house using independently sourced DNA samples: standard curve reproducibility, 
sensitivity, mixture analysis, degradation analysis, and inhibitor tolerance. All parameters 
were compared against the PowerQuant® System and/or Plexor® HY kits (both Promega) 
as commercial equivalents using control DNA of known concentrations under laboratory-
controlled conditions. A further study was performed using only the Quantiplex® Pro RGQ 
kit that used casework samples for mixture analysis. Representative samples from each 
study were further processed by STR profiling using the Investigator® 24plex QS kit 
(Qiagen) to determine if quality calls by each kit’s analysis software (e.g. 
degraded/inhibited) has any impact on the clarity of resulting STR profiles. All DNA 
samples for in-house studies were either sourced commercially or taken from volunteers 
with ethical approval.  
 
3.3.1. Qiagen Beta Test 
Qiagen provided two Quantiplex® Pro RGQ 200X test kits along with unquantified DNA 
samples for analysis. These samples were reported as being un-degraded male DNA; 
degraded male DNA (300 bp and 150 bp degraded); mixtures of male:female DNA (ratios 
1:200,000, 1:400,000, and 1:1,000,000) and degraded male:intact female DNA (ratios 1:4 
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and 1:5000). Seven additional samples were prepared with the undegraded male DNA 
sample and PCR inhibitors of varying concentrations, also provided by Qiagen. Samples 1-
3 mixed 10 µL of undegraded male DNA with 10 µL of humic acid at 500, 660, or 800 
ng/µL concentration, respectively. Samples 4-6 mixed 10 µL of undegraded DNA with 10 
µL of 2500, 3000, or 4000 µM hematin, respectively. Lastly, sample 7 mixed 10 µL of 
undegraded DNA with 10 µL of dilution buffer included with the Qiagen kit as a control. 
The eight DNA samples and seven DNA-inhibitor/buffer mixtures were quantified in 
duplicate on a Rotor Gene Q using the quantification protocol described below. 
 
3.3.2. Quantification Accuracy Studies 
The first set of independent studies assessed standard curve reproducibility and 
sensitivity.  Study One assessed the manufacturers’ claim that either a four- or a seven-
point standard curve would provide reliable quantification for the Quantiplex® Pro RGQ 
and PowerQuant® quantification kits. In this study, three independent replicate standard 
curves were generated using four DNA standards (Quantiplex standard concentrations – 
50 ng/µL, 1.8519 ng/µL, 0.0686 ng/µL, and 0.0025 ng/µL; PowerQuant standards – 50 
ng/µL, 2 ng/µL, 0.08 ng/µL, 0.0032 ng/µL) and seven standards (Quantiplex standards – 
50 ng/µL, 10 ng/µL, 2 ng/µL, 0.4 ng/µL, 0.08 ng/µL, 0.016 ng/µL, and 0.0032 ng/µL; 
PowerQuant standards – 50 ng/µL, 10 ng/µL, 2 ng/µL, 0.4 ng/µL, 0.08 ng/µL, 0.016 ng/µL, 
and 0.0032 ng/µL). The Plexor® HY kit recommends the use of no fewer than a seven-
point standard curve (50 ng/µL, 10 ng/µL, 2 ng/µL, 0.4 ng/µL, 0.08 ng/µL, 0.016 ng/µL, 
and 0.0032 ng/µL) so four-point curves were not generated for this kit. Regression 
analyses for each data set were performed both between kits and within the Quantiplex® 
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Pro RGQ standards. Study Two assessed the sensitivity and quantification accuracy of 
autosomal and Y-target DNA by the Quantiplex® Pro RGQ, PowerQuant®, and Plexor® HY 
kits using commercially sourced female and male DNA of known concentration (Promega 
Corporation; G1471 and G1521, respectively). Six independent replicates at each input 
concentrations (250, 50, 10, and 2 pg/µL) were quantified. Box-and-whisker plots were 
generated by comparing observed quantification values against the expected 
quantification value.  
 
3.3.3. Laboratory-Controlled Mixture, Inhibition, and Degradation Studies  
The second set of studies used previously quantified volunteer DNA to prepare a series of 
male:female mixtures and male degraded samples from commercially-sourced DNA 
(Promega Corporation G1521). Study Three assessed the ability of Quantiplex® Pro RGQ, 
PowerQuant®, and Plexor® HY kits to detect male DNA contribution to a majority female 
DNA sample. Using genomic male and female DNA at 0.5 ng/µL concentrations, 
male:female mixtures were prepared at 1:1, 1:25, 1:50, 1:500, and 1:1000 ratios. Unmixed 
male and female samples were also quantified at 0.5 ng/µL. Three independent replicates 
at each mixture ratio were quantified with each kit. Ratios of male:female DNA 
quantification values were calculated and compared to the manufacturers default mixture 
detection metrics (Quantiplex® Pro RGQ 1:2 Y:autosomal mixture flag; PowerQuant® 1:2 
Y:autosomal mixture flag). The Plexor® HY kit calculates an [Autosomal]/[Y] target ratio 
but interpretation of mixture status is performed manually, instead the software provides 
recommendations for processing the sample further with either Auto- or Y-STR profiling. 
Study Four used DNA degraded under laboratory-controlled conditions. Male DNA 
(Promega G1521) was diluted to 5 ng/µL in amplification grade water in a total volume of 
Chapter Three – Validation of qPCR Assay 
125 
 
120 µL. This DNA sample was sonicated at 35 kHz for 1 hour using a Bandelin Sonorex RK 
31 sonicator. Twelve microlitres of DNA was removed from the sample prior to sonication 
(t=0) and again at 1, 10, 30, and 60 minutes into the sonication procedure. After 30 
minutes of sonication, the sonicator was turned off for 5 minutes and the water replaced 
in order to prevent excess heat from sonication from causing additional unintended 
sample degradation. Degradation of samples was confirmed by running 5 µL of sonicated 
DNA on a 2% TBE ethidium bromide stained agarose gel. Degraded DNA samples were 
diluted to 0.25 ng/µL and 25 pg/µL and quantified using PowerQuant® and Quantiplex® 
Pro RGQ kits. Ratios of high (HMW) and low molecular weight (LMW) DNA were 
calculated and compared against the manufacturers default Degradation Index (DI) 
metrics (Quantiplex® Pro RGQ 1:10 HMW:LMW degradation flag; PowerQuant® 1:2 
HMW:LMW degradation flag). The Plexor® HY kit does not contain markers for the 
assessment of DNA quality so was not included in this study. Study Five assessed kit 
tolerance to PCR inhibitors. Humic acid and hematin were mixed with 250 pg/µL control 
DNA at increasing concentrations (humic acid – 250 and 500 ng/µL; hematin 1000 and 
2000 µM) prior to initiating qPCR. Extent of inhibition was assessed by measuring the 
deviation of sample threshold cycle in the IPC channel from the expected threshold for 
uninhibited samples. The PowerQuant® kit contains a TMR dye-labeled probe for the 
detection of the kit’s internal PCR control. The Rotor Gene Q thermal cycler used for all 
qPCR work does not contain a fluorescent channel that can detect around the maxima for 
this dye, and as such any data for this target is unreliable and cannot be used in this study. 
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3.3.4. Mock Casework Mixture Study 
An additional study was carried out using only the Quantiplex® Pro RGQ kit. This study 
used DNA extracted from mock casework samples as an assessment of how the kit 
performs when using DNA collected in the field. Study Six prepared mixed, mock sexual 
assault samples by spiking male volunteer seminal fluid onto female volunteer buccal 
swabs. Seminal samples and buccal swabs were collected following standard methods and 
were stored in the fridge overnight prior to spiking. Three independent replicate samples 
were prepared for each dilution series to represent a range of mixtures (neat seminal fluid 
at 50 µL, 5 µL, 1 µL, 0.1 µL spiked onto a female buccal swab). After spiking, the swabs 
were subject to RSID testing [201] and DNA extraction was performed on the remaining 
solution using the DNeasy Blood and Tissue kit (Qiagen) [202] before undergoing 
quantification to assess the kit’s ability to detect mixtures.  
 
3.3.5. Quantification and STR Analysis Protocols 
All thermal cycling was carried out using a Rotor Gene Q 5Plex HRM Instrument running 
Q-Rex Software v1.0 with a 20 µL standard sample reaction size. Reaction mixtures for 
Quantiplex® Pro RGQ, Plexor® HY, and PowerQuant® reaction mixtures were assembled 
according to manufacturer’s specifications (Quantiplex Pro RGQ kit – 9 µL Quantiplex Pro 
RGQ Reaction Mix, 9 µL Quantiplex Pro RGQ Primer Mix; Plexor® HY – 10 µL Plexor® HY 2X 
Master Mix, 7 µL amplification-grade water, 1 µL Plexor® HY 20X Primer/IPC Mix; 
PowerQuant® System - 10 µL 2X MasterMix, 7 µL amplification grade water, and 1 µL 20X 
Primer/Probe/IPC Mix). Two µL of either control DNA standard, sample DNA, or 
amplification grade water as a negative control was added to mixtures as appropriate. 
Samples processed with the Quantiplex® Pro RGQ kit used the manufacturers 
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recommended cycling and fluorescence acquisition settings as specified in the technical 
manual (3 minute 95°C initial activation, followed by two-step cycling of 5 s denaturation 
at 95°C and 10 s annealing/extension at 60°C for 40 cycles). Post-qPCR processing of all 
samples was carried out for each fluorescent channel on the RGQ according to the 
manufacturer’s default guidelines (Table 3.1) prior to exporting quantification reports for 
analysis in Microsoft Excel or the Qiagen Data Handling Tool [203]. 
 
Table 3.1: Fluorescent channel processing settings on the Rotor-Gene Q Absolute Quantification 
HID plug-in 
Parameters Green Yellow Orange Red Crimson 





















Use noise slope correction 
Ignore first cycles 
Adjust take-off points 
If take-off point 


























































Thermal cycling of samples processed with the Plexor® HY kit followed the protocol in the 
kit handbook (2 minute initial denaturation at 95°C, followed by 5 s denaturation at 95°C 
and 35 s annealing/extension at 60°C for 38 cycles). The PowerQuant® system, which is 
not optimised for use with the Rotor-Gene Q cycler, was set up using a custom template 
file provided by the manufacturer (Promega Pers. Comm.). This template uses the thermal 
cycling parameters lifted from the PowerQuant® System Technical Manual (2 minutes 98°C 
hold, followed by 39 cycles of 98°C for 15 seconds and 62°C for 35 seconds. Fluorescence 
data was acquired each 62°C stage). Fluorescence data for the autosomal, male, 
autosomal degradation, and internal PCR control targets were collected from the RGQ 
green, yellow, red, and orange channels, respectively. The passive CXR reference dye 
captured by the PowerQuant® System Post-qPCR, raw sample data was analysed using the 
Q-Rex Absolute Quantification HID plug-in. PCR threshold values (0.05) and threshold start 
cycle (5) were set according to manufacturer’s specifications. After analysis, all kit data 
were exported from the Q-Rex software into Microsoft Excel to prepare graphs and 
calculate mixture/degradation ratios.  
STR profiling was performed using the Investigator® 24plex QS kit [204] at 10 µL total PCR 
reaction volume. DNA from representative samples of each in-house study were added to 
each PCR reaction at the concentrations specified in the methods above. Thermal cycling 
was performed according to the manufacturer’s guidelines on a T100™ Thermal Cycler 
(BIO-RAD) (Table 3.2). Capillary electrophoresis was performed using a SeqStudio Genetic 
Analyser (Applied Biosystems). PCR samples were prepared for analysis by mixing 1 µL of 
amplified DNA (diluted 1:10 with DNA-grade water) with 12 µL of a formamide and 0.5 µL 
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DNA size standard 24plex (BTO) mixture. Default instrument and quality control protocol 
parameters for fragment analysis were used as recommended by the Investigator® 24plex 
QS handbook [205], with a 7 second sample injection time. STR profiles were briefly 
reviewed and reinjected with a 30 second injection time if small profiles were obtained. 
Sample data was imported into GeneMapper 6 software [206]. Samples were analysed 
using a custom pre-optimised Investigator 24plex QS allele bin provided by Qiagen. Alleles 
were sized against a BTO size standard. After automatic sizing and allele calling of samples, 
allele calls were checked manually, and any peaks thought to be erroneous (i.e. 
indistinguishable from noise or stutter peaks) were deleted. For each of the six dye sets, 
RFU data was tabulated and exported to Microsoft Excel to prepare graphs. 
 
Table 3.2: Thermal cycling protocol used for PCR of all DNA samples prior to STR profiling.  

















68°C 2 min - 
60°C 2 min - 
10°C ∞ - 
 
 
Chapter Three – Validation of qPCR Assay 
130 
 
3.4. Results and Discussion 
3.4.1 Beta Test Results 
The ability to accurately quantify the amount of DNA recovered from a crime scene 
sample is a key requirement for forensic quantification kits. To ensure that each new kit 
iteration fulfils basic criteria developers routinely publish developmental validation 
studies and invite participants to take part in beta testing to assess end-user experiences 
and generate feedback prior to commercial launch. Such beta testing typically involves 
the analysis of unknown and pre-prepared samples with additional independent testing 
providing some impartial oversight to the commercial narrative. This study tested a novel 
quantification kit from Qiagen and measured its performance against an equivalent 
commercial kit. The data provided in Table 3.3 shows the results from the beta test 
samples provided by Qiagen. Broadly speaking, the data generated concurs with prior 
expectations regarding quantification. With increasing degradation of male DNA (Table 
3.3, DNA 1-3), autosomal and Y-target quantification values decrease. This is expected 
due to the smaller amount of quantifiable DNA remaining in the sample due to 
degradation [207]. As degradation increases, the human and male degradation indices 
calculated by the Qiagen Data Handling Tool software also increase, although this is not 
linear, and the male degradation index reaches a greater value than the human 
degradation index. There is no significant change in the inhibition index for these 
samples, which suggests there was no inhibition of qPCR and that only the quality of the 
DNA was affected by degradation. Ratios of autosomal and Y amplification are broadly 
equal in male samples while the male/female DNA mixtures (Table 3.3, DNA 4-6) provide 
quantification ratios of human and male DNA that are similar to the mixture ratio they 
were supplied as. In the mixtures containing degraded male DNA (Table 3.3, DNA 7 & 8), 
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autosomal to Y-target DNA quantification ratios for 1:5000 and 1:4 give ratios of 1:10,000 
and 1:11, respectively. This means that male contribution to a sample is underestimated 
by a factor of 2. However, male DNA is still able to be quantified, and the quality of this 
DNA is properly captured by the resulting high male degradation index (DNA 8). With 
both replicates of DNA 7 (degraded male:female 1:5000), a result of “not applicable” was 
obtained for the male degradation assessment, due to an undetermined threshold cycle 
for the male degradation target. As the only difference between this sample and DNA 8, 
where a male degradation index was calculated, should be the proportion of female DNA 
present, it suggests that the limit of detection of male DNA has been reached. As there is 
no associated increase in autosomal degradation index in the degraded male/female 
mixtures, the process has accurately captured the quality metrics of the sample by 
flagging the female-source DNA as intact. As expected, increasing concentrations of 
humic acid and hematin are associated with an increasing delay in IPC target threshold 
cycle. Every sample containing inhibitors (sample 1-6) have inhibition index scores above 
the default threshold value for detecting sample inhibition by the Qiagen Data Handling 
Tool (≥1 IPC Ct difference), and the increasing indices accurately reflect the increasing 
level of sample inhibition. Lastly, the 1 in 2 dilution of intact male DNA with nucleic acid 
dilution buffer (sample 7) provides an autosomal and Y-target quantification value 
roughly half of that of the intact male DNA alone. Consequently, the samples provided by 
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Table 3.3: Mean quantification and inhibition/degradation indices obtained from Qiagen beta test samples processed in duplicate. 
DNA 1 Undegraded male DNA 0.31 0.36 16.65 -0.08 0.94 1.04
DNA 2 Male DNA 300bp degraded 0.21 0.20 16.61 -0.04 7.29 6.48
DNA 3 Male DNA 150bp degraded 0.19 0.19 16.62 -0.05 180.75 284.87
DNA 4 Male / female 1:200,000 117.37 0.0008 16.45 0.12 1.19 1.69
DNA 5 Male / female 1:400,000 86.52 0.0004 16.39 0.18 1.11 0.94
DNA 6 Male / female 1:1,000,000 178.83 0.0003 16.37 0.20 1.13 0.81
DNA 7 Degraded male / female 1:5000 165.50 0.02 16.25 0.32 1.12 N/A
DNA 8 Degraded male / female 1:4 0.34 0.03 16.58 -0.02 1.22 271.50
Sample 1 10 µl DNA 1 + 10 µl Humic Acid 500 ng/µl 0.18 0.18 18.42 -1.85 0.93 0.96
Sample 2 10 µl DNA 1 + 10 µl Humic Acid 660 ng/µl 0.19 0.19 19.92 -3.36 1.01 1.17
Sample 3 10 µl DNA 1 + 10 µl Humic Acid 800 ng/µl 0.18 0.12 24.64 -8.08 1.30 1.56
Sample 4 10 µl DNA 1 + 10 µl Hematin 2500 µM 0.16 0.18 17.74 -1.13 0.90 1.12
Sample 5 10 µl DNA 1 + 10 µl Hematin 3000 µM 0.16 0.19 18.25 -1.68 0.95 1.18
Sample 6 10 µl DNA 1 + 10 µl Hematin 4000 µM 0.10 0.07 37.49 -20.93 3.68 N/A
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3.4.2. Quantification Accuracy 
3.4.2.1. Study One 
Both the Quantiplex® Pro RGQ and PowerQuant® kits recommend the use of four 
standards when generating a standard curve to estimate the concentration of unknown 
samples. This is fewer than recommended by other kits [208, 209] and may have a 
negative impact on the linearity of the standard curve if one of the standards is 
incorrectly prepared, causing a high leverage data point. As such, the first point of kit 
validation is to assess this claim from the manufacturers that a four-point DNA standard 
curve provides the same quantification accuracy as a seven-point curve. Average standard 
curve slope equations and R2 values were calculated for each kit at four and seven DNA 
standards (excluding Plexor® HY). The results averaged results of each curve are 
presented in Table 3.4. Regression analysis using Minitab 19.2 software [210] showed no 
significant difference in the y-intercept for the autosomal marker (P = 0.949), the male 
marker (P = 0.744), and the autosomal degradation marker (P = 0.999) between the 
Quantiplex® Pro RGQ and PowerQuant® kits when seven standards were used, suggesting 
that both kits are capable of accurate quantification of both autosomal and male 
components. Performing a regression analysis of Quantiplex® Pro RGQ and Plexor® HY 
kits also showed no significant difference in the y-intercept when four or seven 
Quantiplex standards were used compared against the Plexor® HY kit at seven standards 
for both the autosomal (seven standards P = 0.621, four standards P = 0.605) and male 
(seven standards P = 0.744, four standards P = 0.770) markers. Crucially, there were no 
significant differences in the y-intercept for the autosomal marker (P = 0.961), the male 
marker (P = 0.983), the autosomal degradation marker (P = 0.824) and the male 
degradation marker (P = 0.9049) for the Quantiplex® Pro RGQ kit when either four or 
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seven standards were used, suggesting that four standards can be used to generate a 
standard curve without reducing data quality. 
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Table 3.4: Amplicon size and standard curve metrics for Quantiplex® Pro RGQ, PowerQuant®, and Plexor® HY DNA quantification kits. 
 
 
Slope Intercept R2 Slope Intercept R2
Autosomal (91 bp) -3.25 ± 0.05 22.37 ± 0.20 0.99  ± 0.00 -3.32 ± 0.07 22.90 ± 0.07 0.99 ± 0.00
Male (81 bp) -3.28 ± 0.09 22.06 ± 0.32 0.99  ± 0.00 -3.32 ± 0.04 22.30 ± 0.10 0.99 ± 0.00
Auto Deg. (353 bp) -3.30 ± -0.17 21.65 ± 0.39 0.99  ± 0.00 -3.24 ± 0.13 22.97 ± 0.34 0.99 ± 0.00
Male Deg. (359 bp) -3.37 ± 0.07 21.17 ± 0.67 0.99 ± 0.00 -3.42 ± 0.13 22.05 ± 0.16 0.99 ± 0.00
Autosomal (84 bp) -3.31  ± 0.09 21.88  ± 0.03 0.99  ± 0.00 -3.31 ± 0.06 21.87 ± 0.06 0.99 ± 0.00
Male (81 & 136 bp) -3.03  ± 0.10 22.75  ± 0.08 0.99  ± 0.00 -3.06 ± 0.01 22.80 ± 0.06 0.99 ± 0.00
Auto Deg. (294 bp) -3.25  ± 0.07 22.74 + 0.22 0.99  ± 0.00 -3.26 ± 0.01 22.50 ± 0.34 0.99 ± 0.00
Autosomal (99 bp) N/A N/A N/A -3.66 ± 0.22 25.12 ± 0.24 0.99 ± 0.01






Repeatability with Four Standards 
(Mean ± 1SD)
Repeatability with Seven Standards 
(Mean ± 1SD)Quantification 
Kit
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While the purpose of qPCR kit validation in this thesis is to benchmark performance of an 
existing gold-standard confirmatory technique for DNA detection, the function of the kit 
can also be examined to identify useful features to be integrated into a novel assay. While 
toehold switch assays are typically configured to output qualitative data (e.g colour 
changes), the use of standard curves may enable quantitative data to be drawn from the 
assay, aiding output interpretation. It would be expected that varying the input 
concentration of nucleic acid trigger template to hybridise with the toehold switch and 
initiate gene expression would modify reporter gene output levels within a dynamic range 
as has been previously demonstrated [17]. By preparing multiple toehold switches assays 
with positive control template of known concentrations along a gradient in tandem with a 
sample reaction of unknown concentration, the reporter gene output can be compared, 
allowing an estimate of template present in the unknown sample. Alternatively, if the in-
house assay does not present a dose-response relationship that can be used for 
quantification, the inclusion of singular positive and negative controls similar to those 
employed by immunoassay test strips could be used. This is a process that can be further 
examined during assay optimisation when preparing the assay for deployment.   
 
3.4.2.2. Study Two 
Quantification accuracy was assessed by calculating the difference between the observed 
and expected quantification values across four DNA input levels (Figure 3.1). 




Figure 3.1: Accuracy of DNA quantification values against decreasing DNA input amounts of the 
Quantiplex® Pro RGQ, PowerQuant® and Plexor® HY kits for autosomal DNA and male marker 
DNA. n = six for each concentration. 
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Quantification accuracy was assessed by calculating the difference between the observed 
and expected quantification values across four DNA input levels (Figure 1). All three kits 
provide autosomal quantification values close to the expected concentration of the 
standard. Compared to the PowerQuant® System, the Quantiplex® Pro RGQ kit showed no 
significant difference in its precision in quantifying both autosomal and male DNA at all 
but one of the DNA input concentrations tested (F-Test autosomal DNA; 250 pg/µL P = 
0.2278, 50 pg/µL P = 0.1044, 10 pg/µL P = 0.0144, 2 pg/µL P = 0.1021. F-Test male DNA; 
250 pg/µL P = 0.1382, 50 pg/µL P = 0.2367, 10 pg/µL P = 0.0822, 2 pg/µL P = 0.2657). The 
significant difference in precision between kits observed when quantifying 10 pg/µL 
autosomal DNA is attributed to a single outlying data point with the PowerQuant® system 
that underestimated DNA concentration. Similarly, no significant difference was observed 
between the Quantiplex® Pro RGQ kit and the Plexor® HY kits with the exception of 2 
pg/µL autosomal DNA (F-Test autosomal DNA; 250 pg/µL P = 0.240, 50 pg/µL P = 0.246, 
10 pg/µL P = 0.169, 2 pg/µL P = 0.005. F-Test male DNA; 250 pg/µL P = 0.207, 50 pg/µL P = 
0.116, 10 pg/µL P = 0.386, 2 pg/µL P = 0.169). The significant difference at this DNA input 
level was not due to outlying data points, so this result is interpreted as a genuine 
difference in quantification accuracy, where the Quantiplex® Pro RGQ kit is significantly 
more accurate than the Plexor® HY kit at low autosomal DNA template concentrations. 
Quantification results were supported by STR data generated from both male and female 
samples, which show a trend for decreasing allele peak heights with DNA input (Figure 
3.2). All alleles were observed in in the 250 pg and 50 pg input samples with instances of 
allelic dropout observed in 19 of the 23 loci at the 10 pg input level (Amelogenin, 
D3S1358, D21S11, CSF1PO amplified) and 22 of the 23 loci at the 4 pg input level 
(Amelogenin amplified). The failure to amplify alleles at such low input concentrations are 
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consistent with the manufacturer’s STR validation data [211] again supporting the 




Figure 3.2. Allele peak heights for the smallest size range loci for each dye set observed across a 
DNA dilution series after amplification using Investigator 24plex QS Kit. * Denotes instances of 
observed allelic dropout.  
 
The Quantiplex® Pro RGQ kit is capable of accurately quantifying DNA even with low 
template input. However, the significant allelic dropout observed at 10 pg/µL input and 
below is a concern for development of the synthetic gene network approach as the 
principle of this test relies on the presence of specific genetic markers. There is therefore 
a possibility that male DNA template with the network would not elicit a positive 
response, but qPCR would quantify male DNA, presenting a lack of concordance between 
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the two methods of sex identification. The allelic dropout with reduced template is 
consistent with other STR profiling studies [212, 213] and suggests that synthetic gene 
networks will exhibit reduced efficacy around these concentrations. However, studies 
that have used synthetic gene networks to detect viral RNA markers have found that 
issues that arise from low template input, such as poor fold-change in reporter gene 
expression, can be circumvented with amplification of template [16, 214]. Isothermal 
amplification of template would enable this step to be carried out while minimising 
instrumentation requirements, reducing costs [215].  
Amelogenin is the only allele still present at 4 pg sample quantity, albeit with a greatly 
reduced fluorescent signal. As amelogenin is a gene with alleles on the X (AMEL-X) and Y 
(AMEL-Y) chromosomes [216], it can be used for sex identification by examining 
amplification of the Y-specific form. Additionally, the robustness of this marker to amplify 
even at low template concentration indicates it may be a suitable sequence to base a 
toehold switch around for field-based sex identification.  
Following from this study, the point at which allele dropout is observed should be 
examined in further detail, as the results show a full profile at 50 pg input but failure of all 
but 4 markers to amplify when input quantity is reduced to a fifth. By establishing 
another concentration gradient between 50 and 10 pg input, the quantity of template at 
which any allele dropout first occurs can be identified. This provides information on the 
synthetic gene network’s potential limit of detection as false negatives would be 
increasingly likely to occur below this quantity.  
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3.4.3. Laboratory-Controlled Mixture, Degradation, and Inhibition Results 
3.4.3.1. Study Three 
By quantifying autosomal and sex-linked PCR targets, it is possible to infer the biological 
sex of whomever deposited a particular forensic sample [217]. This can also support the 
detection of mixed DNA samples where male DNA may be present in extremely small 
quantities against a background of female-source DNA. Such samples may be encountered 
in sexual assault casework where male seminal material may be collected alongside 
female epithelial cells during examination. Such samples are usually subject to differential 
extraction to separate the male and female fractions [218] or the entire sample is subject 
to Y-STR typing [219]. Consequently, the ability to detect and quantify minor male 
components in a larger female fraction is important to inform further processing.  
Two mixture analysis comparison experiments were performed. The first experiment, 
comparing the Quantiplex® Pro RGQ and Plexor® HY kits, assessed the limit of detection of 
minor male component in a majority female mixed-source DNA sample, down to a 1:1000 
male:female mixture at 500 pg/µL total. The second experiment, comparing the 
Quantiplex® Pro RGQ and PowerQuant® kits, used smaller mixture ratios of single-source 
DNA (1:1, 1:25, and 1:50) with the intention of taking mixed samples through to STR 
typing. Three replicates of each sample in each study were quantified. Ratios of 
autosomal:male (A:Y) DNA and standard deviations were calculated (Figure 3.3). In all 
samples containing male DNA, all three kits provided a male DNA quantification value 
against a background of female-source DNA, suggesting the limit of detection was not 
reached for any kit. The majority of samples returned average A:Y ratios within error of 
the expected ratios. Statistical analysis shows no significant difference in the A:Y ratios 
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observed between the Quantiplex® Pro RGQ and PowerQuant® kits at any mixture ratio 
(T-Test Male single-source P = 0.19, Male:Female 1:1 P = 0.27, Male:Female 1:25 P = 0.29, 
Male:Female 1:50 P = 0.21), suggesting these kits are roughly equal in performance when 
detecting mixtures. Similarly, no significant difference was seen in the A:Y ratios of 
mixtures with a smaller male component between the Quantiplex® Pro RGQ and Plexor® 
HY kits (T-Test Male DNA P = 0.07, Male:Female 1:50 P = 0.09, Male:Female 1:500 P = 
0.12, Male:Female 1:1000 P = 0.08). However, at 1:50 and 1:500 mixtures, the Plexor® HY 
system underestimated the male component by a factor of two, returning average A:Y 
ratios of 1:115 and 1:966, respectively. This is captured by the higher variance in the 
standard deviation of these samples (Figure 3.3). At 1:1000 male:female mixture, the 
Quantiplex® Pro RGQ kit has an average A:Y ratio of 1:471.60. This is not due to an 
underestimation of male DNA - the male quantification is greater than at the 1:500 
mixture (1.46 pg/µL against 1.21 pg/µL, respectively) - but rather an overestimation of 
autosomal DNA which was quantified at 698 pg/µL. This result is likely due to 
experimental error in assembling the DNA mixture or the Quantiplex reaction mixture 
itself. Regardless, if this mixture ratio was encountered in an actual casework scenario, the 
high A:Y ratio would reliably inform a forensic scientist that a male:female mixture is 
present.  




Figure 3.3: A comparison of the expected (Y-axis) and observed (X-axis) quantification (ng/µL) ratios of male:female DNA mixtures obtained when using the 
Quantiplex® Pro RGQ, PowerQuant®, and Plexor® HY kits. n = three at each mixture ratio. Male DNA was not quantified in the female single-source samples.  
Error bars represent one standard deviation.  
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STR analysis of laboratory mixed DNA samples show that major:major mixtures were 
observed across all loci in male:female DNA samples mixed at a 1:1 ratio concurring with 
the mixture detection result from the quantification kit (Figure 3.3). Furthermore, the 
allele balance between male and female mixtures suggests that the single source samples 
were mixed in equal ratios prior to STR analysis. Major:Minor mixtures were also 
observed at the 1:25 ratio, again supporting the mixture detection result provided by the 
quantification with the minor male contributor easily visible in loci with no neighbouring 
alleles. Where loci had neighbouring alleles the minor male contributor alleles were 
indistinguishable from stutter (Figure 3.4). No mixed profiles were observed at the 1:50 
male:female mixture ratio despite the quantification assay flagging the sample. The 
results suggest that there is a range in which the Quantiplex Pro RGQ kit can predict the 
presence of mixed STR profiles but past a certain ratio (1:25 observed in this study) there 
will be preferential amplification of the major contributor leading to a full, single source 
STR profile. However, as the mixture ratio reported by the quantification kit is relatively 
accurate, careful interpretation of the result should allow a forensic analyst to correctly 
predict the occurrence of mixtures when moving on to STR amplification.   




Figure 3.4. Electropherogram of five representative loci amplified from various mixed DNA samples 
using the Investigator 24plex QS Kit. * Denotes instances of minor contributor alleles in 1:25 
mixtures; Δ denotes instances where minor contributor alleles cannot be differentiated from allelic 
stutter. 
 
No evidence of a mixture in STR profiles at 1:25 and below implies that a synthetic gene 
network approach may see the appearance of false negatives when assessing a genetic 
marker from a minor male contribution in a majority female background sample. Due to 
the nature of the assay’s design, detection of male component in a mixture would appear 
similar to a single-source male sample of low template. A drawback of the SGN approach 
then is that male DNA can only be determined to be present, but not what fraction of the 
sample consists of male DNA without the use of additional controls that detect DNA 
fragments from the X chromosome. This makes the test more suitable for early 
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presumptive testing in the forensic workflow, similar to how forensic ELISA assays are 
currently used [158, 220] but has the benefit of greater specificity and sensitivity than 
these kits.    
 
3.4.3.2. Study Four 
Several commercial qPCR kits contain multiple primer sets that co-amplify both small and 
large DNA fragments to reflect the degradation observed in the autosomal target [197, 
221, 222]. Long DNA fragments are known to be more susceptible to degradation than 
short fragments. A unique feature of the Quantiplex® Pro RGQ kit is the inclusion of 
multiple primer sets for the quantification of long and short fragments of the autosomal 
and Y-specific DNA targets. By calculating the ratio of long and short fragment quantity, a 
degradation index can be generated that provides a measure of the integrity of DNA in a 
sample. As such, the kit may be of utility in laboratories that routinely analyse degraded 
DNA samples. Under default analysis settings by proprietary data analysis software, a 
Degradation Index (DI) value ≥10 (Quantiplex® Pro RGQ) or ≥2 (PowerQuant®) is 
automatically flagged as possibly degraded. The data generated from the laboratory-
controlled degradation study for both Quantiplex® Pro RGQ and PowerQuant® kits show 
that degradation indices increase with the duration of sonication (Figure 3.5). The 
sonicated samples displayed consistently higher DI values for the male target over the 
autosomal using the Quantiplex® Pro RGQ kit, which would imply a higher sensitivity of 
the male marker primer set to the autosomal. One explanation for the observed 
differences in detection is the relative size differences of the autosomal and male targets 
(Table 3.4) which show an amplified fragment length of 353 bp for the autosomal 
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degradation marker and 359 bp for the male degradation marker. Size variation has been 
cited as a possible reason for observed differences in degradation indices between kits 
[195] so may also explain the slight differences observed here. Another possible 
explanation may be that the primer used to amplify the male degradation marker may be 
less efficient at amplification in the assay, consistently leading to fewer copies of the 
larger target being amplified and a bias in the relative ratios. However, the primer 
sequences are unpublished as they are proprietary to the manufacturer. This is 
problematic as it limits interpretation of the results.  
 
 




Figure 3.5: Degradation indices following quantification of 500 (A) or 50 (B) pg of male DNA after 
sonication with the Quantiplex® Pro RGQ and PowerQuant® qPCR kits. N = six at each time point. 
Error bars represent one standard deviation. 
 
At both 250 pg/µL and 25 pg/µL of DNA template, 10 minutes of sonication was enough 
to flag the male marker as potentially degraded with the Quantiplex® Pro RGQ kit 
(Average DIs = 9.75 and 14.32 respectively) whereas the autosomal markers remained 
below the degradation detection threshold. All samples quantified by the Quantiplex® Pro 
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RGQ were flagged by the QIAGEN Data Handling Tool as possibly degraded following 30 
minutes of sonication. The PowerQuant® technical manual recommends flagging 
[Auto]/[Degradation] ratios of ≥2:1 as degraded, which is lower than the 10:1 ratio used 
by the QIAGEN Data Handling Tool. At 250 pg/µL DNA input, autosomal DNA was flagged 
as degraded using PowerQuant® settings at 10 and 30 minutes of sonication but would 
not have been flagged by the QIAGEN Data Handling Tool (Average DIs = 3.53 and 4.23 
respectively). This discrepancy requires careful consideration by the forensic analyst using 
these kits to avoid false positive and negative flagging of samples for further processing 
and may require in-house optimisation based on equipment and sample type. When 
using 25 pg/µL of template DNA, degradation indices using the PowerQuant® kit were 
significantly greater at 10 and 30 minutes compared to using 250 pg/µL input (T-Test P = 
0.006 and P = 0.03 respectively). This suggests that smaller quantities of template are 
more prone to degradation, and that this information will be captured during analysis. 
The range of autosomal DI values reported in Figure 3.5 are markedly lower than the 
average autosomal DI values reported from previous research [195]. In the study by 
Holmes et al., average DI values of ~58, ~75, and ~25 were reported for bone, 
decomposed tissue and formalin-damaged tissue respectively when using the alternative 
QIAGEN quantification kit, Quantiplex® Pro. This suggests that the sonication approach 
used in the study could have been performed over a longer time period to mimic the DI 
values representative of bone and degraded tissue. This said, the STR profiles obtained 
from the laboratory degraded samples shows a decay curve with the percentage of 
amplified loci decreasing with length of sonication and, importantly, size of DNA fragment 
(Figure 3.6). All alleles were observed in un-sonicated samples across all fragment sizes, 
while samples degraded for 1 minute began to show allelic dropout for medium (161-275 
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base pair) and large (304-428 base pair) fragment sizes. Allelic dropout was also observed 
in the samples sonicated for 10 minutes and 30 minutes with whole loci (SE33, D21S11, 
D7S820) failing to amplify in the large fragment size range. 
Figure 3.6. Amplification success (%) for sonicated DNA at various time points. * indicates 
instances where allelic dropout was observed; Δ indicates where locus dropout was observed. 
 
From this study, 3 trends were identified: 1) Reduction in template is associated with an 
increase in susceptibility to degradation by sonication, 2) larger DNA fragments are more 
prone to degradation and allele/locus dropout than shorter fragments, and 3) the 
Quantiplex® Pro RGQ kit’s male degradation index increases at a greater rate than the 
autosomal marker. These trends have implications for the design of a synthetic gene 
network as the use of a larger biomarker for sex identification would therefore be more 
prone to degradation in a sample and would be less likely to be present at sufficient 
quantity in a male sample to elicit a positive reaction. Use of a fragment of a sequence 
that is resistant to nuclease activity would be preferable to minimise effects of 
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degradation and allow for the assay to proceed even with heavily degraded samples. 
Although the planned toehold switch design uses a fragment of approximately 30 bp size 
as the target sequence, the location of this region will be an important consideration to 
take into account, as if the target is present in a region prone to exonuclease activity it 
may be quickly lost by degradation and greatly reduce the efficacy of the network.   
 
3.4.3.3. Study Five 
One concern that arises when quantifying forensic samples is failure of PCR amplification 
due to factors outside of low DNA template input. One of the most common causes of 
PCR failure encountered in forensic casework is due to the presence of PCR inhibitors 
commonly co-collected alongside the target sample [200]. Of these inhibitory substances, 
two of the most common are hematin and humic acid, which are major components of 
blood and soil, respectively. Both substances inhibit PCR by interference with 
thermostable Taq DNA polymerase, although it has also been suggested that humic acid 
binds to template DNA and/or chelates magnesium ions in the reaction mixture [223-
225]. As inhibition of PCR reduces reaction efficiency, the true concentration of DNA input 
in an inhibited sample is underestimated. In order to detect the presence of inhibitors to 
troubleshoot PCR, DNA quantification kits include an Internal Positive/PCR Control (IPC) 
that amplifies a synthetic DNA region included in the PCR chemistry [226, 227]. The IPC 
has an expected PCR cycle threshold (Ct) at which amplification is detected, and inhibition 
is determined by deviation above that cycle number. The Quantiplex® Pro RGQ kit has an 
expected IPC Ct of 15.9, and the Qiagen Data Handling Software under default analysis 
settings will flag samples for inhibition that have a threshold cycle ≥1.0 above this. For the 
PowerQuant® and Plexor® HY systems, a cycle deviation of ≥0.3 and ≥2.0 are flagged for 
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inhibition, respectively. IPC data was collected in each of the previous studies, and in the 
case of all samples processed with the Quantiplex® Pro RGQ and Plexor® HY no inhibition 
was observed. However, IPC data was not able to be collected using the PowerQuant® 
System. This is due to a mismatch in the TMR-labelled dye used for the IPC target in the 
PowerQuant® chemistry and the available fluorescence channels that can be read using 
the Rotor Gene Q thermal cycler software. Although TMR is excited and detected around 
the orange wavelengths (Ex/Em 557/576), it is not close enough to the orange channel of 
the RGQ (585/610) to obtain any amplification data about the IPC target with the 
PowerQuant® system using this reaction setup. As all other studies involving the 
PowerQuant® system have used DNA input under tightly controlled laboratory conditions 
and return quantification values within expected ranges, it can be concluded that these 
samples were free of inhibitors and any change in quantification value is due to reduction 
in template DNA concentration or from controlled sample degradation (see Study Four). 
This leaves the comparison in inhibition tolerance between the Quantiplex® Pro RGQ and 
Plexor® HY kits. The data generated in this study shows that increasing concentrations of 
both humic acid and hematin correlates with an increase in deviation from the expected 
threshold cycle (Figure 3.7). Both kits display inhibition at a concentration of 500 ng/µl 
humic acid suggesting they have broadly similar tolerance. Increasing concentrations of 
hematin also correlates with an increase in threshold cycle, although the two kits show a 
marked difference in tolerance to hematin. The RGQ kit shows good tolerance at the 
ranges tested with the delay ct observed in the IPC never being ≥1.0. This is consistent 
with the beta test results as the highest concentration of hematin tested here (2000 µM), 
is lower than the lowest concentration in the beta test (2500 µM). Compared to validation 
studies from other kits such as Quantifiler Trio [198], the inhibitor tolerance data obtained 
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from this study show similar interactions with humic acid (IC flag at concentrations ~500 
ng/µl) but a much greater tolerance to hematin, with the IC not being flagged even at 
concentrations of 2000 µM. Both Quantifiler Trio and the RGQ kit show greater tolerance 
than InnoQuant HY to both humic acid and hematin [196]. Inhibition indices could not be 
calculated for samples processed using the Plexor® HY kit at 1000 µM or 2000 µM 
hematin as the IPC target was not amplified, indicating heavy inhibition. The Quantiplex® 
Pro RGQ kit appears to have greater tolerance to inhibition than the PowerQuant® 
System, which has been demonstrated to flag for inhibition at 200 ng/µL humic acid and 
500 µM hematin [195]. 




Figure 3.7: The deviation in internal control threshold cycle from the expected threshold cycle in 
500 pg male DNA samples with increasing concentrations of humic acid (A) and hematin (B) in the 
Qiagen Investigator Quantiplex Pro RGQ field test and commercial equivalent qPCR kits. Black 
asterisks denote failed amplification of internal control for the Plexor® HY kit. 
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At this study has demonstrated, the presence of inhibitory molecules commonly co-
collected with forensic samples can have significant impact on the functions of qPCR kits 
to estimate DNA quantity. It follows then that similar issues may be faced when detecting 
the presence of nucleic acids with toehold switches via similar inhibitory mechanisms in 
the case of humic acid. This is a potential hurdle that has not been examined by existing 
literature surrounding toehold switches and will be required to validate during in-house 
toehold switch development.  
 
3.4.4. Mock Casework Mixture Study 
3.4.4.1. Study Six 
The use of immunoassay tests to detect male seminal material is common when 
processing sexual assault samples that may contain both male and female biological 
fractions. An immunoassay approach was used as a comparison against qPCR for the 
detection of male seminal material spiked onto buccal swabs from female volunteers at 
varying quantities. Data from the male:female spiked swabs show that the RSID test can 
detect the presence of seminal material when spiked at 50 µL, 5 µL and 1 µL volumes but 
not at the 0.1 µL (100 nL) volume. This is much less sensitive than previously reported for 
the RSID test which shows seminal material being detected at the 2.5 nL volume [228]. 
The difference in reported limit of detection is likely due to experimental differences 
between this study and others, which often measure sensitivity based on a dilution series 
derived from a single homogenised solution at a high starting concentration [228, 229]. 
The method employed in the current study is considered a more realistic approach to 
describe the sensitivity as the amount of seminal material on the swab was varied before 
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recovery. After the RSID test, the remaining buffer solution underwent DNA extraction 
and quantification where the average autosomal:male marker ratios were never less that 
2:1 (Figure 3.8) meaning the QIAGEN Assay Data Handling Tool flagged all mixtures. The 
amplification of the male DNA target at the 0.1 µL semen spike by the Quantiplex® Pro 
RGQ highlights an instance of non-concordance between the two approaches and 
suggests that there may be instances where male DNA from semen can be recovered after 
a negative RSID result. The amount of male DNA recovered from the 0.1 µL semen spike 
was quantified at 1.1 pg/µL which is below the limit of detection reported by many Y-STR 
kits [230, 231] so it is debatable as to whether the sample would yield an STR profile. 
Differences in detection limits between immunoassay and PCR based approaches are 
common and do not invalidate the use of such tests for sample prioritisation and/or body 
fluid identification, and further testing on a larger number of samples may be required to 
understand the extent to which non-concordant results occur.  
Figure 3.8: Detection of male material from spiked swabs at four different semen volumes. Black 
diamonds represent the number of positive RSID tests detecting semenogelin at that spike volume 
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(right axis). Grey bars represent concentration (ng/µL) of male DNA obtained presented as log 
scale (left axis). A:Y = average ratio of Autosomal to Y target calculated after DNA quantification. n 
= three at each semen volume. Error bars represent one standard deviation.  
 
A mixed STR profile was observed after amplification using the Investigator 24plex QS Kit 
at the 50 µL semen spike but not at the other spike volumes (data not shown) despite the 
quantification software flagging all as possible mixtures. The results are broadly consistent 
with those observed in the laboratory mixed samples in that over-dilution of the male 
contributor will lead to non-amplification of male DNA. The lack of a mixed STR profile in 
the 5 µL spike despite having an A:Y ratio of 12.1 also highlights the stochastic nature of 
amplification at low male contributor levels since only ~20 pg of male DNA was present in 
this sample, whereas a major:minor mixture profile was observed in the laboratory 
controlled samples at a higher mixture ratio 1:25 which also included 20 pg male DNA. 
Together, the data suggests that the Quantiplex® Pro RGQ kit is capable of detecting mixed 
samples across a range of ratios, although the extent to which this is observed in the 
resulting STR profile will vary as a function of mixture ratio and the amount of male 
contributor. Consequently, using the mixture metric to accurately predict a mixture is 
likely possible with each laboratory needing to set their own thresholds for interpretation 
using laboratory-controlled mixtures.  
The results of this study are similar to those seen in the laboratory-controlled mixture 
study (i.e. accurate quantification of minority male contribution, male allelic dropout with 
increasing female background), but the inclusion of a presumptive RSID™-Semen 
immunoassay kit as a comparison provides useful information when considering where to 
apply a novel forensic toehold switch assay. The immunoassay approach exhibits dropout 
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at a level where the qPCR kit is still capable of detecting male contribution to a sample. 
This lack of concordance between field-based presumptive testing used for sample triage 
and laboratory-based confirmatory qPCR suggests that the high sensitivity and specificity 
offered by toehold switch assays could bolster or supersede common presumptive 
techniques and improve the forensic sample triage process. This suggests then that in 
addition to comparing performance of future toehold switch designs to qPCR assays, 
immunoassays should also be included.  





By obtaining experimental evidence of the Quantiplex® Pro RGQ kit across a range of 
metrics and usage contexts, the system has been validated for in-house and commercial 
use and formed a robust benchmark for comparison against a novel sex identification 
synthetic gene network. The data obtained from this series of experiments show that the 
Quantiplex® Pro RGQ kit and PowerQuant® HY kit are similar in terms of quantification 
accuracy and sensitivity against both autosomal and male DNA targets. Additionally, the 
Quantiplex® Pro Kit is both more tolerant to PCR inhibition than the previous-generation 
Plexor® HY kit with the inhibitors tested and is significantly more sensitive in detecting 
low-input template, representing a significant improvement in performance. The 
detection of male:female mixtures from both controlled DNA and mock samples suggest 
that the Quantiplex® Pro RGQ kit may be well suited to sexual assault casework where it 
is necessary to detect low level male DNA in female samples. In addition, the DNA 
degradation data appear to accurately determine DNA integrity in a reproducible manner. 
In all instances, STR data was able to corroborate quantification results, although in the 
case of mixture detection the Quantiplex® Pro RGQ kit provided evidence of minor:major 
male:female DNA mixtures where STR profiles returned a single-source female DNA 
profile. This suggests that laboratories may need to validate their own interpretation 
guidelines to fully utilise the information provided by the quality metrics. 
A consistent observation across studies was of the Quantiplex® Pro RGQ kit’s high degree 
of fidelity at quantifying samples at low template input, high inhibitor concentration, and 
high degradation index. This fidelity exceeded that of the Investigator® 24plex QS kit for 
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STR analysis performed after quantification and the RSID-Semen™ assays that were run 
prior to quantification. As a result, the qPCR data was not always reflected in the results 
of additional sample processing at other points in the forensic workflow. Results from STR 
fragment analysis from laboratory-controlled degraded DNA samples were still capable of 
amplifying sex allele fragments even when quantification data from these samples could 
not be recovered. This highlights genetic recognition as an appropriate assay for sex 
identification from forensic samples. 
The validation of the gold-standard laboratory-based qPCR approach and inclusion of 
field-applicable RSID™ immunoassay tests provides useful information when considering 
where to apply a novel toehold switch assay. To this point, it was originally thought that 
toehold switches could be applied as a field-based confirmatory assay for human DNA 
detection given the high reported sensitivity and specificity. However, the validation data 
of a qPCR kit presents several situations where laboratory techniques are likely to far 
outperform a field-based toehold switch, such as when detecting male/female DNA 
mixtures and low template inputs, both of which are commonly encountered when 
working with forensic samples. This suggests then that toehold switches may be better 
suited as a presumptive tool deployed to bolster standard immunoassay testing in cases 
of unknown sample types (e.g. blood, saliva, etc.) or low expected template. As such, this 
would highlight mRNA from human body fluids as the prime candidates for detection 
from an in-house toehold switch assay moving forward.   




Development of an In-House Cell-Free Protein Synthesis System from 
Escherichia coli for In Vitro Gene Expression 
4.1. Abstract 
A toehold switch synthetic gene network for the field-based detection of DNA for forensic 
investigation would appear to fit neatly as a presumptive tool to supplement laboratory 
qPCR and supplant existing RSID immunoassay tests. For toehold switch genetic circuitry 
to execute its function, a cellular environment complete with transcription/translation 
machinery is essential. The need for simple storage, handling, and field-based 
deployment of toehold switch sensors prevents gene expression within living cells. Cell-
free protein synthesis (CFPS) systems exist that can synthesise protein from genetic 
template in vitro, but commercial formulations are prohibitively expensive for mid- to 
high-throughput use. To circumvent this issue and enable low-cost CFPS, a crude cell 
extract containing the necessary components for protein synthesis was generated in-
house from E. coli BL21 (DE3) cells.  
The method sourced from the literature utilises no significant instrumentation for cell 
disruption besides an ultracentrifuge for final lysate separation, cells are instead lysed 
using a series of treatments known as the “LOFT” (Enzymatic Lysis, Osmotic shock, 
Freeze-Thaw) process. The resulting cell extract, which could be obtained repeatedly, had 
an estimated protein concentration of ≥20 mg/mL as determined by BCA assay. Extract 
was capable of synthesis of wild-type green fluorescent protein (wtGFP) from plasmid 
DNA at a template concentration of 60 ng/µL when incubated with necessary reaction 
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additives. Although start-up costs for obtaining the cell lysate were higher than buying a 
commercial system, the vastly increased number of possible CFPS reactions drastically 
reduced per-test cost, estimated at approximately £0.07. The additives required for CFPS 
(triphosphates, cofactors, etc.) had an estimated per-batch cost of £9.35 and were 
identified as the limiting factor for cost. The extract was deemed suitable for use with 
synthetic DNA constructs, enabling optimisation of the system to begin prior to 
introducing toehold switch sensors for expression and embedding the extract onto paper 
for deployment in the field.  
 
4.2. Introduction 
For the proposed forensic toehold switch sensor to report its hybridisation with a 
complementary target sequence, reporter gene expression must occur following 
unwinding of the toehold stem and exposure of the RBS. This requires synthetic gene 
networks to be present in an environment that allows this pathway to occur. A common 
method for synthetic gene networks to be deployed and studied is via expression in living 
cells [232]. Whilst this has the benefit of self-replication of the network and generation of 
large amounts of synthetic product, it is particularly inflexible in terms of the contexts 
where it can be used [233]. The design brief of a synthetic biosensor that can be easily 
and rapidly deployed at crime scenes or other low-resource environments without the 
need for sophisticated equipment, low-temperature reagent storage, or contamination 
risks prohibits such an in vivo approach. This said, the genetic modules that comprise the 
network require a cellular environment, as many processes such as gene expression 
which are critical to network function utilise cellular machinery endogenous to the host 
cell [9]. This issue can be addressed with the use of a cell-free protein synthesis (CFPS) 
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system. CFPS systems contain the aforementioned cellular machinery necessary for 
protein synthesis that have been liberated from a host cell via lysis [234]. By supplying 
this cell lysate with template DNA and exogenous factors such as amino acids, 
triphosphates, co-factors, and an energy source it is possible to perform full cellular 
transcription and translation of proteins in vitro [235]. As in vitro systems are not 
constrained by the host cell, they are not required to support processes unrelated to 
target protein production e.g. growth and reproduction and have greatly optimised 
reaction yields as a result, into the gram of protein per litre of reaction mixture range 
[234]. Additionally, proteins that are difficult to express/fold efficiently in vivo or are toxic 
to host cells can be produced in vast quantities outside of the cell. While many of the 
components of CFPS reactions require storage at temperatures ≤ -20°C, CFPS solutions 
have been demonstrated to functionally synthesise protein from synthetic gene networks 
after being freeze-dried onto semi-porous paper substrates and stored at room 
temperature [17], which would make this an ideal deployment platform for forensic 
science and developmental goal. The open nature of a CFPS platform allows for 
supplementation of the system with energy sources to boost productivity, or to customise 
the reaction mixture to optimise gene expression [236]. There are a number of CFPS 
systems that have been isolated from different host cells, including Escherichia coli [237], 
wheat germ [238], and rabbit reticulocytes [239]. Whilst each extract system has its own 
advantages and disadvantages, E. coli extracts are of particular use in biosensing due to 
their very high protein yield and relatively low cost [240]. Protein synthesis itself consists 
of four interconnected reactions. These are: transcription, translation, aminoacylation, 
and energy regeneration (Figure 4.1) [241]. 




Figure 4.1: Graphical overview of the four reactions of cell-free protein synthesis. Reproduced from 
Shimizu et al. [241] with permission from Elsevier. 
 
Optimisation of protein expression requires careful balancing of the four reactions 
involved as any of them can become the limiting factor if their pathway inputs or 
cofactors are expended. This highlights the need to produce a cell lysate with a high 
starting level of protein so that optimisation of the system with supplementary reagents 
can progress smoothly. Commercial formulations of CFPS lysates exist, such as the 
PURExpress™ In Vitro Synthesis Kit [242], derived from E. coli. This kit is based on the 
PURE™ system developed by Shimizu et al. [167]. The PURE™ system consists of purified 
components that are involved in the four reactions of CFPS that have been reconstituted 
into a single mixture along in specific ratios with the necessary energy sources, ions, and 
cofactors. The use of these commercial systems for deployment of a field-based sex 
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identification test is inappropriate as the kits are prohibitively expensive for many 
laboratories, especially considering the small number of reactions included with each kit. 
This would hinder any practical applications for the system as a rapid, low-cost alternative 
for field-based body fluid and sex identification. In contrast, developing a CFPS system 
from cell lysates in-house would provide enough lysate for a much greater number of 
reactions, reducing per-test cost. Having a greater number of reactions available has 
benefits both for reaction optimisation as well as deployment of a successful synthetic 
gene network-based test. A key difference between the commercial and in-house 
approaches is in their lysate formulation. Unlike the reconstituted PURE™ system, the in-
house CFPS lysate would be in a crude form, containing all soluble components present in 
the cell prior to ultracentrifugation, excluding cell membrane structural proteins and 
genomic DNA. As a result, it is extremely difficult to identify the various proteins present 
in the final lysate, with protein yields being the only metric used to judge viability for CFPS 
(~20-30 mg/mL of protein is appropriate). Additionally, molecules that are non-essential 
to protein synthesis will be present in the lysate, including molecules such as proteases 
and nucleases, which may actively hinder the CFPS process. This also has implications for 
batch-to-batch variation while in-house CFPS experiments are optimised and 
characterised. The PURE™ system which is made to a standardised process for 
commercial purposes will not have this batch variation (or at least not to any significant 
degree), making it a useful point of reference when benchmarking the performance of the 
in-house CFPS system. Many published protocols for preparing cell lysates use 
instrumentation such as French presses or a sonicator to mechanically disrupt cells [243-
245]. However, this instrumentation was not available, requiring an alternative disruption 
method. There are other disruption techniques that do not require mechanical disruption, 
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instead using biological, chemical, and physical processes [246]. The method used was an 
adaptation of the LOFT (enzymatic Lysis, Osmotic shock, and Freeze-Thawing) treatment 
for cell lysis which has been previously demonstrated to obtain protein concentrations 
similar to standard mechanical disruption [247]. During development, adjustments to this 
protocol were made in-house to optimise lysate production which are discussed in the 
relevant sections. 
This chapter will cover the development of a cell-free protein synthesis system derived 
from E. coli from scratch, adapting and optimising protocols sourced from the literature. 
The capability of these systems to synthesise protein will be briefly examined, but 
optimisation of CFPS reactions using both in-house and commercial cell lysates will be 
covered in greater detail in the following chapter (Chapter Five). 
 
4.3. Materials and Methods  
4.3.1. Preparation of Media, Agar Plates, and Cell Extract Buffers 
Five-hundred millilitres of LB media (0.5% NaCl) was prepared in a 1 L conical flask by 
dissolving 10 g of LB broth base (Invitrogen, #00605031) in 500 mL of distilled water. Salt 
concentration was increased to 1% with the addition of 2.5 g of sodium chloride. Media 
was sterilised by autoclaving at 121°C for 15 minutes. Autoclaved media was stored at 
room temperature until usage (typically overnight). Prior to inoculation of media with 
overnight cultures, 500 µL of ampicillin was added to the media at a final concentration of 
100 µg/mL and briefly swirled to distribute evenly.  
Agar selection plates were prepared by dissolving 3.75 g of agar (Sigma-Aldrich, 
#BCBR1697V) in 250 mL LB media and autoclaving at 121°C for 15 minutes. Molten agar 
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was cooled to ~50°C before addition of 250 µL of ampicillin to a final concentration of 100 
µg/mL. Agar was swirled to mix ampicillin evenly and immediately poured into petri 
dishes in the presence of a Bunsen flame and left in a clean fume hood to solidify and air-
dry. Plates were stored upside-down at 4°C until use.  
After preparing S30 A (10 mM Tris-HCl (pH 8.0), 60 mM potassium glutamate, 14 mM 
magnesium acetate) and S30 B (5 mM Tris-HCl (pH 8.0), 60 mM potassium glutamate, 14 
mM magnesium acetate) buffers, mixtures were sterilised by autoclaving, then stored at 
4°C until use. DL-Dithithreitol (DTT) was supplied to buffer aliquots at 2 mM (Buffer A) 
and 1 mM (Buffer B) concentrations immediately before use.   
 
4.3.2. Transformation and Growth of Escherichia coli cells with pAR1219 Plasmid 
Competent BL21 (DE3) E. coli cells (NEB - #C2527I) and pAR1219 plasmid which expresses 
T7 RNA polymerase under control of the IPTG-inducible lacUV5 promoter (Sigma-Aldrich, 
#T2076) were thawed on ice. Five microlitres of pAR1219 plasmid was added to 50 µL of 
BL21 DE3 cells in a transformation tube, gently mixed, and incubated on ice for 30 
minutes. Plasmid-cell mixture was then heat-shocked in a water bath at 42°C for 10 
seconds and placed on ice for 5 minutes. Volume was made up to 1 mL total by addition 
of 950 µL of SOC media (Invitrogen #1837421). This mixture was incubated in a shaker 
incubator at 250 rpm for 1 hour at 37°C. Following incubation, bacteria was spread evenly 
across the surface of previously prepared ampicillin LB agar plates at 10, 20, 50, 100, and 
150 µL volumes in the presence of a Bunsen flame. Plates were incubated overnight at 
37°C to obtain single bacterial colonies. Overnight cultures of transformed cells were 
prepared by inoculating single bacterial colonies grown on LB agar selected with a sterile 
pipette into 10 mL of sterile LB media containing 10 µL of ampicillin to a final 
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concentration of 100 µg/mL. Tubes were loosely covered with a non-airtight cap and 
incubated overnight in a shaker incubator at 37°C and 180 rpm. Prior to scaling the 
bacterial culture up, long-term stocks of E. coli cells expressing the pAR1219 plasmid were 
prepared by adding 500 µL of overnight culture to 500 µL of sterilised 50% glycerol in a 1 
mL screw-top tube and stored at -80°C. When preparing streak plates from glycerol 
stocks, a sterile wire loop was used to scrape frozen bacteria from the top of the stock in 
the presence of a Bunsen flame and streaked onto LB Agar plates containing ampicillin.  
 
4.3.3. Cell Extract Preparation with Lysing, Osmotic Shock, and Freeze-Thaw (LOFT) 
Treatment 
Extracts from E. coli BL21 (DE3) cells were prepared according to Fujiwara & Doi’s 
protocol with a number of adjustments [247]. Overnight cultures (10 mL) of E. coli BL21 
(DE3) colonies expressing the pAR1219 plasmid for overexpression of T7 RNA polymerase 
were inoculated into 500 mL of LB media containing 100 µg/mL ampicillin in a 2 L conical 
flask. One millilitre of sterile LB media was measured as a spectrophotometer blank for 
optical density measurements of media at 600 nm (OD600). Inoculated cultures were 
placed in a shaker incubator at 180 rpm and 37°C. After each hour of incubation, flasks 
were briefly removed to take a 1 mL sample to measure OD600 against the LB media blank. 
At OD600 = ~0.4, flasks were removed from incubation before supplying the culture with 
100 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) (Thermofisher, #R1171) at a final 
concentration of 0.1 mM to induce plasmid expression. Following IPTG induction, cultures 
were returned to incubation until an OD600 of ~0.8 was reached. At this point, media was 
removed from incubation and allowed to sit at room temperature for ~20 minutes prior 
to centrifugation (4°C, 4000 rpm) for 10 minutes in an Eppendorf 5810 R bench centrifuge 
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equipped with an A-4-62 rotor. Supernatant was discarded as waste and cell pellets were 
collected and stored at -20°C overnight in a sterile 50 mL tube.  
The process of obtaining the cell extract used a combination of enzymatic lysing, osmotic 
shock, and freeze-thaw treatment. The collected cell pellet from the previous day was 
thawed on ice and resuspended in 20 mL of 400 mM sucrose (Sigma-Aldrich #S9378) 
using a paintbrush for rapid resuspension to prevent premature cell disruption. To this 
cell suspension, 400 µL of 20 mg/mL lysozyme (Sigma-Aldrich #L6876), dissolved in 
chloride buffer (20 mM Tris-HCl (pH 8.0), 500 mM KCl), was added. Lysozyme was 
distributed through the cell resuspension by inversion, then incubated on ice for one 
hour. Lysed cells were collected by centrifugation (as above) and washed twice with 15 
mL of pre-chilled 400 mM sucrose. The rapid resuspension technique above was also used 
between washes. Cells were collected by centrifugation and resuspended in S30 buffer A 
at a ratio of approximately 2 mL of buffer per gram of wet cell paste. Cell-S30 suspensions 
were rapidly transferred to 1.8 mL cryovials and stored at -80°C overnight. Frozen cells 
were thawed in ice water for 1 hour per mL of frozen cells. Thawed cells were pooled at 
equal volumes into two 10.4 mL polycarbonate bottles with cap assembly (Beckman-
Coulter, #355603) and centrifuged at 30,000 x g at 4°C for 1 hour in an Optima XPN-80 
Beckman Coulter ultracentrifuge equipped with a 70.1 TI rotor. Supernatant containing 
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4.3.4. Buffer Exchange of Cell Extract 
A buffer exchange of the cell extract was carried out by first spinning down the extract in 
an Amicon® Ultra-15 centrifugal filter unit with a 10 kDa molecular-weight cut off (Merck 
Millipore, #UFC901008) at 4000 rpm for 10 minutes at room temperature. Concentrate 
was reconstituted in 10-fold volume of S30 buffer B and spun down again at the same 
settings to concentrate further. This process was repeated 3 times to a 1000-fold total 
dilution of S30 extract to S30 B buffer.  
 
4.3.5. Estimation of Cell Extract Protein Yield 
Protein concentration of the buffer-exchanged extract was estimated using a Pierce® BCA 
Protein Assay Kit (Thermo Fisher) [248]. A dilution series of bovine serum albumin (BSA) 
from 2000 - 25 µg/mL was prepared with 1X TE buffer as the diluent. BCA reagents A and 
B were mixed at a 50:1 ratio to prepare the working reagent (WR). Cell extract and 
filtrates were diluted ~1 in 10 with 1X TE buffer as their expected concentration was 
outside of the assay’s detection range (0 – 2 mg/mL). Twenty-five µL of BSA standard, 
diluted cell extract or filtrate was pipetted into separate wells of a 96-well microplate in 
duplicate (BSA standards) or triplicate (cell extract/filtrate). WR was added to these 
sample wells at a ratio of 8:1 (200 µL WR) and mixed by a plate shaker at 180 rpm for 30 
seconds. The microplate was covered with cling film and incubated at 37°C for 30 
minutes. After incubation, cling film was removed and the plate was placed in a ClarioStar 
plate reader to measure absorbance at 562 nm of each well, correcting against the blank 
(TE buffer). Absorbance values were exported to Microsoft Excel and a standard curve 
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was generated using BSA standard absorbance data. Cell extract and filtrates had their 
concentrations estimated against this standard curve.  
 
4.3.6. Assembly and Measurement of Cell-Free Protein Synthesis Reactions 
Cell-free protein synthesis reactions performed with the commercial PURExpress In Vitro 
Protein Synthesis Kit (New England Biolabs, E6800) used the manufacturer’s 
recommended protocol with volumes scaled down from 25 µL total to 10 µL total [249]. A 
7 µL master mix was assembled by adding 3 µL of Solution B to 4 µL of Solution A on ice in 
a sterile 0.2 mL centrifuge tube. Plasmid DNA encoding wild-type GFP under control of a 
T7 promoter was added to a final concentration of 60 ng/µL and pipetted up and down to 
mix thoroughly. In-house reaction mixtures consisted of E. coli S30 cell lysate at 15 ng/µL 
final concentration, 3 µL of an additive mixture per reaction (Table 4.1), 20 U of Protector 
RNAse inhibitor (Sigma Aldrich #3335399001) and wtGFP plasmid DNA. 
 
Table 4.1: Reagents involved in the CFPS additive mixture and their final concentrations.  
Reagent Concentration in Final Additive Mixture 
HEPES-KOH Buffer (pH 7.6) 50 mM 
3-PGA 36 mM 
Amino Acids 0.5 mM (each of the 20 amino acids) 
Triphosphates 1.5 mM (ATP and GTP), 0.9 mM (CTP and UTP) 
Potassium glutamate 90 mM 
Magnesium acetate 14 mM 
Cyclic AMP (cAMP) 0.75 mM 
NAD+ 0.33 mM 
Coenzyme A (CoA) 0.26 mM 
PEG8000 2% volume 
IPTG 1 mM 
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Negative controls for both extracts that did not contain wtGFP pDNA had their volumes 
made up with DNA-grade water. After assembly on ice, reaction mixtures were 
immediately pipetted into wells of a 384-well black-frame, clear-bottomed VisionPlate™ 
4ti-0203 microplate (4titude® Ltd) and incubated at 37°C in a ClarioStar™ (BMG LABTECH) 
plate reader. Changes in fluorescent intensity in wells over time were monitored at Ex/Em 
395-25/508-20 by taking a fluorescence intensity measurement every 15 seconds (4-hour 
time course) or every 5 minutes (14-hour time course). Before each measurement, the 
384-well plate was shook at 500 rpm, and reported fluorescence averaged around the 
perimeter of the well (orbital averaging = 3 mm) to obtain consistent results and 
reduce/eliminate false negative readings stemming from inaccurate pipetting into 
microplate wells. In all cases, nuclease-free water was used as a fluorescence blank. The 
focal height and gain were determined by automatic adjustment. Focal height and gain 
settings were kept the same for repeat measurements to make runs comparable to one 
another. 
 
4.4. Results and Discussion 
4.4.1. Development of a Cell-Free Protein Synthesis System Derived from E. coli  
4.4.1.1. Transfer of Literature Protocol In-House 
The intended function of the in-house CFPS system is to synthesise a reporter protein 
from toehold switches following DNA hybridisation of the switch to a forensic target 
marker. A fluorescent approach with wtGFP as a reporter was used due to its ease of 
detection and the availability of a plate reader to conduct measurements with. The 
proposed toehold switch circuit function is a relatively simple process that only involves 
the transcription and translation of the reporter gene at a level that can be distinguished 
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against a negative control. This makes eukaryote-derived CFPS systems superfluous, as 
wtGFP is very easily expressed by prokaryotes such as E. coli [250] and there is no need 
for any post-translational modification of the reporter protein to make it detectable. In 
addition, E. coli extracts are relatively tolerant to additives [251]. This is of particular use 
when considering a cell-free expression system that will be used to process forensic 
samples, as co-collection of contaminants alongside the intended sample that can impede 
processing is a frequent occurrence in this field [200] and was previously highlighted as a 
concern (Chapter Three). As mentioned previously, the method used here was an 
adaptation of biochemical lysing process outlined by Fujiwara and Doi [247]. Initially, the 
minimal process as outlined in this paper’s methods was used, omitting steps that the 
protocol highlighted as not always being essential to obtaining a concentrated lysate, 
such as buffer exchange. The first step involved in preparing a cell lysate is in obtaining a 
sufficient mass of cells such that lysis will release a protein yield high enough for protein 
synthesis, which is approximately 20-30 mg/mL. A high proportion of this protein yield 
should be made up of cellular transcription machinery such as RNA polymerases as this is 
necessary to achieve enough reporter protein synthesis to be detectable at the end of the 
CFPS reaction. To this end, competent BL21 (DE3) E. coli cells were transformed with the 
pAR1219 plasmid. This plasmid carries a gene expressing T7 RNA polymerase (T7 RNAP), a 
key transcription enzyme, under the control of an IPTG-inducible lac UV5 promoter [252]. 
This plasmid also contains an ampicillin resistance gene, ensuring that all colonies grown 
on LB agar plates prepared with 1 in 1000 ampicillin are transformed cells containing the 
pAR1219 plasmid. Extracts were prepared in batches as necessary for the optimisation 
and troubleshooting processes. For the first batch of extract, volumes used in the original 
protocol were scaled down by a quarter, inoculating 5 mL of overnight culture into 250 
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mL of LB media in a 300 mL capacity conical flask. This smaller scale was for the purpose 
of performing a test run of the method and saving on reagents that can be used for later 
production or optimisation. Observed cell growth was very slow in this batch, with a 
measured OD600 of 0.390 against a sterile LB blank after ~4 hours of vigorous shaking at 
180 rpm at 37°C. It was hypothesised that the most preferable induction point for the 
cells would be at an OD600 of 0.6-0.8 as this typically indicates cells have reached mid-log 
phase [253], where the cell density is high enough that a large quantity of protein can be 
produced after induction. Despite the low optical density, expression of T7 RNAP from the 
pAR1219 plasmid was induced by addition of IPTG. Flasks were returned to incubation 
under the same conditions for a further 4 hours, reaching a final OD600 of 0.515, far below 
the suggested harvesting range by the protocol (OD600 1.0-2.0). Cells were harvested by 
centrifugation at 4000 rpm at 4°C to maintain cell pellet integrity. After overnight storage 
of cell pellets at -20°C, cells were thawed and subject to LOFT treatment. Cell pellets were 
suspended in 400 mM sucrose and treated with 50 µL of 20 mg/mL chicken egg-white 
lysozyme once every 30 minutes for 2 hours. Lysozyme is known to cleave peptidoglycan 
[254], a protein that polymerises to form the bacterial cell wall encapsulating the plasma 
membrane. This is highly effective against disrupting gram-positive bacteria [255], but 
less so against gram-negatives like E. coli due to the existence of the outer membrane 
with these bacteria that surrounds the peptidoglycan layer. Lysozyme sourced from 
chicken egg whites is used as this is known to increase the permeability of this outer 
membrane, allowing access of lysozyme to the peptidoglycan layer to disrupt it [256]. By 
attacking the cell wall in this way, it makes the cells more susceptible to disrupting 
entirely under biological or physical stresses, so a combined osmotic and freeze-thaw 
treatment is used to maximise disruption and increase the protein yield liberated from 
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the cells. Cells were washed twice with 0.4 M sucrose. As the cells had already been 
permeabilised by the lysozyme treatment, this has the effect of drastically increasing the 
solute concentration inside the cell. The effects of sucrose washing of E. coli cells are 
known to release various hydrolytic enzymes such as proteases and DNAses into solution 
[257, 258]. This release is selective as osmotic shock affects the region between the 
bacterial cell wall and the cytoplasmic membrane, where these hydrolytic enzymes are 
confined [259, 260]. As such, this process should prevent the loss of enzymes and 
proteins (such as T7 RNA polymerase) that need to be retained for optimal CFPS function. 
The supernatant discarded between each wash step therefore contains a majority of 
unwanted degradative molecules. This is important to note for the application of the 
toehold switch sensor assay as both the reaction input template and sensor elements are 
composed of DNA and the output molecule is a protein. The removal of enzymes that 
could potentially degrade these key molecules is therefore beneficial and may minimise 
or prevent reaction inhibition from endogenous sources. After this stage, the resulting 
cell pellet was weighed at 1 g. Sucrose-treated cells were rapidly dissolved in double-
distilled water at a ratio of 10 mL H2O per gram of cell pellet. Difficulty was observed in 
suspending this pellet, taking far more water to dissolve than was indicated by the 
protocol, which used a 1:1 ratio of DDW to cell weight. The hypotonic environment 
outside of the cell leads to the diffusion of water inside the cell, causing lysis by excessive 
swelling of the membrane. Finally, water-dissolved cells were frozen at -80°C and thawed 
in ice water after overnight storage. This further disrupts any cells that remained intact 
following hypotonic treatment by expanding the water inside cells via freezing, causing 
lysis by physical displacement of the cell membrane. Following ultracentrifugation of the 
cell resuspension at 30,000 x g at 4°C for 1 hour, separation of lysate from insoluble cell 
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waste appeared incomplete, resulting in a viscous supernatant solution that appeared 
translucent green-brown in colour. The viscous nature of the supernatant was not 
deemed unusual as this is how the extract was described in the original protocol. A BCA 
protein quantification assay (Pierce™ BCA Protein Assay Kit, Thermo Fisher Scientific 
#23225) performed on lysate samples estimated the average protein concentration as 0.4 
mg/mL across 6 replicates, falling below the concentration required for cell-free protein 
synthesis by at least a factor of 50, indicating a failure to obtain a full lysate. Whilst it was 
deemed unlikely, it was tested to see if this batch could express wtGFP from a plasmid. 
Plasmid DNA constitutively expressing wtGFP was added to the cell lysate (with necessary 
CFPS additives) at 60 ng/µL final concentration in a 10 µL reaction and incubated for four 
hours at 37°C. As expected, no change in solution fluorescence was observed across a 4-
hour incubation of the batch and other CFPS reaction components at 37°C (Figure 4.2). 
 
 
Figure 4.2: Change in fluorescence over time of reaction mixtures containing combinations of E. 
coli cell lysate, 60 ng/µL wtGFP plasmid, and additives required for CFPS. 
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After blank-correcting fluorescence, every reaction mixture that contained E. coli cell 
lysate displayed fluorescence above the baseline whereas the mixture that only contained 
wtGFP plasmid did not. This suggests that the cell lysate exhibits some level of 
autofluorescence at the wavelengths tested, which will need to be taken into 
consideration for further optimisation.  It was hypothesised that the slow growth of the 
first batch was due to poor aeration of the cells as a result of the low flask:media volume 
ratio. A second batch was prepared that altered this condition, reducing the volume of 
media down to 100 mL (giving a flask:culture volume ratio of 3:1). With this batch, an 
OD600 of 0.675 was reached after ~2.25 hours of incubation, indicating that the greater 
oxygen availability has accelerated the growth of cells and allowed them to reach the 
desired mid-log phase. Cells were induced with IPTG at this point and returned to 
incubation. After 4 hours of post-induction growth, a final OD600 of 1.4 was measured, 
within the OD600 range expected from the protocol. Following disruption treatment, a cell 
pellet with a mass of 2.04 g was obtained. Although this is twice as much material than 
the first batch, the same difficulty was observed in dissolving the pellet, also requiring a 
~10:1 water:pellet ratio. The lysate obtained after ultracentrifugation had the same 
appearance and consistency as the first batch, although a BCA assay estimated the 
lysate’s concentration at 2.65 mg/mL. An endpoint fluorescence intensity measurement 
of this extract containing 60 ng/µL wtGFP pDNA and CFPS additives taken after 14 hours 
incubation at 29°C was indistinguishable from a blank. Although inducing T7 RNAP 
expression in the mid-log phase increased protein content in the lysate, it was still below 
the concentration necessary for CFPS. The assumption was made that the low 
concentration is a result of too few cells being lysed. Increasing the volume of media that 
cells are inoculated into would result in a much greater density of cells at mid-log phase 
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and in turn increase the quantity of liberated protein. To address this, a third batch was 
prepared that scaled up the culture volume from 100 mL to 500 mL in a 2 L flask, which 
also further reduces the flask:culture volume ratio to 4:1, which should further aid media 
aeration. Protein expression was induced with IPTG after ~2 hours of incubation at ~0.7 
OD600 and cells were harvested at ~1.5 OD600 following 4 hours of post-induction 
incubation with shaking at 37°C. Although the cell paste mass was greater in this batch 
following lysozyme treatment and washing (4.54 g), a BCA protein quantification assay on 
the resulting whole cell supernatant varied between 1.5 mg/mL and 4.8 mg/mL, with an 
average concentration of 2.7 mg/ml, the same as the previous batch. Again, taking an 
endpoint measurement of fluorescence intensity after 14 hours incubation with wtGFP 
plasmid did not produce any fluorescence.  
 
4.4.1.2. Adaption of Method for Successful Cell Lysate Separation 
The low final protein concentration of the cell lysates obtained thus far, coupled with 
observations that were inconsistent with the original protocol (i.e. high volumes of DDW 
needed to dissolve cell pellets prior to centrifugation, viscous appearance of final lysate) 
led to the conclusion that premature cell disruption was occurring, leading to the loss of 
cell protein. Three areas in the protocol were identified where issues may be presenting. 
These were: 1) cell harvest OD600; 2) cell media composition; and 3) the lysing process.  
Addressing the first point, the aim of maximising protein yield would lead to harvesting 
cells during the exponential phase of cell growth. Exponential phase is characterised by a 
majority of the cells being alive, able to produce protein, and with a sufficient stock of 
nutrients available in the nutrient broth media [237] to allow for continued exponential 
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growth. For E. coli growing in LB broth, this phase is typically exhibited when cells reach 
an OD600 of between 0.6 to 1.0 [261]. Although the optical density at which T7 RNAP 
expression was induced (~0.7) falls within this range, cells were harvested around a final 
OD600 of 1.4 – 1.5, after most cells have left growth phase. The low concentration of the 
lysate, along with the high cell density making resuspension difficult, suggests inducing 
protein expression and harvesting at an earlier stage would be beneficial, as indicated by 
some crude extract preparation protocols [262]. An earlier harvesting step would reduce 
cell density without necessarily compromising on protein concentration as most cells are 
alive and producing protein. Another consideration is that cell density during growth 
phase can be underestimated from instrumental variation, leading to cell induction and 
harvesting later than desired. To ensure instrument variance was not affecting the 
induction and harvesting timings used, wavelength calibration checks were followed 
according to the spectrophotomer (Cole Parmer 1100) manufacturer’s instructions prior 
to beginning the next batch preparation [263]. Additionally, OD600 measurements were 
cross-referenced with a second spectrophotometer model (BMG Labtech Spectrostar 
Nano [264]) to confirm all further readings. During the lysing process, it is important that 
full lysis is only achieved after the final freeze-thawing step prior to ultracentrifugation. 
Early disruption of cells would lead to cellular protein being discarded along with 
supernatant during the washing process, rendering the lysate unusable. Maintaining the 
osmotic and ionic balances of cells up until this point is desired, and this can be factored 
into the protocol. The liquid LB broth formulation used up to this point contains 0.5% 
NaCl. However, the antibiotic expressed on the pAR1219 plasmid (ampicillin) is not salt-
sensitive, so the NaCl concentration can be increased to 1% without a negative impact on 
the cell culture with the benefit of increased electrolyte concentration, helping to 
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maintain the osmotic balance of cells in the culture. After harvesting cells, the cell pellet is 
slowly re-suspended in 20 mL of 400 mM sucrose prior to lysozyme treatment. The slow 
resuspension of pellet, in addition to the long lysozyme treatment without buffer (4 
treatments of lysozyme across 2 hours) is a potential source of early cell disruption. Rapid 
resuspension of pellet at this stage would be preferable to reduce osmotic stress, and 
lysozyme concentration can be doubled with the incubation time halved to reduce the 
amount of time the cells are in contact with the lysozyme.  
After consulting the literature [247, 262], it was decided that a buffer exchange step may 
be necessary to achieve the protein yields outlined in the protocol. To do this, DDW was 
replaced as a solvent with S30 buffer. There are several recipes for S30 buffers but they 
typically contain Tris-buffered acids, cations such as potassium and magnesium 
conjugated with acetates and glutamates, and stabilisers such as DL-Dithiothreitol (DTT) 
[265-267]. After ultracentrifugation, the cell lysate can be exchanged with a similar buffer 
of more dilute concentration via a filter unit. This concentrates down the lysate, 
increasing final protein concentration. This also has the benefit of removing most 
exogenous materials that were incorporated into the extract during the preparation 
stage, such as the lysozyme or sucrose [268]. Taking these optimisation points into 
account, an amended protocol was produced with the following changes:  
1) Induce expression of T7 RNAP by E. coli cells in liquid culture with IPTG at OD600 = 
~0.4 and harvest by centrifugation at ~0.8-1.0. 
2) Rapidly resuspend cell pellets using a brush in all instances to prevent early 
disruption. 
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3) Lyse cells in a single step by addition of 400 µL of 20 mg/mL chicken egg-white 
lysozyme (dissolved in 400 mM sucrose) to the cell suspension and incubate on ice 
for one hour.  
4) Dissolve sucrose-treated cells in S30 A buffer (10 mM Tris-HCl, 60 mM potassium 
glutamate, 14 mM magnesium acetate, 2 mM DL-Dithiothreitol (DTT)) instead of 
double-distilled water. 
5) Buffer exchange the S30 extract with S30 Buffer B (5 mM Tris-HCl, 60 mM 
potassium glutamate, 14 mM magnesium acetate, 1 mM DTT) in an Amicon Ultra-
15 10k centrifugal filter tube to a final dilution of 1:1000 sample to buffer ratio (3 
dialysis passes).  
 
With this amended protocol, another batch of lysate was prepared. Cells were induced at 
OD600 = 0.5 after 2.5 hours of growth and harvested at OD600 = 0.9 after 2 hours further 
incubation. After biochemical lysing, the cell pellet had a wet mass of 5.44 g, greater than 
any batch so far despite an earlier harvesting time. The pellet was also readily re-
suspended in a 2:1 volume (mL):cell mass (g) ratio of S30 buffer A, compared to 
previously difficult resuspension in much greater quantities of DDW. Ultracentrifugation 
at 30,000 x g of the cell resuspension following freeze-thaw treatment produced ~15 mL 
of a clear, colourless solution that was distinct from the cell pellet which was determined 
to be an instance of successful lysate separation (Figure 4.3).  
 




Figure 4.3: Visualisation of E. coli cell extract immediately following ultracentrifugation at 30,000 x 
g. Clear supernatant contains the whole crude cell extract whereas the pellet consists of unwanted 
cell debris.  
 
4.4.2. Determination of Lysate Protein Concentration 
The clear extract was buffer exchanged with S30 B buffer by first concentrating the 
sample by centrifugation at 4000 rpm, diluted 10-fold in S30 buffer B, then spun again. 
Buffer exchange works on a principle of diafiltration, where an ultrafiltration membrane 
of a given pore size retains macromolecules that are larger than the pores but will allow 
the free passage of solutes through the membrane, which can be discarded [269]. A pore 
size of 10 kDa was used. This is much smaller than many of the macromolecules necessary 
for successful CFPS (e.g. T7 RNAP has a MW of ~100 kDa [270]) but will remove additives 
that were used in the lysing process such as sucrose and lysozyme. The buffer also 
contains small molecules such as GluK and MgAc which assist in CFPS reactions [247] so 
the retention of these molecules in the final lysate may be beneficial for later protein 
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synthesis with the extract. After three cycles of buffer exchange, sample volume 
decreased to roughly a third of the original harvested supernatant, with an approximate 
volume of 5 mL. The protein concentration of the final S30 extract was quantified by BCA 
assay. Given the relatively low dynamic range of the BCA assay (0 – 2 mg/mL) [248] and 
the high expected protein concentration of the extract, a dilution series was prepared of 
neat concentrate, 1:10 and 1:100 dilutions of concentrate with ultrapure water, and 
filtrate from buffer exchange. Filtrate was not calculated as containing any protein 
suggesting buffer exchange was successful and there was no sample loss. As expected, 
neat concentrate was reported at the absorbance maxima (3.5 OD562), and as such the 
concentration value obtained from this sample (~3.6 mg/mL) was deemed unreliable as it 
fell on the extreme end of the scale. Dilutions of concentrate at 1:10 and 1:100 ratios had 
optical densities within the acceptable range for the BCA quantification assay (Average 
blank-corrected ODs of 0.61 and 0.28, respectively). Using a linear regression formula 
derived from the standard BSA curve and accounting for dilution factors, protein 
concentrations of the original samples were estimated at 5.9 mg/mL (1:10 dilution) or 23 
mg/mL (1:100 dilution), respectively. A repeat estimation across all 8 aliquots of the 
prepared extract returned similar results (average concentrations of 6.52 mg/mL, 13.17 
mg/mL and 21.30 mg/mL at 1:10, 1:50, and 1:100 dilutions, respectively) suggesting that 
this phenomenon is indicative of the extract as a whole.  
To understand the reasons for the discrepancy between measurements, and to 
determine which concentration value is most accurate, BSA standards were prepared 
again using S30 buffer B as the diluent instead of water, so as to be directly comparable 
to the lysate samples. Two negative controls were used consisting of only distilled water 
or S30 buffer B. A spectral scan of blank S30 buffer B was performed using the ClarioStar 
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plate reader to determine if this buffer had any absorbance around 562 nm, which may 
be interfering with the assay. No absorbance in this region was observed, but addition of 
the BCA working reagent to the buffer immediately produced a light blue colour, which 
persisted after incubation at 37°C. The same colour change was also noted when adding 
the working reagent to standards containing BSA protein but gave way to the expected 
green-purple colorimetric scale after incubation (Figure 4.4). 
 
Figure 4.4: Image of wells containing BSA protein standards across a concentration gradient with 
S30 buffer B as the diluent after 30-minute incubation at 37°C with BCA working reagent. A-E = 
BSA at 2000, 1000, 500, 250, and 125 µg/mL concentrations, respectively. F = Distilled water only, 
G = S30 Buffer B only. 
 
As per the manufacturer’s kit information [248], the BCA quantification assay is a two-
step reaction whereby Cu2+ in the working reagent is reduced to Cu+ by chelation of 
protein in an alkaline environment, before reacting with BCA to produce the purple 
colour that is then quantified by absorbance at 562nm. As the S30 B buffer is mildly 
Chapter Four – Lysate Development for Cell-Free Protein Synthesis 
186 
 
alkaline (pH = 8.0), the formation of a clear light-blue complex suggests the buffer is 
acting as a chelating agent for Cu2+, and may then be affecting the quantification of the 
extract to some degree. Absorbance measurements of BSA standards diluted in S30 
buffer B at 562 nm revealed that at higher protein concentrations (2 mg/mL, 1 mg/mL 
BSA), optical densities (and thereby protein concentrations) were underestimated by 
between 50-70% against buffers made up in water. This provides evidence to suggest that 
lower dilutions of S30 extract concentrate (i.e. 1:10) are underestimating total protein 
due to the presence of chelating agents, and that greater dilutions (e.g. 1:100) with pure 
water are more accurate as buffer has been diluted out. This led to the conclusion that 
the quantification values obtained from 1:100 dilutions of extract were the best measure 
of extract protein concentration. Averaging the quantification values across all aliquots of 
prepared S30 extract, the total extract protein concentration was estimated at 22.16 
mg/mL, which is within the expected range of 20-30 mg/mL.  
 
4.4.3. Protein Expression In Vitro with an E. coli Cell Lysate 
Having obtained a cell lysate of sufficient protein concentration, CFPS reactions were 
assembled at 10 µL size, with a final lysate concentration of 15 mg/mL (Figure 4.5), then 
incubated in a plate reader at 29°C. Commercial PURExpress cell-free protein synthesis 
reactions were run in tandem as a positive control. Two negative controls were included: 
1) S30 extract and additives without wtGFP plasmid; and 2) wtGFP plasmid only. Volume 
in these reactions were made up with DNA-grade water.  
 
 




Figure 4.5: Change in fluorescence over time in full CFPS reaction mixtures containing E. coli extract and commercial PURExpress kit when synthesising 60 
ng/µL of pDNA encoding wtGFP under T7 control. 
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Wild-type GFP plasmid template at 60 ng/µL concentration was expressed by both in-
house and commercial systems at 10 µL reaction size over 14 hours at 29°C. Interestingly, 
fluorescence was far greater in three of the five replicate in-house reactions compared to 
the commercial kit, rising to the limit of relative fluorescence that can be detected by the 
plate reader within four hours. The lower performance of the PURExpress kit in this 
experiment is attributed to incubating the reaction at a temperature below the optimum 
suggested by the manufacturers (37°C). Fluorescence was observed in the negative 
control well that only contained the E. coli lysate, whereas the well containing only pDNA 
and water did not fluoresce, consistent with observations of autofluorescence in batches 
prepared using the old protocol (Figure 4.2). To ensure that these results were due to the 
changes that were made to the protocol and not by chance, the amended protocol was 
repeated, and another batch of lysate produced. The cell pellet from this batch had a 
weight of 4.54 g prior to resuspension in S30 buffer. Following ultracentrifugation and 
buffer exchange, 5.5 mL of cell extract was quantified at 20 mg/mL total protein by BCA 
assay, which was also able to synthesise GFP from a constitutive plasmid at 60 ng/µL 
input at 37°C but does not fluoresce as greatly, indicating that optimal protein synthesis 
may be achieved at 29°C (Figure 4.6). 




Figure 4.6: Fluorescence over time of CFPS reactions containing LOFT cell extract, wtGFP plasmid, 
and CFPS additives. Error bars represent the standard deviation in RFU (n = 5). 
 
That both batches demonstrated protein synthesis provides evidence of the protocol’s 
reliability and suggests that the amendments made during troubleshooting directly 
improved its performance. A complete comparison of each cell lysate batch is presented 
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Table 4.2: Comparison of E. coli LOFT cell extracts prepared under starting and amended protocols. Protein synthesis was only achieved with batches 
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4.4.4. Cost Analysis 
A key developmental driver for the toehold switch sensor system was to reduce costs 
associated with CFPS, enabling high-throughput use of synthetic gene networks expressed 
in vitro for forensic sex identification. Additionally, the market research questionnaire 
(Chapter Two) identified a cost of <£20 per-test as a key factor in participants’ decisions 
to adopt a novel assay. The PURExpress™ In Vitro Protein Synthesis Kit (NEBiolabs) costs 
£253 for a kit containing enough reagents for 10 reactions at 25 µL reaction size, giving a 
per-reaction cost of £25.30 which is over this limit. However, both the manufacturer’s 
guidance and the data observed here show that reactions can be scaled down to 10 µL 
and still elicit detectable protein synthesis. Assuming a smaller reaction size, the cost per 
reaction is now £10.12. Although generating a cell lysate in-house is more time-intensive 
to produce, a relatively large amount of lysate material could be obtained. Both batches 
produced under the amended LOFT treatment protocol contained ~5 mL of lysate after 
small molecule exchange. As demonstrated, this lysate can also synthesise protein in a 10 
µL total reaction providing enough material for 500 reactions. However, the lysate by 
itself is not enough to initiate protein synthesis. The system requires exogenous additives 
such as NTPs and coenzymes to facilitate CFPS. While some of these additives are cheap 
and available in large quantities such as MgAc and GluK, other molecules can be more 
expensive and supplied in smaller quantities, making them the limiting factor of the 
reaction in terms of cost. In order to properly address cost, cost was examined at both a 
per-lysate batch and per-CFPS reaction basis. Totalling the cost of each reagent involved 
in generating an E. coli cell lysate, an initial start-up cost of £756.84 was calculated before 
tax. Whilst this is more than three times as expensive as the commercial PURExpress 
system, these reagents are obtained in quantities far greater than necessary for 
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producing a single batch. Per-batch cost was calculated by determining the percentage of 
each reagent that is consumed from its total stock in production of a single batch, then 
multiplying its original cost by this percentage. In doing so, a per-batch cost of £33.68 was 
determined. As previously mentioned, a potential 500 reactions at 10 µL size can be 
performed with the average cell lysate quantity obtained, this gives a per-reaction cost of 
a single batch of £0.07, far below the commercial kit. However, the lysate alone is not 
enough for CFPS to take place, and additives must be supplied to the system in order to 
synthesise protein. The reagents involved in preparing an additive mixture (see Table 4.1) 
are independent of assembling the cell lysate so the cost will be considered separately. 
The cost of acquiring the reagents for the additive mixture was calculated at £326.99 
before tax. Adding this cost to the costs for generating an E. coli cell lysate, a total in-
house CFPS start-up cost of £1083.83 was obtained. Additive mixtures are prepared fresh 
with each CFPS reaction mixture. Working stocks of each additive reagent are prepared 
and kept refrigerated/frozen as appropriate before use. As the number of possible 
reactions before exhausting stock is not the same between reagents, different additives 
become limiting factors in terms of cost. This means that reagents must be restocked at 
different rates, incurring repeat costs for in-house CFPS. The most limiting reagent of the 
additive mixture are amino acids. Amino acids are critical for reaction progress as they are 
incorporated into the growing polypeptide chain during translation. Amino acids are 
supplied at 1 mM concentration of the 20 essential amino acids and are used at a 0.5 mM 
concentration in the additive mixture. This means that amino acids comprise 50% of the 
volume of the additive mixture regardless of total volume and as such are the first 
reagent to become exhausted in the mixture by a large margin. Under the 10 µL CFPS 
reaction size used up to this point, 35 CFPS reactions are possible before amino acids 
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must be restocked. The mixture of amino acids used for in-house CFPS cost £44 before tax 
and would need to be restocked 15 times to perform enough CFPS reactions to fully 
deplete one batch of cell lysate, which would have a total cost of £660. Another reagent 
identified as potentially limiting is 3-PGA, a phosphate-containing compound necessary 
for energy regeneration by phosphorylation of di- and mono-phosphates. At 10 µL 
reaction size, approximately 100 reactions can be carried out before 3-PGA must be 
restocked. A stock of 3-PGA costs £14.50 and so would cost £72.50 to restock enough 
times to use up a cell lysate batch. It may be possible to circumvent this issue with the use 
of alternative energy sources such as creatine compounds [271]. The remaining reagents 
such as buffers, ions, and cofactors are made up in stock solutions large enough that 
several hundred reactions (equal to or exceeding the number of reactions possible with a 
single batch of S30 lysate) can be performed before the need to restock. 
The need for reagent restocking before exhausting a single batch of cell lysate has 
implications for the system’s practical use as a field-based biosensor. High-throughput 
laboratories may find these recurring costs a drawback to the system over conventional 
field-based sex identification tests but may not deter low- to mid-throughput usage. 
Assuming no restocking of reagents is made, this would give a total reaction number per 
additive mixture of 35. This gives a per-reaction cost from a single batch of additives of 
£9.35, this is much more expensive than the cost of the lysate (35 reactions worth of S30 
lysate would cost ~£0.97) and is therefore the most resource intensive portion of CFPS. 
However, this combined cost of additives and lysate would still be below the critical £20 
per-test outlined above and similar to existing commercial costs at 10 µL reaction size. 
Obtaining these reagents through different suppliers or isolating/purifying them in-house 
may be alternatives to reduce reaction costs.  




By adapting a protocol from the literature, it has been demonstrated that an E. coli cell 
lysate can be prepared without the use of mechanical disruption equipment. 
Furthermore, large amounts of fluorescence were observed in reaction mixtures 
containing this lysate (with additives) and pDNA encoding a fluorescent reporter gene, a 
strong indicator that batches prepared in this manner are capable of full, prolonged 
protein synthesis. With regards to cost, generating a batch of cell lysate in-house is far 
cheaper than buying in commercial in vitro protein synthesis kits on a per-test basis, but 
additional work is required to reduce costs associated with preparing mixtures of 
additives that are critical to CFPS to enable high-throughput usage of the system in low-
resource environments.  
Following on from this work, the main priority should be to attempt expression of toehold 
switch networks in vitro and optimise protein synthesis by adjustment of reaction 
mixtures and conditions, before moving onto full prototyping of a toehold switch network 
based on a novel forensic sex identification marker. 
 




Optimisation of In Vitro Cell-Free Protein Synthesis and Expression of 
Toehold Switch Networks 
5.1. Abstract 
Chapter Four detailed the preparation of a crude E. coli cell extract by a combination of 
enzymatic, chemical and physical disruption. After optimisation of the lysing process, two 
batches of cell lysate were prepared, both of which had protein concentrations ≥20 
mg/mL and were capable of synthesising wild-type green fluorescent protein in vitro from 
plasmid DNA template at a concentration of 60 ng/µL at 29°C and 37°C.  
To enable the use of cell-free protein synthesis systems as a tool for expressing synthetic 
gene networks for bio-detection, the crude extract was characterised in a series of 
experiments that examined dynamic range, ideal template DNA form, and ideal reporter 
gene. Additionally, a commercial protein synthesis (PURExpress® In Vitro Protein 
Synthesis Kit, NEB) was characterised to serve as a point of comparison. Successful 
protein synthesis was observed in the in-house system down to 300 pg/µL template 
plasmid input. The quantity of fluorescence produced by both cell-free systems could be 
modified up or down by increasing or decreasing template DNA concentration, 
respectively. Following optimisation, a toehold switch sensor was designed in-house 
specific to the recognition of transglutaminase 4 (TGM4), a prostate-specific mRNA which 
enables the sensor to act as a presumptive sex identification test. TGM4 toehold switch 
function could not be executed in either the in-house or commercial cell extract systems, 
indicating an issue with network design. This chapter discusses recommendations for 
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troubleshooting of toehold switch expression in cell-free protein synthesis systems and 
further optimisation.  
 
5.2. Introduction 
The preparation of an E. coli cell lysate that is capable of synthesising protein from pDNA 
is a significant step towards the goal of producing a field-based sex identification test with 
synthetic gene networks as it provides a platform for the networks to execute their 
functions of targeted genetic recognition and downstream gene expression. Therefore, 
optimisation of the in-house CFPS system’s function is a priority to enable the simple 
introduction of toehold switch networks. The data obtained during this process can be 
related back to existing forensic sex identification tests such as the qPCR assay validated 
previously (Chapter Three) to determine if the CFPS assay would be suitable for 
deployment or if further optimisation is required. The preliminary CFPS activity 
experiments performed in the previous chapter (Chapter Four, Figures 4.5 & 4.6) 
demonstrated that the in-house cell extract was capable of synthesising wtGFP from 
pDNA under T7 control at 60 ng/µL template, providing confidence that the system 
should also be able to express genes from more complex templates, such as those from 
synthetic gene networks. To this end, the goal of this chapter was to fully characterise the 
CFPS system and optimise reaction conditions ready for toehold switch sensor expression. 
This characterisation process involved examination of several factors with regards to CFPS 
function, such as suitable template forms, sensitivity/limit of detection, and optimal 
methods to detect reporter gene expression. To facilitate this characterisation process 
and allow comparison of in-house extract performance to an industry standard, 
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PURExpress In Vitro Protein Synthesis and S30 T7 High-Yield Protein Expression system 
reactions were run in tandem with the same templates. Throughout characterisation, 
reaction mixtures and conditions can be optimised to maximise reporter gene expression 
in the shortest amount of time. Additionally, one of the key concerns highlighted during 
development of the cell lysate was reliability of production and batch variation. As the 
lysate is a crude mixture, the exact proportions of critical transcription/translation 
proteins and associated molecules is unknown, in contrast to the reconstituted PURE™ 
system. This gives the in-house system a much larger potential for batch variation that 
may affect efficacy of protein synthesis. By running a series of optimisation experiments 
across batches, any batch variation can be identified, and the impact it has on lysate 
performance can be quantified and addressed.  
Introduction of toehold switch networks as template to CFPS reactions enable the 
assessment of cell-free protein synthesis as a field-based bio-detection tool. For the data 
obtained from this part of assay development to be relevant to forensic end-users, the 
toehold switch used should contain a genetic sequence that is complementary to the 
mRNA sequence of a forensic biomarker. mRNA profiling is a common technique for 
confirmatory detection of body fluids [272-275] but the instrumentation and setup 
required confines this process to the laboratory. Although mRNA is notably unstable 
among RNA families, with a half-life ranging from minutes to days, RNA of sufficient 
quality and quantity for mRNA profiling can be extracted from post-mortem tissue 
samples [276]. Furthermore, the existence of combined RNA/DNA extraction protocols 
allows collection of mRNA during standard sample processing. Field-based techniques for 
the confirmatory detection of genetic sequences do exist, but their accuracy falls below 
the standards required by forensic science [277], presenting a market niche for assay 
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development. Participants in the market research survey (Chapter Two) identified that 
human DNA mixtures and body fluid detection should be highly prioritised in 
development of a novel assay. These two requirements can be combined into a single 
detection assay by identifying a marker that is both present in body fluids and sex-specific 
which would allow its presence to presumptively detect male DNA samples or 
male:female mixtures. Transglutaminase 4 (TGM4) was hypothesised to be a useful 
marker for this dual purpose as it has prostate-specific expression, is secreted in semen 
[278], and has previously been identified as a potential marker for forensic mRNA 
profiling of body fluids [279]. Furthermore, detection of TGM4 mRNA has seen research 
interest in the field of healthcare due to TGM4’s proposed role in prostate cancer 
progression [280, 281]. This provides a further frame of reference that an in-house TGM4 
toehold switch biosensor can be compared against. A toehold switch sensor was 
constructed for TGM4 from its mRNA sequence using published design strategies [38]. 
While toehold switch sensors expressed using CFPS systems have been demonstrated 
previously in the literature as healthcare assays [166, 214], no such application has been 
made to forensic sex identification, making this the first such known sensor of its type. 
The TGM4 switch and its cognate trigger were used as template DNA for an in vitro 
protein synthesis reaction to determine if a sex identification assay was possible using a 
synthetic gene network approach.  
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5.3. Materials and Methods 
5.3.1. Construction of Synthetic Gene Network Components 
A toehold switch synthetic gene network composed of arbitrary nucleotides was 
identified in the literature from Green et al. [38] (see Appendix IV, Green et al. sequence 
#1). This toehold switch has been experimentally validated in vivo by the authors to 
specifically bind to its cognate trigger sequence and initiate production of fluorescent 
reporter GFPmut3b [282]. This particular network had the greatest performance (i.e. 
greatest difference between fluorescence in the activated and repressed network states) 
so was selected as a positive control for toehold switch expression experiments.  
An in-house sex identification biomarker (TGM4) toehold switch was constructed using 
toehold switch construction strategies outlined by Green et al. (Figure 5.1). 
 
Figure 5.1: Design parameters for high-performance toehold switches as outlined by Green et al. 
[38] with nucleotide lengths of each region provided. A trigger RNA containing 33 arbitrary 
nucleotides (regions a* and b*) are flanked by 5’ and 3’ hairpin sequences for transcription 
initiation and termination, respectively. A de novo toehold switch is designed complementary to 
the trigger sequence (regions a and b) where region a is unbound and region b forms a hairpin 
with a complementary downstream region containing a start codon (AUG) mismatch, sequestering 
a ribosome binding site (RBS) from interaction with the ribosome. Alignment of the switch and 
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trigger sequences at region a/a* causes linearisation of the toehold switch RNA by preferential 
binding of the switch to the trigger over the hairpin containing a mismatch, allowing ribosome 
access to the RBS. To aid unwinding, nucleotide triplet base pairs at the top and bottom of the 
stem correspond to those found to unwind most readily upon hybridisation. These bases are 
referred to as “weak” (W – 2 hydrogen bonds – adenine/thymine) and “strong” (S – 3 hydrogen 
bonds – cytosine/guanine). The reporter gene and T7 terminator following the toehold switch 
linker sequence are omitted for clarity. Both switch and trigger sequences contain a 5’ GGG leader 
sequence for transcription initiation efficiency. Figure adapted from Green et al. with permission 
from Elsevier.  
 
The mRNA sequence of TGM4 was accessed via NCBI [283]  and a 30-nt length region 
identified that met all design parameters (e.g. no in-frame start/stop codons, base-pair 
identities at the correct locations in the switch stem). A nucleotide BLAST search was 
performed to ensure there were no human biomarkers with an identical sequence that 
could elicit false positive results [284]. This sequence was flanked by arbitrary nucleotides 
generated using NUPACK software [285] to produce the full trigger. A non-specific 
transglutaminase trigger was designed by aligning the 30-nt TGM4 trigger to the mRNA 
sequence for transglutaminase 2 (TGM2) [286] and applying the same trigger design 
strategy to the region of highest similarity.  
A toehold switch for TGM4 was designed by taking the reverse complement of the 30-nt 
TGM4 trigger to make the toehold switch tail and stem regions. To the 3’ end of this 
sensor element, a pre-RBS region (ATTATTA) followed by a strong RBS sequence sourced 
from the iGEM Registry of Standard Biological Parts [287] (part number Bba_B0030) was 
added. To sequester the RBS region into a hairpin, the following 18 nucleotides were 
complementary to the nucleotides immediately preceding the RBS region, causing self-
binding but leaving a 15 nucleotide overhang at the 5’ end of the sequence which acts as 
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the binding site for TGM4 DNA. An ATG mismatch was inserted between bases 6-9 of this 
self-binding region. A linker sequence of 21 nucleotides (AACCTGGCGGCAGCGCAAAAG) 
was added at the 3’ end of the sequence immediately before the reporter gene.  
A number of different fluorescent proteins were used as reporter genes throughout this 
chapter. Initially, GFPmut3b was used in order to replicate the protocols utilised by Green 
et al. as above and facilitate the transfer of this knowledge in-house. However, 
GFPmut3b’s spectral profile was sub-optimal for measurement with the built-in ClarioStar 
plate reader spectrophotometer which necessitated the use of a reporter with a greater 
Stokes shift, namely wild-type GFP. This reporter was used throughout the 
characterisation stages of expressing plasmid DNA in CFPS systems. Finally, when 
expressing an in-house toehold switch based on the TGM4 biomarker, the Superfolder 
GFP (sfGFP) protein was used for its superior fluorescence and folding capabilities over 
wtGFP [288]. Toehold switch constructs containing reporter genes did not include a start 
codon at the beginning of the protein coding sequence as this was already present in the 
toehold switch stem. NUPACK software was used simulate nucleotide binding between 
constructs under default ionic conditions at 37°C and 29°C.  
The TGM4-specific toehold switch and trigger constructs were commercially inserted into 
separate pYes2.1/V5-His-Topo cloning vectors and synthesised by ThermoFisher 
GeneArt™ services. This plasmid contains an ampicillin resistance gene, T7 promoter prior 
to the insert region, and the V5 and 6xHis tags. However, each construct contained a 
transcriptional terminator at the 3’ codon (TAA), which prevents the tagging of the gene 
product (Figure 5.2).  
 




Figure 5.2.: Plasmid maps of the pYes2.1/V5-His-Topo cloning vectors containing TGM4 switch and TGM4 trigger inserts. The insert for the TGM4 switch 
contains a GGG leader sequence, the TGM4 hairpin (as described above) attached to the coding sequence for superfolder GFP and a 3’ T7 terminator. The 
TGM4 trigger vector contains a 33 bp sequence of TGM4 DNA (as described above) flanked by 5’ and 3’ hairpins as described previously (see Figure 5.1).  
Inserts do not contain any in-frame start or stop codons, besides the start codon engineered into the TGM4 switch hairpin necessary for gene expression.   
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Constructs were obtained as both 100 µg plasmid preparations in 1X TE buffer and as 
glycerol stocks for further production by plasmid preparation in-house. All plasmids were 
supplied with documentation confirming the nucleotide sequence order and 
concentration of pDNA in TE buffer. 
 
5.3.2. Synthesis of Oligonucleotides and Plasmids 
The positive control switch and trigger described above was also synthesised as a linear 
oligonucleotide by Eurofins Genomics. Oligonucleotides were amplified by PCR using the 
HotStar HiFidelity Polymerase Kit (QIAGEN) using the manufacturer’s protocol [289]. A 50 
µL PCR reaction master mix was assembled at room temperature, containing 10 µL 5X 
HotStar HiFidedlity PCR buffer, 2.5 units of HotStar Hifidelity DNA Polymerase, 1 µM each 
of forward and reverse primers, with the master mix volume made up with nuclease-free 
water. Reagents were mixed thoroughly before 9 µL of master mix was dispensed into 5 
individual PCR tubes, and 1 µL of template DNA added to a final concentration of 
approximately 900 copies per µL. Tubes were spaced evenly in a Rotor Gene Q (Qiagen) 
and cycled under the following settings (Table 5.1):  
Table 5.1: PCR cycling protocol for amplification of linear DNA oligonucleotides. 
  Time Temperature (°C) 
Activation Step 5 mins 95 
3-Step Cycling Program     
Denaturation 15 sec 94 
Annealing 1 min 62 
Extension 1 min 72 
Number of Cycles 35   
Final Extension Step 10 min 72 
Indefinite Hold ∞ 4 
 




PCR product was stored at -20° until use as template DNA with cell-free protein synthesis 
reactions. 
A Nanodrop 2000 spectrophotomer (Thermo Fisher Scientific) was used to confirm 
documented pDNA concentration immediately prior to each use. Nucleic acid 
concentration measurements were taken by first blanking the spectrophotomer with 2 µL 
of TE buffer, before cleaning the sample stage and measuring the optical density of 2 µL 
of sample pDNA at 260 nm (OD260). The ratio of absorbance at 260 nm and 280 nm was 
used as an assessment of sample purity, with an OD260/280 reading of ~1.8 accepted as 
pure DNA.   
Where necessary, more plasmid DNA was prepared by streaking pre-made glycerol stocks 
of E. coli transformed with the plasmid to be prepared onto LB agar plates containing 
1:1000 ampcillin and incubating overnight at 37°C. Single colonies were identified and 
added to liquid LB media (~3 mL, 1:1000 ampicillin) and incubated overnight at 37°C with 
shaking at ~220 rpm. Plasmids were isolated from overnight cultures by preparation with 
the QIAprep Spin Miniprep Kit (Qiagen) following the manufacturer’s instructions [290], 
with the exception of using DNA-grade water to elute DNA instead of elution buffer EB. 
Plasmid DNA concentration from plasmid preps were quantified by spectrophotometry as 
above, using DNA-grade water as a blank instead of 1X TE buffer.   
 
5.3.3. Reaction Mixture Assembly and Incubation 
Cell-free protein synthesis reactions using commercialised kits were carried out following 
the manufacturer’s protocols, scaled down to 10 µL from 25 µL (PURExpress®) or 50 µL 
(S30 T7 High-Yield). Both kits specify in their technical manuals that scaling down of 
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reaction volumes to this level should not impact final gene expression levels [249, 291]. 
Reagents were thawed on ice prior to use. S30-T7 master mixes were assembled by 
adding 3.6 µL of Circular T7 S30 Extract to 4 µL of S30 Premix Plus per reaction in a 0.2 mL 
PCR tube and mixing thoroughly. With PURExpress® mixtures, 3 µL of PURExpress 
Solution B was added to 4 µL of PURExpress Solution A per reaction and mixed 
thoroughly. Master mixes were aliquoted for the appropriate number of reactions into 
individual wells of a 384-well black-frame, clear bottom microplate (4titude, #4ti-0203). 
Template DNA was added at appropriate concentrations and nuclease-free water added 
to make up volume if necessary. Reactions were mixed by pipetting up and down before 
placing the microplate in a ClarioStar™ plate reader for incubation and detection of 
reporter gene expression. Unless noted elsewhere, 5 replicates were performed for each 
cell-free protein synthesis reaction condition. 
 
5.3.4. Detection of Reporter Gene Expression 
Fluorescent reporter gene expression was detected using microplate photometry and 
fluorescence microscopy. All microplate photometry was performed on a ClarioStar™ 
Plate Reader (BMG Labtech) running the manufacturer’s proprietary Reader Control 
Software and MARS Data Analysis Software [292, 293]. Microplates containing reaction 
mixtures assembled as described above were incubated at 37°C (4 hour measurements) 
or 29°C (14 hour measurements) under the following conditions (Table 5.2): 
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Table 5.2. Measurement settings of the ClarioStar™ microplate reader used to measure reporter 
gene expression. 
Parameter Setting 
Measurement Type Fluorescent Intensity 
  
Scanning Plate Mode 
  
Gain Automatic Adjustment 
  
Focal Height Automatic Adjustment 
  
Optics Bottom read 
  
Orbital Scanning On, 2 mm diameter 
  
Excitation/Emission 395-25/510-15 (wtGFP) 
488-10/533-30 (GFPmut3b/sfGFP) 
  
Cycle Number 1000 
  
Flashes per Cycle Automatically adjusted 
  
Additional Shaking 500 rpm before each measurement 
 
Measurement results were opened in MARS data analysis software following incubation 
to examine fluorescent profiles before exporting results to Microsoft Excel for further 
transformation of the data.  
All fluorescence microscopy was performed using an EVOS™ FL microscope equipped with 
a GFP light cube (Excitation 470, Emission 510, Thermofisher #AMEP4651) with a constant 
gain used across wells. Commercial sulfate FluoSpheres™ at 20 nm size (ThermoFisher, 
#F8848) were used as positive fluorescent controls. Images were magnified with a Plan 
Fluorite objective lens (Thermofisher, #AMEP4624). Image files were exported from the 
fluorescence microscope as .png files and imported into GIMP 2.10 software [294]. Using 
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the colour picker tool, regions of greatest fluorescence in each image were highlighted 
and red-green-blue (RGB) channel values for each well were obtained. 
In some instances, sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) was used to assess CFPS reaction mixtures for synthesised protein. Mini-PROTEAN® 
TGX Stain-Free™ 12% Precast Gels (Bio-Rad, #4568041) were assembled inside a Mini-
PROTEAN® Tetra Cell (Bio-Rad, 1658005EDU) electrophoresis tank. Buffer chambers were 
filled with 1x running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS AKA 
Tris/Glycine/SDS) and gel combs removed to load samples. 
Samples were prepared for electrophoresis by adding 2.5 µL of 4x Laemmli sample buffer 
containing 1 in 10 v/v of 2-mercaptoethanol to 7.5 µL of reaction mixture in a ventilated 
fume hood. Samples were boiled at 95°C for 10 minutes in a heat block to denature 
proteins before being placed immediately on ice. Cooled samples were loaded into 
precast gel wells alongside Precision Plus Protein™ All Blue Pre-Stained Protein Standard 
(Bio-Rad #1610373). Laemmli buffer was loaded into spare wells to prevent shifting of 
bands during electrophoresis. Gels were run at 150V for 10 minutes to ensure correct 
separation of bands from the protein ladder, which was then increased to 250V for ~15 
minutes or until the ladder had completely migrated down the gel. Following 
electrophoresis, power was turned off and running buffer discarded before removing gels 
from their cassettes ready for visualisation. All gels were visualised using a ChemiDoc™ 
MP Imaging System (Bio-Rad) using pre-programmed Stain-Free protein protocols. All 
images were exported at 600 dpi.  
Following visualisation, some gels were preserved for Western blotting. These gels were 
rinsed with water, then equilibrated in 1x transfer buffer (25 mM Tris, 192 mM glycine, 
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pH 8.3) alongside two stacks of pre-cut filter paper and a nitrocellulose membrane. A 
transfer blotting sandwich was assembled in the following order (bottom to top): filter 
paper stack, nitrocellulose membrane, SDS-PAGE gel, filter paper stack. A roller soaked 
with transfer buffer was used to remove any air bubbles that formed during assembly. 
The blotting sandwich was placed into a transfer cell which was placed into an SDS Trans-
Blot Turbo Transfer System (Bio-Rad). Transfer was initiated by running the transfer 
system at 25V for ~15 minutes. The transfer stack was disassembled and nitrocellulose 
membrane was visualised in the ChemiDoc™ MP Imaging System under pre-programmed 
stain-free and green fluorescence protocols. After imaging and image export, the 
nitrocellulose membrane was placed between two pieces of filter paper cards 
approximately twice the size of the membrane. The stack was weighted down and stored 
in a cool, dry area overnight. After overnight drying, membranes were labelled with 
identifying information, placed in a plastic sleeve and stored long-term at -20°C for later 
reference.  
 
5.3.5. Data Analysis 
All data analysis was performed using Microsoft Excel after importing raw data from 
proprietary software to create Excel reports.  
Fluorescence intensity data obtained from ClarioStar™ microplate reader assays was 
normalised by first subtracting blank-corrected fluorescence of sample solutions from the 
negative control mixture at each time point of the reaction to obtain a correction value. 
Correction values were averaged between 10 and 50 minutes into the reaction to avoid 
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skewing data from early fluorescence aberrations or later protein synthesis. Average 
correction values were then added to each sample data point to obtain normalised data. 
 
5.4. Results and Discussion 
5.4.1. Characterisation of Commercial CFPS Systems 
5.4.1.1. Characterisation with Linear Oligonucleotide Template 
Before generating expression performance data from the cell lysate developed in-house, 
it would be useful to characterise existing CFPS systems that are commercially available to 
act as performance benchmarks and positive controls.  Two commercial systems were 
considered for use as standards, the PURExpress™ In Vitro Protein Synthesis Kit (New 
England Biolabs) [242], and the S30 T7 High-Yield Protein Expression System (Promega) 
[163]. Both are coupled transcription/translation (TX/TL) systems that can fully synthesise 
protein from nucleic acid template in a single reaction, making them directly comparable 
to the in-house system which functions in the same manner.   
The first point of characterisation was to identify the appropriate forms of nucleic acid 
template for network structures and cell-free expression. Linear DNA is cheap to 
synthesise de novo and can be easily amplified with standard PCR techniques, but can be 
readily degraded by nucleases which are found ubiquitously in biological samples [295, 
296]. Conversely, plasmid DNA (pDNA) is much more stable, but is both more expensive 
to acquire and requires a cloning process to amplify. It would be expected that stability is 
crucial for toehold switches to maintain structure and repress gene activity in the absence 
of a suitable trigger. Demonstration of protein expression from linear oligonucleotide 
template would reduce the running costs associated with the system further.  
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To assess this, the positive control toehold switch and its cognate trigger as linear 
oligonucleotides were used as template in commercial cell-free protein synthesis 
reactions. Toehold switch function is identical to the graphical representation visible in 
Chapter One, Figure 1.3B, where hybridisation of the trigger mRNA sequence to the 
unbound toehold tail initiates the break-up of the switch hairpin, allowing ribosome 
access to the RBS to begin protein synthesis.  
Lyophilised pellets of both switch and trigger were re-suspended in nuclease-free water 
to stock concentrations of 16 µM (switch) and 100 µM (trigger) dsDNA. Commercial 
reaction mixtures for the PURExpress® and S30-T7 High Yield systems were prepared 
according to manufacturer’s specifications, scaled down to 10 µL with template DNA 
quantities within the recommended input range. Six reaction conditions were prepared 
with both commercial extracts. These were: 1&2) Extract with only switch oligonucleotide 
at 1.6 or 0.16 µM final concentration, respectively with 5 µM trigger oligonucleotide; 
3&4) Extract with switch oligonucleotide at 1.6 or 0.16 µM final concentration only, 
respectively; 5) Extract with trigger oligonucleotide at 5 µM only; and 6) Extract only as a 
negative control.  After assembling reaction mixtures on ice, 10 µL of solution was 
pipetted into individual wells of a 384-well black-frame, clear-bottom microplate and 
inserted into a ClarioStar™ microplate reader. The plate was incubated at 37°C for 4 hours 
with a fluorescent intensity measurement at Alexa Fluor 488 (Ex/Em: 488-10/533-30) 
settings taken every 15 seconds to measure change in relative fluorescence over time as 
GFPmut3b should be produced (Figure 5.3).  This experiment was not equimolar by 
design, the hypothesis being that an excess of trigger sequence would readily enable the 
interaction between switch and trigger sequences to occur.  




Figure 5.3: Averaged (n = 3) relative fluorescence intensity over time in PURExpress® (A) and S30-
T7 High Yield (B) reaction mixtures containing arbitrarily-designed synthetic gene network 
components at Alexa Fluor 488 (Ex/Em: 488-10/533-30) measurement settings. Relative 
fluorescence was corrected against a blank reaction mixture containing only commercial extract 
prior to plotting. 
 
There was no detectable change in relative fluorescence across the time course in any of 
the reaction mixtures, indicating that expression of GFPmut3b has not occurred.  In the 
S30-T7 reaction mixtures, all fluorescent profiles lie at the baseline along with the 
reaction blank as would be expected. Interestingly, the fluorescent profiles of 
PURExpress® reaction mixtures after applying corrections are stratified into three 
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categories dependent on the input quantity of toehold switch oligonucleotide. The 
reaction containing only extract and trigger oligonucleotide displayed fluorescence at the 
baseline along with the reaction blank, but reaction mixtures containing 0.16 µM or 1.6 
µM switch DNA remained static at ~500 RFU and ~1250 RFU, respectively. This may be 
attributed to leaky expression of GFPmut3b from the switch. The lack of difference 
between reactions containing switch DNA with or without trigger oligonucleotide 
indicates failure to express GFPmut3b beyond the apparent leakiness of the system. 
Referring to each kit’s technical manual, the PURExpress® kit is capable of synthesising 
protein encoded by linear DNA. However, the S30 T7 High-Yield Expression System 
contains nuclease activity. As linear DNA is unprotected, it is susceptible to degradation 
by this system. As such, the S30 T7 High-Yield Expression System was discounted from 
further testing.  
Although switch and trigger templates were supplied to the reactions at concentrations 
within the range recommended by the manufacturers, it was at the lower end of this 
range. It was thought that use of PCR to amplify the switch sequences to rapidly obtain 
high concentrations of network components could be beneficial, as it would both increase 
the fluorescence of the system with greater input, and enable the cheap and reliable 
deployment of the system, given the ease of modern molecular biology laboratories to 
engage with PCR. Using the HotStar HiFidelity Polymerase kit (QIAGEN), switch 
oligonucleotide was amplified. Product was quantified by Nanodrop 2000 
spectrophotomer after amplification at 668.6 ng/µL. Switch PCR product was substituted 
as DNA template with the PURExpress® extract at a final concentration of approximately 
66 ng/µL or 660 ng quantity, six times greater than the previous most concentrated 
oligonucleotide reaction; trigger concentration was used in excess at 10 µM (Figure 5.4).  





Figure 5.4: Averaged (n = 3) relative fluorescence intensity of GFPmut3b over time in PURExpress® 
reaction mixtures containing arbitrarily-designed synthetic gene network components amplified by 
PCR under Alexa Fluor 488 measurement settings. Sample fluorescence was corrected against a 
negative control (PURExpress solution without template DNA). 
 
Despite the much higher concentration of switch template in this reaction, there was no 
change in the fluorescence of solutions containing both switch and trigger components 
compared to those only containing switch DNA across the incubation period. Additionally, 
the autofluorescence from leaky GFPmut3b expression of the switch is not present in this 
experiment. This was most likely a result of incorporation of nucleotide errors in the 
switch and/or trigger sequences during PCR. Although the polymerase enzyme used 
(HotStar HiFidelity Polymerase) has a fidelity ten-fold greater than that of standard Taq 
polymerase [297], the switch amplicon of 807 bp length coupled with 35 rounds of PCR 
increases the likelihood that errors are being incorporated into the switch. This has 
severe implications for the secondary structure of the switch which depends on an exact 
sequence to maintain its hairpin and facilitate binding with the cognate trigger sequence. 
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A deviation in either sequence of even a single-digit number of base pairs would be 
enough to prevent binding and linearisation of the switch, as evidenced by the single 
base-pair fidelity of published toehold switches used for viral RNA detection [17, 214]. 
Errors incorporated into the coding sequence for GFPmut3b would affect folding of the 
protein and fluorophore formation as a result and would explain why no 
autofluorescence is observed when using switch PCR product over linear oligonucleotide. 
Furthermore, although the reaction is not stoichiometric, it was thought that given the 
reaction length, at least some fluorescence would be visible above the baseline if the 
switch and trigger sequences were capable of interacting.  
Given the unsuitability of PCR product as reaction template in these experiments, and the 
known presence of nucleases in body fluids such as semen [298, 299], it is unlikely that 
linear nucleic acid constructs would be suitable for a field-based forensic bio-detection 
assay although full-length mRNA transcripts have been demonstrated as suitable 
template [17]. To address this, and to rapidly transfer cell-free protein synthesis 
technology in-house while avoiding costly and iterative troubleshooting, plasmid DNA was 
investigated as template.  
 
5.4.1.2. Characterisation with Plasmid DNA Template 
In the interest of observing distinct cell-free protein synthesis from commercial kits, it 
was decided to simplify the template away from an inducible network to a system that 
constitutively expresses a fluorescent reporter gene. Doing so reduces the number of 
“moving parts” involved in a successful reaction and eases the optimisation and 
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troubleshooting processes, while allowing for toehold switch characterisation to be 
returned to after becoming comfortable with CFPS. 
A plasmid was constructed and commercially synthesised that contained the coding 
sequence for wild-type GFP (wtGFP) under T7 control. The reason for this change in 
reporter gene from GFPmut3b is due to differences in Stokes shift between the two 
genes. The Stokes shift is the difference between the excitation and emission maxima for 
a fluorescent molecule [300]. GFPmut3b has an excitation maximum of 501 nm, with an 
emission maximum of 511 nm. This gives a Stokes shift of only 10 nm, which is smaller 
than the minimum shift distance between excitation/emission allowed by the ClarioStar™ 
plate reader’s settings. Trying to measure at these wavelengths would cause a significant 
proportion of excitation light to be read back by the plate reader as emitted fluorescence, 
contributing a lot of noise to the data and making interpretation difficult. This reporter 
was measured under Alexa-Fluor 488 wavelength settings (Ex/Em 488/525) outside of the 
maxima which is sub-optimal and would reduce signal output. Wild-type GFP however 
has a major excitation peak at 395 nm with an emission maximum at 509 nm [301]. This 
gives a Stokes shift value of 114 nm, which is far greater than GFPmut3b’s, and allows for 
a custom filter set to be applied to both maxima, ensuring fluorescence is read optimally 
(Figure 5.5).   




Figure 5.5: Excitation (grey line) and emission (black line) spectra of enhanced GFP mutants and 
wtGFP. Shaded area represents the wavelengths at which a portion of excitation light would be 
read back as emitted fluorescence. Peak height represents maximal absorption and fluorescence 
intensity when excited and measured at the corresponding wavelength. 
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T7-wtGFP plasmid was used as template in CFPS reaction mixtures using the PURExpress® 
kit. Plasmid concentration was varied along a gradient to identify a dose-response 
relationship (Figure 5.6). 
 
Figure 5.6: Average (n = 3) relative wild-type GFP fluorescence intensity over time in PURExpress® 
reaction mixtures containing constitutively wtGFP-expressing plasmid DNA across a concentration 
gradient. Data was corrected by addition offset between 10 and 50 minutes.   
 
In all reaction mixtures that contained wtGFP pDNA, fluorescence was observed that was 
distinct from background noise and negative controls. The increase in relative 
fluorescence over time in all samples containing wtGFP pDNA is an indication that protein 
synthesis was successful. Furthermore, this increase is proportional to the concentration 
of pDNA in the reaction mixture, with more pDNA template producing a greater amount 
of fluorescence. This effect becomes less pronounced at the highest concentrations 
tested, as the average sample RFU is very similar between 156 ng/µL and 30 ng/µL pDNA 
template (42481 and 47125, respectively), suggesting the upper end of the system’s 
dynamic range has been reached. Although successful protein synthesis has been 
observed, it is difficult to relate this data to practical forensic application of DNA 
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detection assays as the template is circular, unlike linear genomic DNA isolated in forensic 
investigation [302]. However, the small difference in RFU between 1 ng/µL pDNA and the 
negative control after 4 hours incubation suggests that the cell-free approach may not be 
as sensitive as qPCR approaches, which routinely detected the presence of DNA down to 
single picogram DNA template (Chapter Three). Following optimisation of pDNA input, 
the process will need to be repeated using linear DNA to directly relate experimental 
results to the assay’s intended use at the crime scene detecting DNA from crude 
biological samples.  
Inspecting the fluorescent profile of each sample, two particular phenomena stand out. 
The first is that relative fluorescence in every sample is very high for approximately the 
first 5-10 minutes of the incubation period before sharply reducing to the baseline. This is 
attributed as a side effect of how the reaction mixtures are prepared. To maintain the 
stability of all of the reaction’s components, master mixes were prepared and pipetted 
into microplate wells on ice. The microplate was transferred to a pre-heated ClarioStar™ 
plate reader at 37°C immediately following sample pipetting, giving no time to acclimate 
the plate to this temperature. Fluorescence is a temperature-dependent measurement, 
with an increase in temperature being associated with a decrease in fluorescent intensity 
of solutions [303]. This sharp drop in RFU within the first 10 minutes of incubation is likely 
a result of the microplate and its sample wells being measured at sub-zero temperatures 
before equilibrating to 37°C as the phenomenon is observed even in the blank well only 
containing water. As such, the first 10 minutes of these reactions were discounted when 
applying baseline corrections and performing other data analysis. This also indicated that 
a pre-incubation step may be preferable when measuring fluorescent gene expression.  
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The second phenomenon is that even in the negative control reaction, which only 
contained PURExpress® components without pDNA there is a minor increase in 
fluorescence over time, with an endpoint RFU value below that of the lowest wtGFP 
pDNA concentration tested (1 ng/µL). One possibility for this result is a side effect of 
microplate layout. Sample conditions were separated by row, with samples containing the 
same concentration of DNA kept on the same row. Highest pDNA template samples were 
pipetted into the top-most wells of the plate, with the second-highest template 
concentration samples in the row below, and so on. The close proximity of the wells may 
have allowed fluorescent signal to “spill” over into the wells immediately surrounding it. 
To prevent this from affecting the negative controls in subsequent experiments, sample 
wells of different pDNA concentrations were spaced further apart.   
Previously, gain and focal height of the plate reader had been automatically adjusted by 
the instrumentation prior to each measurement to maximise the likelihood of observing 
fluorescence in samples wells while minimising noise. Gain is a measure of the voltage 
being passed through the photomultiplier tube which is used by the plate reader to 
detect emission light. A higher gain represents a greater voltage which makes the sensor 
more sensitive to light and increases fluorescent signal (and non-fluorescent background) 
proportionally. Focal height, also known as z-height, is defined as the distance between 
the bottom of the microplate well and the focal plane used to measure emitted 
fluorescence light. These values were automatically adjusted against a sample well 
thought to produce the greatest fluorescence (156 ng/µL pDNA) so as to provide the 
cleanest data.  
Chapter Five – Optimisation of In Vitro Protein Expression 
220 
 
Having obtained a successful protein synthesis reaction, focal height and gain values (3.6 
mm and 2237, respectively) were kept the same for further experiments in order to make 
the results from these directly comparable.  
To determine if this result was repeatable, five independent replicates of PURExpress® 
reaction mixtures containing 30 ng/µL wtGFP pDNA were incubated for 4 hours at 37°C. A 
single measurement of RFU was taken for each replicate following incubation and 
compared against a negative control containing no template DNA (Figure 5.7).  
 
Figure 5.7: Fluorescence intensity measurements of PURExpress® reaction mixtures containing 
extract with or without 30 ng/µL pDNA constitutively expressing wild-type GFP. Error bars 
represent the standard error of the mean (n = 5).  
  
Samples containing pDNA had significantly greater endpoint fluorescence at the emission 
maximum for wtGFP than the negative control (two-sample T-test: P = 0.001), indicating 
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negative control despite spacing of samples in microplate wells. This is attributed 
therefore to the autofluorescence of the PURExpress® system at these wavelengths as 
was previously observed (Figure 5.3A). Regardless, data shows that commercial CFPS 
systems are capable of expressing genes under T7 control. This provides enough evidence 
to repeat these studies using in-house cell extract.  
 
5.4.2. Characterisation of In-House Cell Extract 
In-house extract was briefly demonstrated to produce fluorescence from wtGFP template 
in excess of the PURExpress® system at 29°C during development (Chapter Four, Figure 
4.5), but this comparison had not been made at 37°C which is the optimum for 
PURExpress® performance. Performance comparisons at this temperature necessary as it 
will determine if the in-house system is suitable for real-world application in place of 
existing standards. The cost of generating a CFPS system in-house was considered in the 
previous chapter and found to be less costly than using commercial kits, which is a prime 
benefit for field deployment of the system and its use in resource-poor environments. 
However, if this reduction in cost is also associated with a significant decrease in 
performance then this needs to be addressed during optimisation of the system. A 
microplate measurement was performed directly comparing the performance of a 10 µL 
PURExpress™ reaction with 10 µL of 15 mg/mL E. coli LOFT cell extract (with and without 
CFPS additives) at 37°C (Figure 5.8). 
 
 




Figure 5.8: Averaged (n = 3) change in wtGFP fluorescence intensity at 37°C of reaction mixtures 
containing PURExpress® and in-house cell extracts (with or without CFPS additives) expressing 60 
ng/µL wtGFP pDNA. Error bars represent the standard error of the mean at each time point.  
 
At 37°C, the fluorescence intensity of the commercial and in-house extracts in the first 4 
hours of incubation is remarkably similar, with RFU values of 26434 and 27554, 
respectively, reached by 240 minutes. Furthermore, the endpoint fluorescence of the 
PURExpress® reaction mixture is very close to the previous experiment (50881 vs. 51154 
RFU, Figure 5.6), indicating the repeatability of the method. It would be expected then 
that result interpretation from either kit being applied to a forensic sex identification test 
would be roughly equal.  
Applying a logarithmic line of best fit to the data, rate of fluorescence production by both 
systems fits neatly, with R2 values of 0.979 (PURExpress®) and 0.909 (in-house extract). 
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This is consistent with other studies on the rate of wtGFP fluorophore maturation which 
displays the logarithmic S-shaped curve [304].  No fluorescence above the baseline is 
observed in the reaction mixture which contains the in-house extract and 60 ng/µL 
plasmid but without CFPS additives. The failure of this solution to produce fluorescence is 
consistent with previous omission assays that deemed the molecules in this mixture 
(Table 4.1) essential for CFPS to occur [247]. 
Examining the rate of wtGFP production by plotting change in RFU per minute of 
incubation, it is observed that the PURExpress® system has a greater production rate of 
fluorescence than the in-house extract, but this difference drops as the reaction 
continues (Figure 5.9). Rate of fluorescence production did not reach 0 for either extract 








Figure 5.9: Average (n = 3) rate of wtGFP production by commercial and in-house cell extracts as 
calculated by difference in RFU per minute. 
 
The earliest point at which fluorescence from cell extracts containing pDNA became 
distinct from the negative control was ~120 minutes in. While a result within two hours 
would fulfil the need for a rapid test, this is outside of the ideal time-to-result parameters 
identified by forensic stakeholders (Chapter Two, Table 2.2.) which was a 10 - <30-minute 
workflow. As such, more work is required to maximise early fluorescence production and 
reduce waiting times.  
Having demonstrated protein synthesis at 37°C comparable to a commercial standard, 
the in-house extract was subject to a concentration gradient of pDNA to determine if a 
similar dose-response relationship could be observed. A concentration gradient of wtGFP 
pDNA (60, 30, 10, 1, and 0 ng/µL) was used a template with the in-house extract and 
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fluorescence intensity was measured across 4 hours at 37°C. At the end of the incubation 
period however, no fluorescence was visible in any of the reaction mixtures compared to 
an extract and DNA-free blank (data not shown), indicating some form of error in the 
system. Due to the number of components involved in cell-free protein synthesis, it is not 
immediately apparent where the error has arisen. To determine if the cell extract 
components or wtGFP plasmid was at fault, a second batch of cell extract was prepared 
following the same in-house protocol used previously (Chapter Four, Section 4.3.3.) and 
wtGFP plasmid was prepared from glycerol stock and quantified by spectrophotometry at 
500 ng/µL. An additive mixture was also freshly prepared to ensure all components were 
present at the correct concentrations. Wild-type GFP pDNA at 30 ng/µL from both 
batches was supplied to both of the independently-prepared in-house cell extracts in a 
14-hour incubation at 29°C to initiate troubleshooting (Figure 5.10).     
 
 




Figure 5.10: Average (n = 3) relative fluorescence change over time of independently-prepared in-
house cell extracts containing 30 ng/µL of wtGFP pDNA supplied by a commercial provider or 
generated in-house via plasmid preparation.  
 
Profiles of extracts that contained the old batch of wtGFP plasmid appear similar to each 
other and are characteristic of the negative control from previous experiments at 29°C 
(Chapter Four, Figure 4.5), suggesting that addition of this plasmid batch has not led to 
any significant production of wtGFP. Conversely, both S30 extract batches exhibited 
fluorescence when mixed with 30 ng/µL of the newly-prepared plasmid batch, although 
the fluorescent profile, displaying a large increase in fluorescence towards the end of the 
time-course, was not similar to previous observations. From this experiment, there is 
evidence to suggest that instability of the original wtGFP plasmid batch was responsible 
for failure of the concentration gradient experiment. This instability was most likely 
introduced during freeze-thaw of the reagents for CFPS. This wtGFP plasmid preparation 
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generated from the glycerol stock was used as template in future experiments and 
aliquots were prepared to avoid freeze-thaw cycles. The concentration gradient 
experiment was repeated again with both extracts using the new batch of wtGFP plasmid 
(Figure 5.11). 
 
Figure 5.11: Average (n = 5) change in fluorescent intensity at 509 nm of the first (A) and second 
(B) independently prepared in-house extracts containing a concentration gradient of wtGFP 
plasmid from 60 ng/µL to 0 ng/µL at 29°C overnight incubation. 




Interestingly, every reaction condition including the negative control without wtGFP 
plasmid behaves similarly with the second extract (Figure 5.11B) and displays the same 
profile as was observed during the reagent troubleshooting experiment. As replicates 
were prepared independently, this result was not thought to be due to contamination 
during reaction assembly or an artefact of plate reader measurement. In contrast, the 
original batch of in-house extract does display differences between reaction conditions, 
but these did not fall into the expected dose-response relationship where a greater input 
of wtGFP plasmid leads to a greater fluorescent output. Instead, all reaction conditions 
(except 3 ng/µL wtGFP) appear within error of one another. Furthermore, fluorescence in 
these samples varied greatly across replicates leading to high standard errors (error bars 
omitted from figure for clarity). As this result was unexpected and inconsistent with 
previous experiments, more troubleshooting was required. Although quantification of the 
wtGFP plasmid confirmed that the concentration of plasmid being added to the reaction 
was correct and the OD260/280 ratio indicated pure nucleic acid, the secondary 
measurement of purity (OD260/230) was below the expected value of 2.0 in this batch, 
indicating that the plasmid contains contaminants that may be interfering with the TX-TL 
reaction. To remove these contaminants, a DNA precipitation was carried out using 
sodium acetate and 70% ethanol and re-suspended in DNA-grade H2O [305]. 
Quantification of the precipitated DNA solution returned expected OD260/280 and OD260/230 
values for pure DNA. A concentration gradient from 30 to 1 ng/µL precipitated wtGFP 
pDNA was used as template with the first batch of extract at 29°C (Figure 5.12).  




Figure 5.12: Average (n = 5) fluorescence-over-time profile (A) and endpoint fluorescence (B) of an 
in-house S30 extract reaction mixture containing wtGFP plasmid along a concentration gradient at 
29°C. Error bars represent the standard error of the mean.  
 
With precipitated pDNA, there is some indication of a dose-response relationship, 
however this is unlike that seen using the PURExpress® system as increasing the pDNA 
template concentration above 3 ng/µL does not lead to an increase in fluorescence. It 
also appears contradictory to previous in-house experiments where 60 ng/µL wtGFP 
pDNA was clearly expressed. It is possible then that this reduction in the dynamic range of 
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the extract is a function of shelf-life, as the extract used had been stored for -80°C for 
several months between these experiments. However, without the time to produce 
further extracts, and the unusual profiles obtained from the second batch of extract, it 
was necessary to carry out further troubleshooting work using the first batch of extract. 
To unpick the dose-response relationship further, 5 true replicates of 3 ng/µL pDNA 
reaction mixtures were prepared and measured to discount the possibility of human error 
in reaction assembly for this experiment. All 5 replicates displayed the same profile as the 
3 ng/µL condition in Figure 5.12, with an average endpoint RFU of 80371.4. This provides 
confidence that results are repeatable and there is no variation being introduced during 
the reaction mixture assembly process that is impacting results. It is known that wild-type 
GFP is prone to aggregation [306, 307]. As such, overexpression of wtGFP from a high 
plasmid input concentration may lead to the formation of aggregates that reduce 
fluorescence by forming away from the scanning region of the microplate. It is possible 
then that the in-house extract undergoes a hook effect at high pDNA concentration. To 
determine if reducing pDNA input could elicit a linear dose-response relationship, a 
concentration gradient of pDNA with the first extract between 3 ng/µL and 300 pg/µL was 
prepared (Figure 5.13). 




Figure 5.13: Average (n = 3) measurements of wtGFP fluorescence over time (A) and at reaction 
endpoint (B) by an in-house extract at varying wtGFP pDNA input concentrations at 29°C. Error 
bars represent the standard error of the mean.  
 
Reducing the concentration of pDNA in the reaction mixture from 3 ng/µL by a third to 1 
ng/µL does not lead to a discernible change in endpoint fluorescence. However, 
decreasing the concentration by a further third (to ~300 pg/µL) provides a profile and 
endpoint fluorescence that is near identical to the autofluorescence from the negative 
control, suggesting that a linear dose-response relationship may be observed between 1 
ng/µL and 300 pg/µL. A new concentration gradient was prepared (1000, 825, 650, 475, 
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300 pg/µL) and used as template DNA for reaction mixtures with both batches of in-house 
extract (Figure 5.14). 
 




Figure 5.14: Averaged (n = 3) fluorescence over time and endpoint fluorescence measurements for independently-prepared in-house cell extracts expressing 
wtGFP pDNA between 1 ng/µL and 300 pg/µL concentration at 29°C. A&B = Extract 1, C&D = Extract 2.  
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The concentration gradient with the first batch of extract shows a general decrease in 
fluorescence as pDNA concentration is reduced as expected, although there is a relatively 
high degree of standard error between replicates. This was attributed to instrumental 
error, as a sudden decrease in fluorescence is visible in the reaction mixtures at ~350 
minutes into the reaction (Figure 5.14A). The 300 pg/µL condition appears similar to the 
negative control, consistent with previous data which suggests that the difference in 
fluorescence between reaction mixtures is solely a result of differing expression levels of 
wtGFP. With the second batch of extract, the same fluorescence profile as previous 
experiments was observed here, where there is little increase in fluorescence for the first 
several hours of incubation, before an increase is observed after 500 minutes that 
proceeds to the end of the incubation period. Comparisons of the endpoint fluorescence 
of reaction mixtures do not return the same dose-response relationship as in the first 
batch. The drastic difference in dose-response relationship and fluorescent profiles 
between batches is a strong indicator of batch variation. This has significant implications 
for both the production of the cell lysate and scaling up of production for 
commercialisation of any forensic detection assay that employs this method. Significant 
variability has previously been identified as a major hurdle to adoption of cell-free protein 
synthesis [308]. This variability has been suggested as being caused by differences in 
metabolite quantities between batches or human error that has significant effect even 
with minor pipetting errors [309, 310]. Recently, studies have been published for the 
robust development of E. coli cell lysates that can reduce the variability between batches 
by as much 95% [311, 312]. It is therefore necessary to investigate these proposed 
methods for batch variation reduction during later optimisation to ensure that the cell 
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lysate can be produced consistently, and that resulting lysate activity fits a similar 
dynamic range between batches.  
To further investigate the dose-response relationship with wtGFP pDNA, reaction 
mixtures from Figure 5.14 were removed from incubation and analysed under an EVOS-FL 
fluorescent microscope with GFP filter. It is important to note that the GFP light-cube 
used to provide excitation light does so at a wavelength of 470 nm as it is optimised for 
use with enhanced GFP mutants with a shifted major excitation peak. wtGFP does possess 
a minor excitation peak at this wavelength (Figure 5.5) which allows for wtGFP 
fluorescence to be identified, but will be underestimated compared to actual values. Due 
to the low endpoint fluorescence, visually distinguishing images taken with the 
fluorescent microscope became difficult. To make the data easier to read and compare, 
microscopy images were imported into GIMP 2.0 software. The colour picker tool was 
used to identify the region with the highest green-channel intensity, which would 
correspond to highest wtGFP fluorescence emission. Red-Green-Blue channel intensities 
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Table 5.3: Comparison of colour channel intensities in fluorescence microscopy images of wells 
containing in-house cell extracts and varying concentrations of wtGFP pDNA after overnight 
incubation at 29°C. 
    
Average RGB Channel Intensity at 
Point of Maximum Fluorescence 
(Pixel Value)  
Batch  wtGFP Plasmid Concentration (pg/µL)  R  G  B  
1  
1000  0  29  8  
825  1  22  6  
650  0  29  6  
475  1  30  7  
300  0  23  5  
0  0  16  5  
2  
1000  0  6  2  
825  0  5  1  
650  0  12  2  
475  1  23  6  
300  1  20  5  
0  0  5  1  
Blank  N/A  1  1  1  
 
The same general trends for both extracts are again observed with numerical 
fluorescence data from microscopy images. Although the green-channel intensity does 
not linearly decrease with pDNA concentration, reducing template is associated with a 
decrease in blue-channel intensity at the region of maximal fluorescence, suggesting that 
fluorescence intensity is decreasing. The same bell-curve shaped trend seen in extract 
batch 2 fluorescence measurements are replicated here, indicating that those results 
were not due to instrumental error. Taken together, the data suggests that a dynamic 
range of the in-house extract is vastly reduced compared to the PURExpress® kit, likely a 
result of degradation through long-term storage, but is capable of protein synthesis 
within this range. Comparing the limit of detection of the first batch of extract to RSID sex 
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identification assays (Chapter Three, Figure 3.8), an RSID-Semen assay provided positive 
results across replicates from a 1 µL spike of seminal material quantified at 10 pg/µL male 
DNA. This suggests that the cell-free approach is currently less sensitive than existing 
commercial immunoassays for forensic body fluid and sex identification. As one of the key 
factors in the decision to develop a toehold switch assay using cell-free synthesis for field-
based biomarker detection was improved sensitivity and specificity, this is a significant 
concern and one that must be overcome and optimised if the CFPS approach is to have 
any practical application. However, this is a secondary objective to demonstrating toehold 
switch activity in a cell-free system. The second batch of extract’s fluorescent profile was 
not able to produce a predictable dose-response relationship like the first batch or 
PURExpress® kit, so was discarded from later use to avoid further rounds of 
troubleshooting that is not relevant to expressing synthetic gene networks in either 
system.  
 
5.4.3. Construction of a Toehold Switch Network for Sex Identification 
Both commercial and in-house CFPS systems have been experimentally demonstrated to 
synthesise protein from a plasmid under T7 control. Furthermore, the fluorescence 
output of both systems could be shifted up or down by increasing/decreasing the input 
concentration in the reaction mixture of wtGFP plasmid, respectively. Although both 
systems appeared to have different dynamic ranges, there is enough confidence that both 
systems function as intended to return to the expression of toehold switch networks. 
Instead of returning to the use of an arbitrarily-designed positive control network that 
was attempted at the beginning of the characterisation phase, it was instead decided to 
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design a synthetic gene network targeted to sex identification in-house. This brings 
novelty to the system, as there has not been a published demonstration of synthetic gene 
networks being applied to sex identification. In addition, data gathered using this network 
can be directly related to existing forensic sex identification assays.   
To develop a test for sex identification, the target biomarker must be a gene that is 
expressed differently between sexes. One of the primary areas of forensic investigation 
where sex identification of a sample is critical is in processing of sexual assault casework 
samples. A target that is both expressed differently between male and female donors and 
would be present in sexual assault samples would be genetic biomarkers of semen. 
Transglutaminase 4 (TGM4) is a protein that is specifically expressed and secreted in the 
prostate and deposited in semen [313], fulfilling both requirements for a sex 
identification test. It has been used successfully as the basis of ELISA antibody detection 
kits [278], making it an ideal target to investigate further with a synthetic gene network 
approach. 
Construction strategies for second-generation synthetic gene networks outlined by Green 
et al. [38] were followed (see section 5.3.1. Construction of Synthetic Gene Network 
Components) and applied to a region of TGM4 mRNA to construct a DNA toehold switch 
with an unbound region of specificity to TGM4. To confirm that the correct DNA 
secondary structure would be made by the switch, the sequence was entered into 
NUPACK software under NUPACK’s default ionic conditions. The intended hairpin 
structure was observed at both 29°C and 37°C (Figure 5.15). 




Figure 5.15: NUPACK In silico simulation of the secondary structure formed by the nucleotide 
sequence corresponding to the TGM4 toehold switch construct at 37°C and 29°C under default 
ionic conditions. Nucleotide identities are colour-coded and presented in the 5’ to 3’ direction. 
 
As Figure 5.15 shows, there is no difference to secondary structure when folding at 37°C 
or 29°C, indicating that it may be possible to use this design at lower temperatures. The 
secondary structure(s) of this design fits the toehold switch design parameters outlined 
previously by Green et al. for high-performance toehold switches so would be expected 
to have a significant difference between reporter gene output in the repressed and 
activated (unwound) states. There is a single instance of complementary bases not 
forming a base pair between the A/T bases that immediately precede the stem. This 
makes the TGM4 stem one base pair shorter than expected but was not expected to have 
an impact on the ability of TGM4 trigger to bind and initiate unwinding. 
To determine if the TGM4 switch would properly unwind in the presence of its specific 
trigger, a simulation was set up using two strand species (the TGM4 toehold switch and 
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the TGM4 trigger sequence) with the maximum number of complex strands (10) to 
identify all possible structures formed when the two sequences interact. In a real-world 
application of this network, the assumption would be made that the trigger sequence 
would be in excess of the toehold switch. To represent this in the software simulation, 
concentration of TGM4 trigger was set at 10 µM, double that of the TGM4 toehold switch 
(5 µM). As expected, only one DNA-DNA complex is formed, which is the unwound 
toehold switch. This linearises the rest of the molecule and exposes the RBS sequence 
and ATG start codon which is necessary to initiate gene expression. The entire proportion 
of the TGM4 switch binds to the TGM4 trigger, generating linearised product with 
exposed RBS site, with the remaining unbound TGM4 trigger left over (Figure 5.16).  
 
Figure 5.16: Secondary structure of the complex formed upon interaction of TGM4 switch with the 
TGM4 trigger. Red arrows at the top and bottom of the complex represent the 5’ end of the TGM4 
trigger and switch sequences, respectively. Nucleotide identities are colour-coded and 
presented in the 5’ to 3’ direction. 
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Existing immunoassays that target TGM4 have some cross-reactivity with similarly 
structured proteins, including other transglutaminases [314]. One of these known cross-
reactants – transglutaminase 2 (TGM2) – is a protein that is expressed in a variety of 
tissues, but is particularly upregulated in female tissues such as the endometrium [315, 
316]. In mixed male-female samples encountered in sexual assault investigation, co-
collection of TGM2 with male seminal material may be possible. To investigate if TGM2 
could potentially induce gene expression with the TGM4 toehold switch, the 30 bp TGM4 
trigger was aligned to the entire TGM2 mRNA sequence to find the region of greatest 
similarity. This revealed a 30 bp region of TGM2 that differed from the TGM4 trigger 
sequence by only 4 bp. This TGM2 trigger was inserted in place of TGM4 trigger in 
NUPACK simulations with TGM4 toehold switch (Figure 5.17). 
 
Figure 5.17: NUPACK In silico simulation of secondary structure(s) of the switch-trigger complex 
formed between TGM4 toehold switch and TGM2 trigger. Red boxes denote the intact TGM4 
switch hairpin. Nucleotide identities are colour-coded and presented in the 5’ to 3’ direction. 
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Importantly, while the in silico secondary structure simulations of the TGM4 toehold 
switch with the non-target TGM2 trigger mRNA show binding to form a single complex, 
this complex is localised to the freely-available toehold switch tail and does not cause 
unwinding of the toehold stem hairpin (see red boxes in Figure 5.17). This is due to the 
lack of complementarity between the TGM2 mRNA sequence that aligns to the 
nucleotides in the stem hairpin. As such, the hairpin will not unwind from its preferential 
pairing with itself, thus maintaining repression of gene expression. This is consistent with 
toehold switch sensors that exhibit single base resolution in their discrimination of target 
sequences [16, 17]. Furthermore, in a simulation that included three strand species 
(TGM4 toehold switch, TGM4 trigger and TGM2 trigger), the TGM2 trigger sequence was 
entirely outcompeted for toehold binding by the TGM4 trigger, due to the greatest level 
of complementarity between the TGM4 trigger and the toehold switch. This suggests that 
this synthetic gene network system of sex identification should not activate in the 
presence of non-target related sequences, a significant benefit over existing sex 
identification assays that utilise TGM4 as a marker.  
Superfolder GFP was used as the reporter gene for the TGM4 toehold switch, with the 
coding sequence appended to the 3’ end of the toehold switch linker. Superfolder GFP is a 
derivative of the enhanced folding mutants of GFP containing the substitution mutations 
S30R, Y39N, N105T, Y145F, I171V and A206V [317], in addition to the “cycle-3” mutations 
F99S, M153T, V163A [318] and enhanced fluorescence mutations F64L and S65T [319]. 
The result of these series of mutations is that reporter gene product should have a 
significantly increased maturation rate relative to wtGFP, which has been reported to fold 
poorly in vivo when expressed in E. coli [320]. This should decrease the amount of time it 
takes in the assay before fluorescence can be detected. This change should therefore 
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address the key issue of time-to-result not being within the 10 - <30-minute range as 
identified previously. Additionally, the enhanced GFP mutations F64L and S65T increase 
potential fluorescence intensity from gene expression by approximately 100-fold [319].  
Another problem being encountered during the troubleshooting stage of in-house cell 
extract CFPS was a lack of dyes of a suitable wavelength to use as a positive control and 
benchmark.  This is a significant issue as it prevents relative fluorescence data from being 
converted to an objective, quantifiable metric. This data is essential to collect to provide 
performance information on the assay and draw comparisons to existing bio-detection 
assays for optimisation purposes. In fluorescence intensity assays, a dye with the same 
photometric qualities as the reporter gene being measured is often included as a control 
to ensure the microplate is correctly exciting samples and reading emission light at the 
correct wavelengths. However, there are no commercially available dyes with identical 
excitation/emission wavelengths to wtGFP, making it difficult to draw conclusions from 
these experiments. In contrast sfGFP, which has a shifted excitation band to 485 nm, has 
numerous dyes around this wavelength which are suitable for inclusion in fluorescence 
assays. Commercially available microspheres coated with fluorescent molecules (Sulfate 
FluoSpheres™, 20 nm size, ThermoFisher, #F8848) were included as positive controls for 
TGM4 toehold switch CFPS experiments. A benefit of using fluorescent microspheres is 
that it allows the conversion of relative fluorescence to known fluorescence, as the 
microspheres have a known fluorescence intensity independent of relative 
measurements. It is also useful if settings such as gain and focal height need to be 
changed as measurements can still be compared, such as when optimisation of the 
system increases fluorescent output to a point that saturates the microplate reader. To 
characterise the beads, a 1 in 10 stepwise dilution of beads with water was performed 
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before measuring beads fluorescence at Alexa Fluor 488 settings at a single point using 
the ClarioStar™ plate reader. Beads were mixed well with water to prevent microsphere 
clumping and localisation. When measured neat, bead fluorescence saturated the 
microplate reader, so this value was deemed inaccurate. Microsphere dilutions at 1/10, 
1/100, and 1/1000 dilutions with nuclease-free water were within the plate reader’s 
detection range, measuring averages of 56,000 RFU, 5400 RFU, and 500 RFU, respectively. 
The beads fluorescence decreasing by 90% with each 1 in 10 dilution demonstrates that 
microspheres are an appropriate source of fluorescence for a positive control for sfGFP 
measurements. Fluorescent microspheres at a 1 in 10 dilution with water were used as 
the positive control for further experiments. To convert the relative fluorescence from 
this set of data to a known intensity, the following formula was used as outlined in the 
manufacturer’s manual: 
6C ∗ 10
p ∗ π ∗ ϕ
 
Where C is the concentration of suspended beads in g/mL (known to be 0.02 in a 2% 
solids suspension), p is the density of the polymer in g/mL (known to be 1.05 for 
polystyrene) and φ is the diameter of microspheres in µm (0.02 for a 20 nm microsphere). 
Entering these values into the formula, a value of 4.55 x 1014 microspheres per mL was 
obtained after accounting for the 1 in 10 dilution with water. This means that in a 10 µL 
suspension of beads, roughly 4.55 x 1012 beads are present. According to the 
manufacturers, the fluorescence intensity of a single 20 nm microsphere is equivalent to 
1.8 x 102 fluorescein molecules, giving a fluorescence intensity equivalent to 8.19 x 1014 
fluorescein molecules in 10 µL at a 1 in 10 dilution of beads. 




5.4.4. Expression of a Sex Identification Toehold Switch Network in a Cell-Free System 
The TGM4 toehold switch and trigger sequences were assembled into plasmids using the 
same cloning vector as wtGFP (pYes2.1/V5-His-TOPO) using ThermoFisher GeneArt™ 
services (See Figure 5.2). These vectors were used as they were commercial vectors 
containing both T7 promoters necessary for expression of the system and contained 
ampicillin resistance genes, consistent with the cloning steps used previously in this 
thesis. Cell-free protein synthesis reactions were set up using TGM4 constructs as 
template. TGM4 toehold switch pDNA was included in sample mixtures with or without 
the associated TGM4 trigger at 250 ng and 1000 ng quantities. In all reaction mixtures 
that contained both TGM4 switch and trigger plasmids, trigger plasmids were in excess of 
TGM4 switch plasmid by a ratio of 2:1 to ensure activation of the assay. Ten microlitres of 
fluorescent microspheres were diluted 1 in 10 with water and pipetted into separate 
microplate wells as a positive control for fluorescence (Table 5.4).  
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Table 5.4: Average relative fluorescence intensity of PURExpress® and LOFT cell extract reaction mixtures containing TGM4 switch and/or trigger constructs.  
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With both CFPS systems, none of the reaction mixtures that contained TGM4 constructs 
displayed fluorescence distinguishable from a blank (DNA-grade water), suggesting that 
the protein expression reaction has failed. This experiment is difficult to troubleshoot 
given the number of variables involved. Reaction failure could occur at any point in the 
transcription-translation pathway or be caused by an inability of the expressed TGM4 
constructs to interact. To eliminate faults with the cell extract’s ability to express pDNA as 
a cause of reaction failure, a troubleshooting experiment was devised. This experiment 
utilised SDS-PAGE to visualise protein expression in CFPS reaction mixtures following 
incubation. The expected outcome of this experiment would be that when incubated 
alone, CFPS mixtures containing only the TGM4 switch or trigger plasmids would not 
express any sfGFP as expression is repressed. In mixtures containing both TGM4 switch 
and trigger plasmids together, the de-repression of the RBS in the switch caused by 
linearisation should enable expression of sfGFP, which can be visualised as the 
appearance of a protein band in the ~27 kDa range. The PURExpress® commercial kit is 
supplied with a control template plasmid expressing dihydrofolate reductase (DHFR) 
protein under T7 control. DHFR regulates tetrahydrofolate levels, which is important for 
the regulation of cell growth and proliferation [321], as well as being involved in DNA 
synthesis [322]. This plasmid was used as a positive control in order to ensure that the 
system works as intended. Reaction mixtures were prepared for both PURExpress® and 
in-house extracts in individual 0.2 mL PCR tubes. The recommended input quantity of 
DHFR plasmid of 250 ng was used for a control reaction with both extracts. Additional 
reactions used TGM4 switch (with or without cognate trigger) at 250 and 1000 ng 
quantities to compare CFPS activity of the synthetic gene network relative to the DHFR 
control. After four hours of incubation at 37°C, reaction mixtures were mixed with 
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Laemmli sample buffer and denatured at 95°C on a heat block before being 
electrophoresed on precast 12% stain-free polyacrylamide gels alongside a pre-stained 
protein ladder (Precision Plus Protein™ All Blue Prestained Protein Standard, Bio-Rad 
#1610373) in a Mini-PROTEAN® Tetra Cell (Bio-Rad, #1658005EDU). Gels were analysed 
using a ChemiDoc MP Imaging System with 5 minutes of UV exposure using a pre-
programmed Stain-Free protein imaging protocol (Figure 5.18). 




Figure 5.18: SDS-PAGE of PURExpress® and in-house CFPS reaction mixtures. Red asterisk at the 20 
kDa band in the PURExpress® positive control reaction denotes successful DHFR protein 
production. 
All gel lanes containing PURExpress® and in-house extracts are characterised by the 
appearance of numerous protein bands across the observable size range of the gel. This is 
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expected as both extracts are made up of liberated proteins and enzymes from cell 
lysates. In the PURExpress reaction mixtures, a faint band is visible at 20 kDa in all lanes. 
However, the positive control reaction containing DHFR, a 20 kDa protein, has a much 
darker band in this region than the other reaction mixtures, indicating successful 
expression of the control plasmid. In contrast, the wells containing both TGM4 switch and 
trigger plasmids do not lead to pronounced band formation at ~27 kDa corresponding to 
superfolder GFP synthesis, which indicates that these reactions failed. Using the in-house 
extract, protein corresponding to cellular machinery was present in all reaction mixtures, 
but no synthesised protein was visible in positive control DHFR or TGM4 sample wells, 
indicating complete failure of protein synthesis. To confirm that no sfGFP was present at 
all, gels were Western blotted onto nitrocellulose membranes. Western blots were 
examined using a pre-programmed green fluorescence blotting protocol on a ChemiDoc™ 
MP Imaging System (Figure 5.19). 
 
Figure 5.19: Western blots of PURExpress® and in-house extract reaction mixtures under a green 
fluorescence imaging program. 
No green fluorescence was visible in any sample containing TGM4 constructs around 27 
kDa, confirming that sfGFP was not expressed by either system. Some fluorescence is 
visible in the All Blue protein ladder at 10 kDa which appears to bleed across into the 
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reaction wells, which is simply attributed to autofluorescence of these components. The 
appearance of the positive control band in the PURExpress® reaction mixture discounts 
faulty protein synthesis components as a reason for failure to express sfGFP, implying 
that TGM4 constructs are being synthesised by this kit, but the switch and trigger are not 
interacting as expected which is preventing unwinding of the switch and initiation of 
sfGFP expression. The failure of the in-house extract to synthesise DHFR stands in 
contrast to the numerous previous reactions with this extract where wtGFP was 
successfully synthesised which had also been backed up by fluorescence microscopy. 
There are two primary possibilities for this discrepancy. Firstly, although freeze-thaw 
cycles of in-house extract had been kept to a minimum, time constraints prohibited the 
production of more batches of extract, necessitating re-use of existing stock. 
Approximately three freeze-thaw cycles had been performed on this aliquot of extract 
prior to this reaction which is likely to have an adverse effect on CFPS performance. 
Secondly, it may be that the natural shelf-life of the components had been reached, 
which may also explain the diminished dynamic range of the extract in recent wtGFP 
synthesis experiments. This particular batch had been in storage/use for around 6 months 
and could potentially have lasted longer if freeze-thaw cycles were eliminated. 
The inability of both kits to express sfGFP points to an issue in TGM4 construct binding. 
However, there are three categories of secondary structure change following sequence 
interaction: 1) No interaction between TGM4 sequences; 2) TGM4 switch and trigger bind 
but do not initiate switch unwinding or initiate partial unwinding; or 3) TGM4 switch and 
trigger bind, initiate full switch linearisation, but translation of the sfGFP fails. The latter 
category is the least likely as there is experimental evidence to demonstrate the 
PURExpress® kit is capable of protein synthesis. Instead, it suggests that linearisation of 
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the switch is not occurring, preventing formation of the translation initiation complex 
around the ribosomal binding site. Under the assumption that the TGM4 sequences are 
being properly transcribed to mRNA as evidenced by the successful production of DHFR, 
and the exact sequence of the TGM4 plasmids was verified during production, it is not 
likely that the sequences are unable to bind. In silico simulations during the design phase 
of the switch and trigger showed full linearisation of the switch, exposing the RBS and 
ATG start codon. This may not be occurring in practice due to subtle differences in the 
ionic composition of the cell extracts, or the presence of the nucleotide sequence for 
sfGFP (which was not accounted for in simulations) is impacting the secondary structure 
of the hairpin and post-RBS regions. It may also be that the use of eukaryotic vectors (see 
Figure 5.2) to express synthetic gene networks that were originally designed for 
expression in E. coli is negatively impacting the production of either the switch and/or 
trigger constructs, or the expression of sfGFP due to the differences in codon usage.  This 
gave a number of potential troubleshooting avenues that could be explored with further 
experimentation and optimisation of the system. However, by this point the time 
restriction on experimental work for the thesis had been reached, prohibiting further lab 
work to optimise the system.   
 
5.5. Summary 
Returning to the original aims and objectives of this chapter, the success of employing 
CFPS as a sex identification assay for forensic investigation can be assessed. These aims 
were to identify a suitable genetic biomarker for combined body fluid and sex 
identification, construct a toehold switch network using this target, benchmark and 
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optimise toehold switch performance in CFPS reactions against commercial standards, 
testing the assay with TGM4 sourced from “real-world” crude samples, and finally 
applying the network reaction to a paper-based deployment platform via freeze-drying. 
To this end, a suitable male-specific sex identification marker in TGM4 was identified, and 
the synthetic gene network that was devised using part of the TGM4 sequence showed 
superior specificity to existing TGM4 immunoassays with in silico simulations. Although 
cell-free expression of a toehold network based on TGM4 was not achieved, a large 
amount of characterisation data was obtained with both the in-house and commercial 
cell extracts which will aid further optimisation and troubleshooting of the system outside 
of the scope of this thesis. Furthermore, novel protocols from the literature for the 
reduction in batch variability were identified which should aid this process. The failure to 
express a TGM4-specific toehold switch in cell-free systems despite the network design 
being in-line with high-performance toehold switch design strategies highlights a lack of 
concordance between design and performance, and suggests a need for novel 
frameworks for toehold switch design that can reliably predict performance and aid 
design.    
The sensitivity of the system to low template input is a factor that should be prioritised to 
improve upon as much as possible, as the in-house extract was less sensitive than RSID-
Semen immunoassays, and existing DNA detection systems are capable of generating STR 
profiles from picogram levels of genomic DNA recovered from crime scenes [323]. 
Without doing so, there is little benefit in further producing toehold switch networks for 
forensic purposes as commercialisation would most likely fail. The only goal in which 
none of the laboratory work was started was the use of real-world samples as a source of 
TGM4 DNA. This goal was dependent on first optimising the system using synthetic 
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genetic components transcribed from pDNA as a positive control. As goal on which this 
was dependent was not met, work could not begin on this more complex step. The 
success of optimising reactions involving constitutively fluorescent plasmids with both in-
house and commercial CFPS systems suggests that the same process could be achieved 
rapidly with synthetic gene networks once a successful reaction had been demonstrated. 
A number of further troubleshooting steps for toehold switch expression reactions were 
identified, indicating that successful expression of toehold switches in vitro may be 
achieved within only a few more rounds of troubleshooting. This would immediately open 
up a number of characterisation and validation opportunities, such as those performed 
on the qPCR kit in Chapter Three.  
While fluorescent reporter genes have been used throughout the characterisation 
process for its ease of detection in the laboratory, fluorescence is not particularly 
convenient as a reporter method at the crime scene as specialised equipment is required 
to detect it. Fortunately, after toehold switch expression optimisation is achieved and 
circuit activity is maximised, it would be a simple process to take this toehold sequence 
and pair it with a different reporter gene; this change would not be expected to impact 
circuit function. As market research data suggested visual detection would be most 
preferable in a novel field-based test, reporter gene activity that can be visualised with 
the naked eye would be useful. With regards to paper-based testing, this could be 
achieved through production of a substance of distinct colour as has been shown with 
LacZ [17], or perhaps the localisation of toehold switches and TX-TL machinery to a “test 
strip” on a larger platform that is rehydrated with sample DNA to produce a visible band 
indicating reaction success. This simplified workflow at the crime scene would be 
consistent with recent trends in forensic science which has favoured miniaturisation of 
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equipment to enable field-based sample detection and introduce the test to more end-
users. 




Melting Curve Analysis as a Screening Framework for Synthetic Gene 
Network Design and Activity 
6.1. Abstract 
The reported high specificity and sensitivity of toehold switch networks, as well as low 
cost of production and ease of use makes them ideal platforms for a field-based bio-
detection assay. However, design of toehold switches is hampered by issues regarding 
predictability in performance, as observed with the failure to express a switch specific to 
the semen biomarker TGM4 in Chapter Five. Poor performance is typically overcome 
either by iterative wet laboratory testing or redesigning of the network entirely. Existing 
screening frameworks for network component designs are not fit for purpose, 
necessitating alternative frameworks to be identified.  
A screening framework for toehold switch design and performance based on melting 
curve analysis was devised in-house to attempt to address this issue. A set of 15 DNA-
based toehold switches and their cognate triggers of known performance (5 each of 
“high”, “medium” and “low”-performance) as identified in the literature were purchased 
as oligonucleotides and subjected to high-resolution melting curve analysis with 
EvaGreen® intercalating fluorescent dye to determine if melting profiles exhibited similar 
characteristics at similar performance levels. Additionally, another 11 toehold switches 
were designed in-house for the detection of the forensic markers ALAS2, HTN3, and 
Amelogenin-Y (AMEL-Y). These switches were also subject to melting curve analysis with 
results compared to those derived from the published sequences in an attempt to predict 
performance. To supplement and aid interpretation of melting curve analyses, an in silico 
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thermodynamic analysis approach was used. NUPACK software was used to calculate free 
energies of toehold switch secondary structures and trigger binding to determine 
correlations between free energies and network performance.  
Results show that melting curve analysis was able to reliably differentiate between the 
repressed toehold switch and the activated switch-trigger duplex state for all networks 
tested when supplemented with 0.125 mM MgCl2. Melting temperatures of both the 
switch and switch-trigger duplex structures for the 15 pre-characterised networks did not 
correlate with performance, but G/C base-pair content in high-performance networks 
was significantly lower than in low-performance networks (P = 0.001). Thermodynamic 
analysis showed that toehold switch secondary structure free energy factors previously 
thought to correlate with performance in RNA-based networks (particularly ΔGRBS-Linker) 
were maintained in DNA-based networks at the same ionic conditions used for melting 
curve analysis. Retroactive fitting of thermodynamic screening onto melting curve 
analysis of in-house biomarker toehold switch designs was able to predict performance 
and recommend designs to be discarded or studied further, but due to low sample size 
the variance of the predictions are high and require further refinement. The results and 
screening methodology are discussed in relation to the use of toehold switches and in 
silico analysis in the surrounding literature.  
 
6.2. Introduction 
A decade after the “five hard truths” for synthetic biology were published in Nature [10], 
many of the outlined obstacles to the widespread adoption of the field remain present. In 
particular, design frameworks for the production of synthetic gene networks with 
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predictable and reliable activity are not widely available [324]. A lack of these frameworks 
means that assessment of network activity is first encountered at the experimental in vivo 
validation stage of development without prior design assistance. Due to the frequently 
unpredictable activity of biological components in synthetic circuits [325, 326], this can 
lead to failure of network function, which may require expensive and time-consuming 
iterative testing to fix and/or optimise [327]. In cases where software is available for in 
silico gene network design, expert-level knowledge of biological components, circuitry, 
and their interactions in vivo is often required to set up initial design parameters and to 
successfully generate and optimise component libraries [328]. Thus, there is a need for 
network design and screening frameworks that a) minimise the need for trial and error in 
circuit design; b) do not require expert-level knowledge to apply; c) minimise hands-on 
molecular biology time and running costs; and d) act as reliable predictors of component 
and network activity. Establishment of a screening framework that fulfils these conditions 
would be directly applicable to the development of synthetic gene networks for sex 
identification as it would allow for more networks to be characterised without laborious 
wet laboratory testing. This would enable the development of multiple putative networks 
for sex identification at once and greatly increase the system throughput.  
It was hypothesised that these requirements could be fulfilled through the use of a 
screening framework based around melting curve analysis. The reasoning for this is that 
all of the components involved in the toehold switch network structure are composed of 
nucleotides and the network’s proposed function involves the linearisation of switch 
secondary structure following complementary binding to a trigger sequence to initiate 
gene expression (Chapter 1, Figure 1.3B). The secondary structure of nucleotides are 
partly influenced by temperature – as temperature increases, so does dissociation of 
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double-bonded nucleotide strands until passing a specific temperature (the melting 
temperature) after which point the strand duplex becomes completely dissociated [329]. 
Using a fluorescent DNA-intercalating dye, the degree of strand dissociation can be 
quantified by plotting dye fluorescence across a wide temperature range to produce a 
melting curve [330]. This method has high fidelity and is able to resolve single-nucleotide 
differences between sequences [331, 332], as is seen in high-resolution melting (HRM) 
single nucleotide polymorphism analysis in the field of genetics [333]. This fidelity is 
conferred by the difference in number of hydrogen bonds between A/T (2) and C/G (3) 
base pairs. Hybridised nucleic acid sequences with 100% complementarity to one another 
are more stable than those containing mismatches or only bind partly, which is reflected 
by greater melting temperatures of stable configurations [334]. This could be applied to 
toehold switch design by examining the melting temperatures of toehold switch in 
trigger-bound or unbound states and identifying differences between networks of known 
performance levels. Melting curve analysis has also been applied to the field of forensics 
for the presumptive detection of DNA in the field [128, 335] and indeed detection of 
mRNAs from body fluids [336], highlighting the potential application of this method for 
synthetic gene network design. Additionally, the equipment required for generating and 
interpreting melting curves are minimal and typically available in a standard genetics 
laboratory, consisting of a standard real-time PCR cycler, dsDNA oligonucleotides and 
intercalating dye. Modern real-time PCR cyclers can process upwards of 100 samples in a 
single instrument run [337] which makes this method amenable to screening and analysis 
of many network components at once, and also requires little training to operate. For this 
proposed screening framework to be developed and applied efficiently, a toehold switch 
data set of sufficient size is required. As it would be outside of the scope of this thesis to 
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generate an extensive library of toehold switch designs, validate their performance in 
vivo, then apply the proposed screening framework to them, the screening methodology 
devised here will be retroactively fitted onto a data set available in the literature. 
Green et al. [38] designed and experimentally assessed in vivo the performance of 168 
RNA-based synthetic toehold switches and cognate trigger sequences whose overall 
structure and functions are the same as previously described (Chapter One, Figure 1.3B, 
Chapter Five TGM4 Switch Design). The difference in network reporter (GFPmut3b) 
fluorescence between the repressed (OFF) and activated (ON) states in terms of fold-
change was used as a measure of switch performance. By leaving important sequence 
factors such as ribosome binding sites and RNA recognition motifs such as YUNR 
complexes [338, 339] unbound in a loop, sequence constraints that are otherwise placed 
on the trigger RNA and the toehold region when designing synthetic gene networks are 
removed. In addition, a lack of common sequence motifs between multiple network 
designs also greatly improves the orthogonality of the system and provides low crosstalk 
between components in vivo [17, 38]. This also makes toehold switches an ideal system 
for studying screening methods, as there should be minimal contribution from outside 
factors on network activation and performance. These toehold switches and trigger 
sequences were under T7 control and with the exception of conserved switch sequences 
such as the RBS, AUG start codon, and fluorescent reporter gene GFPmut3b, were made 
up of arbitrary nucleotides generated by an in silico nucleic acid software package [340]. 
This ensured that each design was unique in its nucleotide sequence and that the correct 
toehold structure was formed. Whilst generation of toehold switch designs is both simple 
and rapid, the authors’ characterisation studies showed a clear issue in that the 
performance of the switches (i.e. fold-change in GFPmut3b fluorescence after induction) 
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varied significantly despite their similar structure (Figure 6.1). This lack of concordance 
between design and testing presents a significant hurdle for applying toehold switches to 
novel detection targets. Although forward engineering of high-performance toehold 
switches by Green et al. did generally further increase output fluorescence, high 
performance variability was still observed. From a developmental standpoint, this 
requirement for extensive library generation and iterative testing is non-ideal. 
Additionally, consistency in toehold switch performance would be a necessity if applied to 
a commercial detection assay.   
 
 
Figure 6.1: GFP fluorescence produced by 168 toehold switches 3 hours after induction with 
cognate trigger sequence as a ratio of ON to OFF state fluorescence change. Brackets and red 
asterisks denote the 15 sequences used for melting curve analysis (sequences #1-#5, #45-#49, and 
#144-#148). Adapted from Green et al. [38] with permission from Elsevier.  
 
Together, this presents a clear need for tools that can reliably screen toehold switch 
designs for performance at the early design and prototyping stages, bypassing or at least 
minimising the need for extensive performance assessment in the laboratory. 
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Furthermore, any laboratory screening that is required by such a process should also be 
minimal, rapid, and simple to enable its use by a greater number of laboratories, as 
characterisation of networks within living cells can be prohibitively costly to perform for a 
large number of networks. Melting curve analysis is appropriate for application to this 
data set as it meets these process requirements. Although each network conforms to the 
same basic structure, the designs all differ in the sequence of nucleotides that make up 
the toehold switch stem where target specificity is conferred, and these differences 
should be reflected in their melting curves. As the switches exhibited a great range of 
performance in terms of their ON/OFF reporter gene fluorescence ratio, the nucleotide 
differences are likely to have an impact on switch linearisation and initiation of reporter 
gene expression. 
In conjunction with the wet laboratory approach to screening with melt curve analysis, 
bioinformatics has the potential to be a powerful tool in aiding the design of synthetic 
gene networks. Whilst there are already robust network design frameworks that utilise 
bioinformatics approaches [341, 342], many of them are based around configuring 
standardised biological parts in a network. This limits their application with novel parts, 
such as the toehold switches generated during development of the sex identification 
assay. There are many individual factors involved network design that may impact 
network performance (nucleotide sequence length, melting temperature, G/C content, 
etc.), where manual data analysis or iterative wet laboratory optimisation experiments of 
these factors can quickly become time consuming and/or expensive. An in silico screening 
method that can quickly identify sequence parameters correlated with high network 
performance would greatly aid sequence design and inform which designs should be 
processed further in the laboratory.  Given the vast amount of data to be analysed to 
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devise a screening framework, methods that reduce data points into meaningful 
subgroups would be useful. Thermodynamic changes in free energy from switch-trigger 
binding can be measured in silico using free software packages such as Nucleic Acid 
Package (NUPACK) and would provide useful quantitative data regarding free energy and 
switch unwinding efficiency that is difficult to achieve using a melting curve analysis 
approach alone [343]. Additionally, predicted secondary structure can be visualised using 
NUPACK to ensure that toehold switches are conforming to the necessary structure 
required for assay function [344] which will aid optimisation and/or troubleshooting. 
Thermodynamic calculations will be performed on various aspects of the network 
components and results will be used to identify correlations between particular motifs, 
free energy, and network performance.  
This chapter will cover the development of a melting curve analysis method for predicting 
the performance of toehold switch network components, supplemented with an in silico 
screening framework based on thermodynamic parameters. This screening framework 
will be applied to validated toehold switch networks identified in the literature and novel 
toehold switches specific to the detection of body fluids and sex markers generated in-
house.  
 
6.3. Materials and Methods 
6.3.1. Selection of Green et al. Toehold Switch Designs 
Fifteen switch-trigger pairs of arbitrary sequences were identified from Green et al.’s list 
of 168 characterised networks (Figure 6.1). These networks ranged in performance 
(defined as fold-change difference in GFPmut3b fluorescence between the “on” and “off” 
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states) from 292 to 0.6 ON/OFF fluorescence. Of these 15 networks, 5 were classed as 
high-performance (ON/OFF state GFP fluorescence ratio range 292-253), 5 were classed 
as mid-performance (ON/OFF state GFP fluorescence ratio range 41.4-38.7), and 5 were 
classed as low performance (ON/OFF state GFP fluorescence ratio range 1.9-2.0). Switch 
and trigger components were synthesised as dsDNA oligonucleotides by Eurofins 
Genomics and obtained as lyophilised DNA pellets, which were rehydrated with DNA-
grade water to a final concentration of 100 µM. Switch sequences did not include the 
linker or a downstream reporter gene as these were considered superfluous to the 
melting temperature of the switch hairpin. These 15 sequences are referred to as 
“positive control” sequences in the text. 
 
6.3.2. Design of Toehold Switches for Forensic Body Fluid and Sex Identification 
Eleven novel toehold switches were designed complementary to a range of mRNA 
sequences commonly identified in human body fluids for forensic detection. The 
biomarkers chosen were ALAS2 (peripheral blood, GenBank Accession numbers 
NM_000032.5, NM_001037967.3, NM_001037968.3), HTN3 (saliva, NM_000200.2) and 
AMEL-Y (male sex determination, NM_001364814.1) (See Appendix IV).  
In-house toehold switch and triggers for forensically-relevant body fluid biomarkers were 
designed using the following manual in silico approach (Figure 6.2).  
 




Figure 6.2: A) Overview of design process used to produce designs for toehold switches in-house 
that were specific to recognition of genetic sequences present in human body fluids. Left-hand 
flowchart describes the method, right-hand flowchart provides a demonstration using mRNA from 
the gene ALAS2 as an example. B) A graphical representation of the secondary structure of the 
ALAS2 toehold switch design. 
 
Messenger RNA sequences were accessed through the National Centre for Biotechnology 
Information’s (NCBI) GenBank database. In the case of ALAS2, which has multiple 
transcript variants, the variant mRNAs were aligned using Clustal Omega software to 
identify regions of absolute homology [345]. Thirty nucleotide-length regions were 
selected from the biomarker mRNA coding sequences to act as triggers, with the 
restriction that they could not include an in-frame start codon as this would affect the 
activity of the toehold switch. A BLAST nucleotide search was performed [284] to confirm 
specificity to the forensic biomarker sequence for all transcript variants. Complementary 
toehold switches were designed by generating the reverse complement of the 30-nt 
trigger sequences. The first 12-nts of this reverse complement beginning from the 5’ end 
correspond to the unbound toehold tail region, and the following 18-nts correspond to 
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the stem region that will form the switch hairpin. To the 3’ region of this switch sequence 
a strong RBS site is attached (Registry of Standard Biological Parts, BBa_B0030) followed 
by an 18-nt reverse complement to the stem ascending region. As this region is 
complementary to the ascending stem it initiates self-binding, forming the characteristic 
toehold switch hairpin, leaving the 12-nt toehold tail region unbound but available, and 
sequestering the RBS in an unbound loop region. This reverse complement contains an 
ATG mismatch at nucleotide positions 7 – 9 following the RBS site, which is introduced to 
act as the start codon for expressing the downstream gene. Finally, a conserved 21-nt 
linker region was appended to the end of the hairpin sequence 
(AACCTGGCGGCAGCGCAAAAGATGCGTAAA) following Green et al.’s design parameters. 
This linker codes for low-molecular weight amino acids and separates the hairpin from 
the regulated reporter gene.  
To design a switch that can potentially differentiate between male and female DNA, and 
thus be used for genetic sex identification, the human amelogenin gene was chosen as a 
basis it resides on both the X- and Y-chromosomes but differs slightly on each [346]. 
Messenger RNA coding sequences for Amel-X (GenBank Accession #M55418) and Amel-Y 
(GenBank Accession #M55419) were aligned using Clustal Omega software. When the 
sequences were aligned, a 6-bp deletion on the Amel-X coding sequence corresponding 
to base pairs 669-674 on the Amel-Y sequence was observed (Figure 6.3). The chosen 32-
nt trigger sequence contained a 20-nt stem consisting of nucleotides immediately 
upstream of and including the observed deletion, and a 12-nt tail of nucleotides 
immediately downstream of the deletion. This design should confer specificity of the 
switch to the target Amel-Y sequence, as the common sequence would allow binding of 
both Amel-X and –Y to the available tail region, but the differing stem sequences caused 
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by the deletion should prevent Amel-X from annealing to and unwinding the stem to 
initiate translation.  
 
Figure 6.3: Alignment of AMEL-Y and AMEL-X mRNA sequences in the region 601 – 720 using 
Clustal Omega software. Stars represent identical bases at the same position, dashed lines 
represent deleted bases. Amelogenin X and Y triggers consist of a common 12-nt toehold tail (red) 
and a 20-nt stem (blue) that differs around the AMEL-X deletion to confer specificity to the Y-
chromosome form of the gene.   
 
The toehold stem region is 2-nts longer than the other toehold switch designs in order to 
avoid an in-frame stop codon (TGA) from being incorporated into the descending stem 
while still conserving the full 6 bp deletion difference.  
Five designs were produced for ALAS2 and HTN3 markers, with a single design for AMEL-
Y. A single design was used for AMEL-Y as there were limited regions of sequence 
differences between AMEL-X and AMEL-Y which could be used to base a toehold switch 
sensor around. Nucleotide sequences corresponding to triggers and switches for each 
biomarker are presented below (Table 6.1).   
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Table 6.1: Toehold switches and triggers for each of the forensic biomarker designs. Nucleotides in red correspond to the 5’ toehold region where trigger 
binding initiates. Blue and black nucleotides correspond to the ascending and descending stem of the switch, respectively. Green nucleotides correspond to 
the pre-RBS and RBS sites which are sequestered in an unbound loop region. The 21-nt linker sequence and downstream reporter gene are not presented 
here for clarity. 
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To confirm that toehold switches would adopt the correct hairpin conformation under 
experimental conditions, switch sequences were entered into the mfold web server DNA 
folding form [347] and analysed under default parameters (linear DNA sequence, 37°C 
folding temperature, 1 M [Na+], 0 M [Mg2+]. Any switch designs that did not fold into a 
structure corresponding to the characteristic toehold switch hairpin design or also 
exhibited secondary folding structures were discarded and redesigned. Primers for the 
switch sequences were designed manually by following standard PCR primer design 
strategies (18-24 nucleotide-length, 40-60% G/C content, Tm between 50-60°C). Specificity 
checks for each primer pair was performed in silico using Primer-BLAST software [348]. 
Primers were obtained from Eurofins Genomics. All synthetic gene network components 
were synthesised as short double-stranded DNA oligonucleotides. A full list of all 
sequences used in these studies and the hairpin structures formed are available in 
Appendix IV. 
 
6.3.3. Assembly of Oligonucleotide Reaction Mixtures for Melting Curve Analysis 
Melting curves of toehold switches, triggers, and switch-trigger duplexes were generated 
by assembling reaction mixtures of these components in vitro and subjecting them to a 
hybridisation and melting step using a thermal cycler. Components consisted of 
commercially synthesised dsDNA oligonucleotides rehydrated with TE buffer. All reactions 
were assembled in 0.2 mL round-bottom PCR tubes. Reaction mixtures were assembled 
differently during and after optimisation of the melting curve analysis protocol.  
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6.3.3.1. Reaction Mixture Assembly Optimisation Conditions 
Three aspects of the oligonucleotide reaction mixtures were individually optimised to 
achieve maximum separation of the melting curves of toehold switch and switch-trigger 
duplex structures. These were: 1) switch and trigger oligonucleotide concentrations; 2) 
Mg2+ concentration; and 3) fluorescent reporter dye. First designs of toehold switch 
oligonucleotides for the positive control (Green et al. sequence #1) and each biomarker 
(ALAS2 #1, HTN3 #1, AMEL-Y) were initially examined at 1 µM final concentration. Two 
separate optimisation experiments were performed for assessing switch-trigger duplex 
formation, in which only the first positive control design was assessed in both. In the first, 
toehold switch oligonucleotide was kept constant at 10 µM final concentration with 
trigger oligonucleotide varied on a concentration gradient from 1 to 20 µM. In the 
second, switch and trigger oligonucleotides were combined in a final concentration of 10 
µM. The combinations used for switch/trigger and trigger/switch were 10 µM/0 µM, 9.9 
µM/0.1 µM, 9 µM/1 µM, and 5 µM/5 µM. 
To optimise the concentration of magnesium ions in the reaction mixture, MgCl2 at 0 mM, 
0.125 mM, 0.25 mM, 0.375 mM, or 0.5 mM concentration was supplied to 
oligonucleotide mixtures containing either positive control or body fluid marker toehold 
switch at 10 µM final concentration, or both toehold switch and trigger at 5 µM final 
concentration each. Initial melting curve analyses used PowerUp™ SYBR® Green 
(ThermoFisher, #S7563) fluorescent dye as a reporter of double-stranded structure 
formation both for switch hairpin and switch-trigger duplexes.  
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6.3.3.2. Final Reaction Mixture Assembly Conditions 
All of the melting curve analyses performed on oligonucleotides after achieving optimum 
reaction conditions assessed the interactions of toehold switches with cognate triggers. 
Toehold switch oligonucleotides at 10 µM were mixed with cognate trigger 
oligonucleotides at 20 µM. Reaction mixtures contained EvaGreen® (Biotium, #31000) dye 
at 1X concentration as the fluorescent reporter and were supplemented with 0.125 mM 
MgCl2 as a source of magnesium for secondary structure stability. Reaction volume was 
made up to 10 µL with DNA-grade water. Negative control reaction mixtures contained 
only 20 µM trigger sequence. All reactions were performed in triplicate. 
 
6.3.4. Melting Curve Analysis Protocol 
Assembled reaction mixtures were mixed by pipetting up and down, then briefly spun 
down using a microcentrifuge to remove air bubbles before being placed in a Rotor Gene 
Q thermal cycler (Qiagen) with a 72-sample complement rotor. Melting curve analyses on 
these components using the Rotor Gene Q instrumentation were performed by setting up 
a two-step hybridisation and melt profile. The first step consisted of heating samples to 
90°C and cooling to 25°C step-wise at a rate of 1°C per step to encourage the formation of 
switch-trigger duplexes. Each temperature step was held for 5 seconds, with a pre-melt 
conditioning step before the first step lasting 90 seconds. Fluorescence was acquired to 
the green fluorescence channel (source wavelength = 470 nm, detection wavelength = 
510 nm). Melting curves were obtained by reversing the first step, ramping the 
temperature from 25°C to 90°C at the same rate settings as the hybridisation step. Green 
fluorescence was acquired again to a separate output channel to differentiate results. 
Gain optimisation was performed before the first acquisition was made on the melt step 
Chapter Six – Melting Curve Analysis Screening Framework 
272 
 
to give a gain value of 7.33.  Rotor Gene Q software [349] was used post-run to visualise 
raw fluorescence data. Melting curves were generated from raw fluorescence by using 
the melt analysis option with Rotor Gene Q software to automatically calculate and plot 
first derivatives of the melt step channel data for every sample. Melting curves were 
analysed for melting temperature and peak height manually. 
 
6.3.5. Calculation of Thermodynamic Parameters 
Thermodynamic parameter values for toehold switch structures were calculated using the 
NUPACK software suite [285]. Reaction conditions were 37°C, 0.05 M Na+, 0.0015 M Mg2+, 
with switch and trigger sequences in equal concentration as separate nucleotide strands 
(10 µM). Maximum complex size was set to two strands. 
 ΔG values were calculated by inserting specific parts of the nucleotide sequences into 
NUPACK. These included intact switches and switch-trigger duplexes, as well as individual 
regions of the switch structure. To determine the effect of ΔG on network activity, ΔG was 
calculated for the secondary structures of various parts of the switch hairpin and switch-











Table 6.2: Descriptions of the thermodynamic metrics used as predictors of fluorescence in toehold 
switch networks.  
 
ΔG values for each parameter were plotted against log10 fluorescence of 168 validated 
networks to observe correlations. Lines of best fit were applied to obtain linear regression 
formulas. Linear regression formulas were used to predict network performance of 
unknown forensic toehold switch designs. The appropriate thermodynamic parameter 
was inserted into the formula and a log10 fluorescence value was calculated. Log10 
fluorescence was converted to estimated ON/OFF fluorescence fold-change by taking the 
anti-log of this value.  
 
Chapter Six – Melting Curve Analysis Screening Framework 
274 
 
6.3.6. Data Analysis 
Raw fluorescence and first-derivative melt data was exported to Microsoft Excel as a .csv 
file for manual calculations of average melting temperatures and generation of melting 
curve graphs. Raw data was also exported in text file format (.txt) for HRM analysis using 
a dedicated software package (uAnalyze v2.0 [350]). This text file was uploaded to the 
software and automatically analysed under default conditions.   
Melting temperatures of toehold switch and switch-trigger duplexes were predicted using 
OligoAnalyzer Tool (Integrated DNA Technologies) at the appropriate oligo and ionic 
concentrations for each construct and reaction mixture being examined [351]. Where 
principle component analyses were performed, Qiagen proprietary Rotor-Gene 
ScreenClust HRM software was used [352]. Raw melting channel data (*.rex files) were 
normalised by applying a line of best fit through the highest and lowest fluorescence 
values. Median fluorescence values of all samples were calculated and residual plots 
generated by subtracting melt traces for each sample from the composite median curve. 
Principal component analysis was performed on this transformed data to generate a plot 
of sample variance along two principal components corresponding to melting 
temperature and fluorescence.  
Two-sample t-tests were used to compare the average melting temperatures and G/C 








6.4.1. Performance Screening of Characterised Networks by Melting Curve Analysis 
6.4.1.1. Optimisation of Melting Curve Approach with Green et al. Designs 
Melting curve analysis is a cheap and reliable method for genotyping and studying 
interactions between DNA sequences. Advancements in instrumentation and fluorescent 
intercalating dyes and probes have enabled the use of high-resolution melt (HRM) 
analysis with real-time PCR instruments [332].  HRM is powerful enough to distinguish 
single nucleotide polymorphisms (SNPs) [353] between sequences from their melting 
profiles and can be performed quickly, making it suited to screening large data sets of 
oligonucleotide designs. It was hypothesised that toehold switch network designs that 
displayed high performance (i.e. greatest fold-change in fluorescence between ON and 
OFF states) would have characteristic melting profiles distinct from networks of lower 
performance either in the intact toehold hairpin or unwound switch-trigger duplex state. 
To assess if melting curve analysis was an appropriate method to visualise secondary 
structure folding, the toehold switch corresponding to the highest-performing positive 
control network (Green sequence #1) was subject to hybridisation and melting steps at 1 








Figure 6.4: Melting curve profile of Green sequence #1 switch at 1 µM final concentration using 1X 
SYBR Green I dye.  
 
The appearance of peaks in the melting curve indicates that SYBR Green® fluorescent dye 
is intercalating with the double-stranded DNA. Two separate peaks were observed. The 
first is a minor, broad peak around 35-50°C, along with a sharper peak at ~68°C. The 
minor peak was thought to correspond to a suboptimal secondary structure or self-
binding occurring outside of the primary switch hairpin as the hairpin itself is known to be 
stable around 37°C. The higher peak was thought to correspond to the true melting 
temperature of the switch hairpin as this is the region of greatest stability. Additionally, 
this is close to the expected melting temperature as calculated using OligoAnalyzer 
software (61.9°C). 
To determine if inclusion of trigger oligonucleotide into the reaction mixture would 
generate a switch-trigger duplex melting profile of different appearance to the switch, 
cognate trigger sequence was added to 10 µM of positive control toehold switch on a 































Figure 6.5: Melting curve profile of positive control switch and trigger components incubated 
across a temperature range with SYBR Green dye following a hybridisation step. Inset: 
magnification of the melting curve profile between 60-75°C.  
 
Here, the melting curve of the switch hairpin alone appears similar to the profile in Figure 
6.4, although fluorescence is greater, thought to be a result of increased oligonucleotide 
concentration. This suggests that adjustment of the switch concentration alone should 
not have a significant effect on the resulting melt curve. Trigger sequence alone displays a 
very small peak of ~0.80 RFU around 40°C. Visualisation of the trigger sequence in 
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NUPACK showed some self-binding, which is being intercalated by SYBR Green dye. It was 
hypothesised that interaction of the trigger with the switch sequence would cause an 
increase in product melting temperature, as the linearised switch-trigger duplex contains 
twice as many base pairs as the hairpin alone (30 vs 15). This increase in bonding should 
require more energy to melt, thereby increasing the melting temperature. However, 
introducing the trigger sequence to the hairpin only increases the fluorescence of the 65-
75°C peak, with greater concentrations of trigger correlating with greater fluorescence up 
to a maximum of 8.4 RFU at the 20 µM trigger condition. This increase in fluorescence 
must be associated with switch-trigger product formation as switch concentration was 
kept constant and the trigger sequence alone does not fluoresce in this range. It was 
noted that at lower trigger concentrations, the resulting melting profile was lower than 
without trigger (67.5°C and 68.5°C). A reason for this phenomenon may be that addition 
of low concentrations of trigger produces a small amount of switch-trigger duplex relative 
to the switch alone. This small amount of product is destabilised first, resulting in a lower 
melting temperature. This highlights the need for reaction conditions to be optimised to 
generate the maximum amount of switch-trigger duplex in order to obtain useful melting 
profiles for interpretation.  
A second concentration gradient experiment was performed where positive control 
switch and trigger components were mixed in a total concentration of 10 µM to attempt 
to obtain a clearer transition between the switch and switch-trigger duplex melting 
profiles (Figure 6.6). This experiment transitioned to the use of EvaGreen® intercalating 
dye as SYBR® Green stocks had been exhausted. 




Figure 6.6: Melting curves of positive control network products across a concentration gradient 
using EvaGreen® dye.  
 
Immediately there are two notable differences in the resulting melting profiles compared 
to previous experiments. Firstly, peaks in the 60-75°C range are absent, a feature that was 
previously present in all profiles containing switch or switch-trigger duplex. Instead, peaks 
are all localised to ~40°C. This difference was not thought to be caused by the change in 
dye as both SYBR Green and EvaGreen® have the same mode of action and should not 
generate any fluorescence where dsDNA bonds are not present. This difference in melting 
temperature may be due to the presence of DNA-stabilising ions such as magnesium in 
the EvaGreen® dye. Secondly, fluorescence is much higher in this region than compared 
to previous experiments. Switch sequence alone at 10 µM fluoresces at ~5.2 RFU at the 
same gain settings as the previous experiment, where 10 µM of switch displayed ~1.2 
RFU. The greatly increased fluorescence is thought to be a function of the fluorophore 
employed by the dye and should enable higher resolution of the differences between 

























Hairpin 9.9µM, Trigger 0.1µM
Hairpin 9µM, Trigger 1µM
Hairpin 5µM, Trigger 5µM
Hairpin 1µM, Trigger 9µM
Hairpin 0.1µM, Trigger 9.9µM
Trigger 10µM
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concentration was associated with a decrease in fluorescence as expected, but the 
inclusion of cognate trigger sequence did not appear to generate a different profile that 
could be attributed to the formation of the switch-trigger duplex. Taken together, these 
experiments indicate that intercalating dyes can visualise oligonucleotide structure, but 
that further optimisation of reaction conditions are required to discriminate between 
products. 
Cations such as sodium (Na+) and magnesium (Mg2+) in a free state are known to bind 
DNA as it carries a poly-anionic charge. Binding of DNA by Mg2+ is known to increase 
stability of DNA duplexes, which also aids in folding of higher structures such as secondary 
and tertiary assemblies [354-356]. It was thought that this could be exploited to aid 
visualisation of the switch-trigger duplex in melting curves. Reactions mixtures of positive 
control toehold network components were assembled with or without 0.5 mM MgCl2 and 
subject to melting curve analysis (Figure 6.7).  
Figure 6.7: Melting profiles of positive control network components with and without 0.5 mM 
MgCl2 in the reaction mixture. 











































Without magnesium, switch, trigger, and switch-trigger mixtures appear similar to the 
previous experiment with single peaks at ~40°C. With the addition of 0.5 mM MgCl2, the 
melting profiles of the switch and switch-trigger duplex change drastically, with melting 
temperatures increasing to 63°C and 65.5°C, respectively. Furthermore, fluorescence of 
the switch-trigger mixture is much greater than the switch alone, approximately double 
the relative fluorescence (6.4 RFU vs 3.2 RFU). This implies that the full switch-trigger 
duplex has been formed as this product has twice the nucleotide base-pairs of the switch 
hairpin alone and should therefore fluoresce twice as bright with intercalating dye. 
Additionally, the peak corresponding to the switch-trigger duplex at 0.5 mM MgCl2 is 
narrower than the switch-only peak. This indicates the product is more stable and is not 
undergoing transitional melting which would be expected of the fully hybridised switch-
trigger duplex. Lastly, the trigger-only sample at 0.5 mM MgCl2 appears identical to the 
melting profile of the trigger without magnesium, which suggests that this shifting in 
melting temperatures and profiles is not universal and as such is having the stabilising 
effect that was hypothesised. To determine if this difference in melting profiles was 
significant, melting data of switch and switch-trigger products were further analysed 
using principal component analysis (PCA) with Rotor-Gene ScreenClust HRM software. 
Principal component analysis is a statistical technique that reduces the dimensionality of 
a data set whilst also allowing for data trends and differences between data sets to be 
identified [357]. Data points are transformed onto uncorrelated dimensions (principal 
components) [358], then ordered by the percentage of variability in the data they account 
for. Melting curve data of three replicates of switch-only and switch-trigger reactions at 0 
mM and 0.5 mM MgCl2 were uploaded into ScreenClust software, using temperature and 
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fluorescence as variables for the PCA. The resulting cluster plot from products at 0 mM 
MgCl2 did not neatly separate replicates by their sample identity but did at 0.5 mM MgCl2 
(Figure 6.8). The separation of switch and switch-trigger products containing magnesium 
by PCA indicates interpretation can be automated, and that the highest degree of 
variability (the first principal component) is explained as a function of temperature. This 
gives further confidence that differences in melting temperature may be a potential 
screening mechanism for synthetic gene network function.  




Figure 6.8: Cluster plots following principal component analyses of positive control switch and 
switch-trigger samples at 0 mM (A) and 0.5 mM (B) magnesium. Switch only sample IDs: 1, 2, 3, 
10, 11, 12; Switch-trigger sample IDs: 4, 5, 6, 13, 14, 15.  
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Lastly, magnesium concentration was optimised to determine if differences in product 
melting profiles could be further amplified. Using the same oligonucleotide 
concentrations from the previous experiment, MgCl2 was supplied at 0.125, 0.25, 0.375, 
and 0.5 mM concentration. The melting temperature and fluorescence of each peak was 
recorded for switch and switch-trigger samples (Table 6.3). 
 
Table 6.3: Effect of MgCl2 concentration on melting temperature and fluorescence of positive 
control network components. Averages are taken from 3 replicates.  
 
 
Again, the addition of magnesium greatly increased melting temperature of structures, 
with melting temperature increasing with greater concentrations of magnesium. In all 
reactions that contained magnesium, both switch-trigger Tm and fluorescence was greater 
than switch-only samples indicating successful duplex formation. The greatest difference 
in structure Tm was observed at 0.125 mM MgCl2 with a difference of 4°C between switch 
hairpin and switch-trigger duplex, highlighting this condition as the most preferable to 
differentiate network components in the OFF and ON states from one another.  
 
 
Magnesium Concentration (mM) Switch Only Switch-Trigger Switch Only Switch-Trigger
0 40.5 40.5 5.1 5.7
0.125 56.5 60.5 6.8 8.9
0.25 61.5 62.5 4.1 9.3
0.375 62.5 64.5 3.6 8
0.5 63.5 65.5 3.5 6.6
Average Fluorescence (RFU)Average Melting Temperature (°C)




6.4.1.2. Final Green et al. Melting Curve Analysis Results 
By performing melting curve analysis on multiple networks of known performance, the 
resulting profiles can be compared to identify any shared characteristics between 
networks of similar performance. Fifteen positive control toehold switches and cognate 
triggers of known performance (in terms of ON/OFF fluorescence) previously 
characterised by Green et al. [38] were obtained as lyophilised dsDNA oligonucleotides. 
Five networks were classed as high-performance and corresponded to the networks with 
the highest ON/OFF fluorescence. Conversely, five low-performance networks were 
identified that had the lowest ON/OFF fluorescence. The remaining five networks had 
performance levels in-between the high- and low-performance network groups. These 
networks were subject to the optimised melting curve analysis procedure described 
above with 0.125 mM MgCl2, and the average peak melting temperatures and 













Figure 6.9: Averaged melting profiles of 15 networks of known performance (n = 3). Networks 1-5 are high performance (average fluorescence fold-change 
270.9, networks 6-10 are medium performance (average fluorescence fold-change 39.9), and 11-15 are poor performance (average fluorescence fold-change 
1.9).  All networks consisted of 10µM switch oligonucleotide, supplied with 20 µM trigger oligonucleotide and 0.125 mM MgCl2 to enable switch-trigger 
duplex formation. 
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The melting profiles of the 15 positive control switches behave similarly to previous 
melting curve analysis experiments, where addition of 20 µM oligonucleotide resulted in 
a peak of higher Tm than the switch alone with greater fluorescence. This was not the case 
for networks #12 and #14 however, both belonging to the low-performance category, 
which did not generate any peaks or had lower switch-trigger duplex than switch 
fluorescence, respectively. The lack of a melting profile in network #12 was thought to be 
due to human error during assembly of the reaction mixture rather than the inability of 
the switch and switch-trigger duplexes to conform to the correct secondary structures but 
was not repeated due to time and reagent constraints. This network was not accounted 
for in further analysis as result. The effect of switch-trigger duplex formation was more 
pronounced in some networks than in others, with the designated high-performance 
networks (#1-#5) having both the greatest average fluorescence for both switch and 
switch-trigger duplex peaks (5.31 and 10.39 RFU), as well as the greatest difference in 
fluorescence between the two structures. Fluorescence of the switch-trigger duplex 
structures generally decreased with performance, with the low-performance category 
(networks #11-#15) having an average fluorescence of 5.93 RFU, almost half that of the 
high-performance category with medium-performance networks (#6-#10) in between the 
two at 7.91 RFU. These results suggest that the high-performance networks adopt the 
correct secondary structure in both cases, with proper hairpin and switch-trigger duplex 
formation providing double-strands for EvaGreen dye to intercalate with and fluoresce. 
Conversely, networks of lower performance may be conforming to undesirable structures 
with poorer stability or engaging in incomplete hybridisation. There is further evidence 
for this in the height of the melting curve peaks, as it was previously demonstrated that 
the full switch-trigger duplex should have approximately double the fluorescence of the 
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switch alone due to having double the number of base-pairs in the full structure. This 
ratio is observed in the majority of high- and medium-performance networks, but not in 
any of the low-performance networks.   
The high-performance networks had the lowest average Tm for both switch 
hairpin/switch-trigger duplex structures (63.5°C/72.6°C). Melting temperature did not 
however correlate with performance, as the medium-performance networks had a 
greater Tm than the low-performance networks for both structure types (68.1°C/76.0°C 
and 65.5°C/74.7°C respectively). Although there is a lack of correlation for this factor, the 
lower Tm values exhibited by the high-performance networks are a point of interest to be 
investigated further. The function of the switch hairpin is to linearise through breaking of 
the base-pairs making up the switch hairpin as the free single-stranded 5’ toehold region 
binds to its cognate trigger. Theoretically, this process could proceed more efficiently in 
networks with switches that have lower Tm values, requiring less energy to break the 
hairpin bonds and hybridise with the trigger sequence. The two processes involved in 
toehold switch activation (unwinding of the switch hairpin and stable formation of a 
linear switch-trigger duplex) are directly affected by the trigger sequence’s ability to 
readily interact with the toehold switch. This presents specificity and nucleic acid 
sequence of the trigger as highly important factors to control to ensure balance between 
these processes. As melting temperature is a function of G/C content, the G/C content of 
each switch was studied in closer detail (Figure 6.10): 




Figure 6.10: Average G/C content of 5 network switches belonging to high-, medium-, and low-
performance categories. Error bars represent two times the standard error of the mean. 
 
While G/C content does appear to increase as network performance decreases, a two-
sample t-test did not find the differences between the high/medium and medium/low 
categories significant (P = 0.122 and 0.231, respectively) but did find a significant 
difference between the high/low performance categories (P = 0.001). It was inferred from 
this result that melting temperature/GC content is correlated with network performance 
in some manner. Given that switch performance is inherently linked to proper 
folding/unwinding of the switch, it may be that it is not only the number of G/C base-pairs 
but also their position in the sequence that affects efficiency of downstream gene 
expression. A toehold switch that contains weaker bonds (A/T instead of G/C) in key areas 
such as the beginning or end of the stem may unwind more readily upon activation with 
its cognate trigger and form the switch-trigger duplex easier. This would lead to more 
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fluorescence. Three of the five positive control switches contain three A/T base pairs 
immediately preceding the RBS loop which would appear to support this hypothesis. 
However, one of the middle-performance switches also has this triplet identity, and four 
of the five low-performance switches tested contain two A/T base pairs in this region. 
This implies that toehold switch unwinding efficiency is multifactorial, and that further 
sequence analysis is required. A drawback of the melting curve analysis approach is that 
while single polymorphisms can be easily distinguished between sequences, the switches 
differ greatly in sequence which cannot be easily picked up by the comparison of melting 
curves. In order for melting curve analysis to accurately capture the contribution of 
changes in base pair identity to melting profile as a measure of performance, a vastly 
greater number of toehold switches would need to designed, each differing from the 
other by a single base pair at each nucleotide in the switch sequence. As a toehold switch 
data set of this size and specification is not available, a need is presented for additional 
methods to supplement existing melting curve analysis and further characterise the 
relationship between network structure melting temperature and performance.  
 
6.4.2. Performance Screening of Forensic Markers with Melting Curve Analysis 
6.4.2.1. Optimisation of Melting Curve Approach with Forensic Biomarkers 
Having developed an optimised approach for melting curve analysis using pre-
characterised positive control toehold switches, this process was applied to forensic 
biomarkers that were designed in-house. As magnesium concentration was deemed a key 
factor in differentiating between toehold switch and switch-trigger duplex profiles, a 
magnesium gradient was applied to single designs for ALAS2, HTN3, and AMEL-Y 
biomarkers between 0 and 0.5 mM MgCl2 as before. Although these networks have no 
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accompanying ON/OFF fluorescence data as they have not been expressed as a part of a 
network and characterised, preliminary secondary structure predictions in silico have 
demonstrated successful hairpin formation in the switch, and linearisation when binding 
to the cognate trigger. These toehold switch designs behaved similarly to the positive 
control toehold switches, where there is little differentiation of profiles at 0 mM 
magnesium, but addition of magnesium is associated with an approximate 20 - 30°C 
increase in melting temperature and clear visual separation of the switch and switch-
trigger profiles (Table 6.4).  
 
Table 6.4: Averaged Tm and intercalating dye fluorescence of toehold switches/switch-trigger 
duplexes designed against single designs of forensic biomarkers ALAS2, HTN3, and AMEL-Y.  
 
 
Again, similarly to the positive control, increase of magnesium concentration with each 
biomarker is correlated with an increase in structure melting temperature as a result of 
increased stability. The inclusion of 0.125 mM magnesium in reaction mixtures appears to 
be the optimal condition for analysing melting profiles as with the positive control switch 
Biomarker Magnesium Concentration (mM) Switch Only Switch-Trigger Switch Only Switch-Trigger
0 41.5 41.5 4.4 4.3
0.125 65.5 71.5 1.8 4.0
0.25 64.5 72.5 2.0 3.5
0.375 65.0 73.5 2.0 3.2
0.5 65.5 73.5 1.9 2.8
0 44.5 44.5 5.1 4.6
0.125 64.5 58.5 4.1 4.7
0.25 65.5 59.5 3.2 4.9
0.375 66.5 60.5 2.9 4.4
0.5 67.5 61.5 2.6 3.9
0 45.5 45.5 3.2 3.0
0.125 56.5 61.5 3.8 7.2
0.25 62.5 66.5 2.2 3.9
0.375 65.5 67.5 2.0 3.8
0.5 65.5 68.5 2.0 3.4




Chapter Six – Melting Curve Analysis Screening Framework 
292 
 
tested earlier. The AMEL-Y hairpin demonstrated clearest separation of switch and 
switch-trigger structures at this condition both in terms of fluorescence and product 
melting temperature difference. While the ALAS2 network does not have the greatest 
separation in melting temperature between products at 0.125 mM magnesium, 
difference in fluorescence between products greatest and there is still a clear separation 
of the switch and switch-trigger duplex. The melting profile of the HTN3 switch-trigger 
duplex did not behave as expected, as the switch-trigger duplex had a lower melting 
temperature than the switch alone in all instances. To troubleshoot this result, the HTN3 
switch sequence was examined using NUPACK to visualise hairpin secondary structure. 
Visualisation of the HTN3 design used revealed that it was able to conform to several 
different secondary structures at equilibrium. The structure of lowest Gibbs free energy 
had a larger pre-RBS/RBS loop region than intended and encompassed the ATG mismatch 
in the stem region. As it is a natural tendency for strands of DNA to conform to the 
structure of lowest free energy, this structure would be the consensus of any solution 
containing this oligonucleotide. This led to sub-optimal trigger binding, resulting in a 
lower melting temperature. Interestingly, higher dye fluorescence is still observed in this 
structure despite the lower melting temperature. This is most likely due to small (< 3-nt 
length) self-binding regions in the unwound switch-trigger duplex’s post-RBS region as 
indicated by NUPACK binding simulations. As this HTN3 marker design does not function 
as intended, it was discarded and redesigned to fit parameters prior to further analysis. 
The separation of switch and switch-trigger structures from one another with all 
biomarker designs tested provide confidence that the melting curve analysis method 
optimised using sequences from Green et al. is appropriate for distinguishing 
oligonucleotide structures of novel sequence.  
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6.4.2.2. Final Forensic Marker Melting Curve Analysis Results 
Having demonstrated an optimal method for visualising toehold switch and switch-trigger 
duplex by melting curve analysis, this method was applied to all eleven of the novel 
biomarker switches that were designed in-house (five designs of ALAS2, five designs of 
HTN3, and one design for AMEL-Y). Whilst work on positive control networks did not 
establish a clear link between melting profile and performance alone, melting profile 
characterisation of forensic biomarkers is necessary to ensure that all designs engage in 
proper unwinding and linearisation, and to obtain melting data that may be useful later as 
the screening framework is refined. Each of the eleven designs was subject to 
hybridisation and melting with either 10 µM switch oligonucleotide only or 5 µM each of 
switch and trigger sequences (Figure 6.11). In the case of the AMEL-Y design, two 
different trigger sequences were used. The first, the AMEL-Y trigger, is the exact reverse 
complement of the AMEL-Y switch tail and stem region and was expected to function 
similarly to all other switch designs. The second trigger, referred to as AMEL-X, 
corresponds to a region of the AMEL-X gene that closely aligns with the AMEL-Y trigger 
but is the site of a 6 bp deletion (Figure 6.3). This difference between triggers is 
hypothesised to confer specificity of the AMEL-Y switch to the AMEL-Y trigger only which 












Figure 6.11: Averaged melting profiles of the switch and switch-trigger duplex structures of eleven forensic biomarkers designed in-house supplemented with 
0.125 mM magnesium. N = 3.  
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In all instances, addition of cognate trigger to the appropriate switch results in an 
increased melting temperature, indicating formation of the switch-trigger duplex 
structure. This is also associated with an increase in EvaGreen® dye fluorescence for all 
designs except ALAS2 design #3. Within biomarkers, there is a high degree of variation in 
terms of structure melting temperature, fluorescence, and the differences of these values 
between switch and switch-trigger duplexes. This is unlike the melting profiles of positive 
control toehold switches within performance groups (Figure 6.9) where general trends 
were observed. All of the forensic biomarker toehold switch designs conformed to the 
correct parameters during the design phase and in silico simulations predicted proper 
secondary structure formation of the hairpin and unwinding in the presence of the 
trigger, which demonstrates the unpredictability of network performance from the design 
stage.  
Considering the HTN3 biomarker designs, clear separation of the switch and switch-
trigger melting profiles were obtained in all instances. Of these designs, #3 had both the 
greatest difference in melting temperature between products and the greatest dye 
fluorescence for the switch-trigger duplex, suggesting that this design would be optimal in 
performance. The first HTN3 design has an unusual melting profile for the toehold switch 
in that there is a single wide, shallow peak across almost the entire temperature range. 
However, the characteristic switch-trigger profile is still observed upon addition of trigger 
sequence suggesting that binding and linearisation proceed as normal. The unusual 
switch melting profile may indicate poor formation of the switch hairpin at the 
concentrations tested. This has implications for regulation of the downstream reporter 
gene, which is repressed by hairpin formation and may result in leaky gene expression, 
reducing the network’s effectiveness as a bio-detection tool.  
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Generally, ALAS2 designs had lower fluorescence of both the switch and switch-trigger 
structures compared to other biomarkers. Additionally, the switch-trigger structures at 
each design at a greater melting temperature than other biomarkers, averaging at ~75°C. 
The greatest separation between products was observed in designs #2 and #4, indicating 
these designs would be optimal for further analysis.  
Addition of AMEL-Y trigger to its cognate switch elicited a structural change characteristic 
of the switch-trigger duplex melting profiles observed previously. However, the difference 
in melting temperature between the two structures is not as drastic as with other 
biomarkers or the positive control sequences, differing by only two degrees (56.5°C and 
58.5°C). This is slightly different to the previous magnesium optimisation experiment 
where a switch-trigger melting temperature of 61.5°C was observed at the same 
concentration of magnesium used here. This has implications for the repeatability of 
melting curve analysis as a screening tool, but further work would be required to fully 
assess the impact of this. Addition of AMEL-X trigger to the AMEL-Y switch also produced 
a different melting profile, indicating structural change, but the resulting structure had a 
reduced fluorescence and melting temperature relative to the toehold switch. This is 
consistent with NUPACK binding simulations, which showed binding of the AMEL-X trigger 
to the AMEL-Y toehold switch tail region, but an inability to initiate unwinding of the 
hairpin itself. This is due to the commonality of the AMEL-Y and AMEL-X trigger 
sequences in the toehold switch tail binding region which enables initial binding at the 
toehold tail, but the difference in the stem-binding region caused by the 6 base-pair 
deletion present on the AMEL-X gene prevents stem unwinding and switch linearisation. 
This is evidence for the high specificity of toehold switches as a bio-detection tool, as two 
similar sequences do not elicit the same activation of the switch when mixed. Taken 
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together, these results indicate that the AMEL-Y switch is capable of differentiating 
between X- and Y-chromosome specific forms of the same gene and should be considered 
further as the basis for a genetic sex identification test.  
 
6.4.3. Development of an In Silico Screening Framework for DNA-Based Toehold Switches 
6.4.3.1. Adaptation of an RNA-Based Screening Framework to DNA-Based Toehold 
Switches 
Melting curve data of both positive control and forensic biomarker toehold switches were 
not conclusive in screening of networks by performance, highlighting a need for 
supplementation by another method to provide more information and identify data 
trends. For a method to both supplement melting data and fulfil research aims, it must be 
simple, rapid, and not require any additional laboratory work. An in silico approach would 
be most preferable as it fulfils all of these requirements. It was thought that secondary 
structure formation would be a useful parameter to assess as secondary structure is 
determined by thermodynamic favourability – nucleic acids in solution will always 
conform to the most stable configuration for a given temperature and ionic composition 
of its surroundings. For optimal assay function, it must be thermodynamically favourable 
for DNA to form the switch hairpin, and to bind and linearise in the presence of its 
cognate trigger. The position and identity of bases in the sequence are important for 
these processes to occur.  
Returning to Green et al.’s data set, the authors utilised in silico thermodynamic analysis 
of RNA-based switches to calculate spontaneity of formation (Gibbs free energy or ΔG) of 
toehold switch hairpins, switch-trigger duplexes, and various sections of the switch. This 
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allows for multiple data points to be obtained for each design, which would make 
identification of key factors in melting profiles easier. Thermodynamic parameters can be 
correlated with ON/OFF fluorescence by means of a linear regression analysis. Green et 
al. found that the key parameter in their system for predicting performance was the ΔG 
value of the region spanning the unwound hairpin’s pre-RBS region to the end of the 
linker sequence (ΔGRBS-Linker) in switch designs that contained an A-U base pair 
immediately preceding the RBS loop region. The relationship they found did not account 
for all performance variability in the system but had a strong positive correlation and 
could form the basis for a basic screening protocol (R2 = ~0.7). From a molecular 
standpoint, it is logical that this parameter would be linked with network performance, as 
it represents the energy required for the ribosome to complete linearisation of the 
hairpin loop and initiate translation of the downstream gene by assembly of the 
ribosomal subunits. A higher ΔGRBS-Linker value (i.e. less negative) would require less energy 
to break and thus unwind easier, increasing efficiency of protein translation. However, it 
would not be appropriate to assume this correlation is the case with the DNA toehold 
switches used in this chapter, given the known differences between stability of RNA and 
DNA secondary structures, where RNA duplexes tend towards greater stability (i.e. lower 
ΔG values) than DNA [359-361]. To assess if ΔGRBS-Linker correlates with performance in a 
DNA-based system, a set of 13 switch and trigger RNA pairs were converted to DNA and 
analysed using NUPACK software at default temperature and ionic conditions (37°C, 1 M 
Na+, 0 M Mg2+) and melting curve analysis experimental conditions (0.125 mM Mg2+). 
These switch-trigger pairs correspond to a set of forward-engineered toehold switches 
designed by Green et al. which had the greatest performance of all networks in their data 
Chapter Six – Melting Curve Analysis Screening Framework 
299 
 
set. ΔGRBS-Linker values were plotted on a logarithmic scale against fluorescence and lines of 
best fit plotted to calculate slope and R2  values (Figure 6.12).  
 
Figure 6.12: Correlation between the ΔGRBS-Linker values of toehold switch network regions spanning 
the unwound pre-RBS to the end of the arbitrary linker with DNA and RNA under different 
conditions.  
 
The assumption made here is that the conversion of RNA sequences to DNA would not 
affect performance to any degree. While this is not particularly likely, it would be 
expected that the relative differences between network performances would be 
maintained as the number of weak/strong base pairs in the switch hairpin would not 
change during conversion. RNA-based switches under default NUPACK analysis settings 
had the lowest average ΔGRBS-Linker value at -5.46, conveying greater stability, which is 
consistent with previous reports on the improved stability of RNA/RNA duplexes 
compared to DNA/DNA duplexes. Additionally, an RNA structure had the lowest ΔGRBS-























Forward-Engineered Networks ΔGRBS-Linker vs Fluorescence
ΔG RBS-Linker RNA ΔG RBS-Linker DNA ΔG RBS-Linker DNA (experimental conditions)
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calculating free energy saw increased ΔGRBS-Linker values for all but one switch design, 
reflecting reduced stability.  
In one instance, a DNA structure with 381-fold change in fluorescence had the same 
ΔGRBS-Linker value (-6.57) as the lowest-performing network with a 33-fold change in 
fluorescence. The presence of this outlier negatively affected the correlation of ΔGRBS-Linker 
with fluorescence when using DNA and returned a greatly reduced R2 value of 0.29. This 
suggests that at default NUPACK conditions (1 M Na+, 0 M Mg2+), ΔGRBS-Linker is not an 
appropriate screening parameter. However, this effect was reversed when analysing the 
same DNA sequences under the ionic conditions used for melting curve analysis (0 M Na+, 
0. 125 mM Mg2+), which reverts the R2 value to 0.71, comparable to the RNA switches and 
suggesting use of this parameter in screening networks may be of interest. With both 
RNA and DNA switches under experimental conditions, there is grouping of several high-
performance data points at the peak ΔGRBS-Linker value for each system (-4.2 and -2.59, 
respectively). While this is expected based off the previous observation that higher ΔGRBS-
Linker values correlate with increased performance, fold-change difference in fluorescence 
varies at peak ΔGRBS-Linker by 377-fold. While this variation at higher fold-changes is not a 
concern from an assay development standpoint – all of these networks would produce 
great quantities of fluorescence when supplied with appropriate trigger sequence – it 
highlights that further work with a subset of a larger sample size may be required to fully 








6.4.3.2. Identification of Thermodynamic Parameters for DNA-Based Toehold 
Switch Performance Screening 
With evidence that correlations between thermodynamic free energy and switch 
performance could be maintained in a DNA-based system, ΔG values for each parameter 
in Table 6.2 were calculated for the 168 first-generation toehold switches characterised 
by Green et al. after converting RNA sequences to DNA. To categorise the data and make 
trends easier to identify, networks were categorised into 8 groups depending on the 
identity of the base pairs immediately preceding the RBS loop (Table 6.5).  
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Table 6.5: R-squared values of linear regressions between calculated free energies of DNA switch /switch-trigger duplex regions with log10 on/off 
fluorescence as a measure of network performance. Networks were grouped according to the identity of the base-pair triplet at the top of the stem. Base-
pair order is top-down from the very top of the switch stem before the loop. W = “weak” base-pair (A/T), S = “strong” base-pair (G/C). Number of switches in 
each category: 19 (WWW), 14 (WWS), 24 (WSW), 11 (WSS), 48 (SWW), 26 (SWS), 15 (SWW), 11 (SSS). R-squared values above 0.2 are highlighted in bold. 
 Identity of base pairs at the top of toehold switch stem 
Thermodynamic Parameter WWW WWS WSW WSS SWW SWS SSW SSS 
ΔGHairpin 0.01 0.02 0.04 0.22 0.00 0.02 0.16 0.01 
ΔGDuplex 0.07 0.02 0.05 0.24 0.00 0.08 0.01 0.33 
ΔGTrigger 0.00 0.02 0.01 0.18 0.01 0.07 0.03 0.07 
ΔGStem 0.25 0.00 0.09 0.34 0.00 0.00 0.15 0.02 
ΔGToehold binding 0.00 0.13 0.02 0.02 0.00 0.30 0.07 0.00 
ΔGRBS-Linker 0.41 0.08 0.39 0.07 0.01 0.05 0.00 0.38 
ΔGRBS-Stem 0.06 0.00 0.02 0.01 0.01 0.10 0.07 0.44 
ΔGMFE 0.09 0.01 0.00 0.13 0.00 0.01 0.25 0.09 
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ΔGRBS-Linker was positively correlated with log10 fluorescence in two of the four switch 
groups that contained A/T base-pairs at the top of the switch stem (WWW and WSW), 
along with the switch category that contained only G/C base pairs in this region (SSS). The 
correlation was strongest in the WWW switch group (R2 = 0.41) which was also the 
second strongest correlation in the entire data set, possibly reflecting the enhanced ease 
of stem unwinding. This is similar to Green et al.’s findings with RNA-based switches, but 
that data set found correlations with all four switch groups that contained a weak base-
pair at the top of the switch stem. This suggests that the thermodynamics of DNA binding 
differ from RNA due to decreased stability and should be taken into account when 
designing DNA-based toehold switches. Additionally, ΔGRBS-Stem was only found to 
correlate in the SSS switch group, but this was the strongest correlation observed (R2 = 
0.44). This parameter was not tested in the literature but its correlation with fluorescence 
in this group is interesting as it suggests further that it is the identity of bases in the stem 
that has the greatest impact on fluorescence. There is further evidence for this in the 
ΔGStem metric which correlated positively with performance in both WWW and WSS 
groups which both have a weak base-pair preceding the RBS loop.  
Free energy values corresponding to the intact toehold switch and unwound switch-
trigger duplex structures (ΔGhairpin and ΔGduplex) positively correlated with fluorescence in 
the WSS group, though ΔGduplex also correlated in the SSS group. These results are close to 
those obtained by Green et al. which suggests changing toehold switches to DNA would 
not significantly impact the thermodynamics hairpin formation. However, the R2 values 
from this correlation may be skewed due to the lower number of samples in the WSS and 
SSS subgroups (11 each). The change in free energy upon trigger sequence binding to the 
toehold region of the switch did not correlate with fluorescence in RNA-based networks 
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but did weakly positively correlate with DNA switches in the SWS category. This factor 
was not expected to generate a correlation as binding of the trigger to the 5’ switch 
toehold would only initiate unwinding, not complete the linearisation into the switch-
trigger duplex. The correlation in the SWS category is deemed an outlier in this regard.  
The difference in free energies between the intact hairpin and unwound switch-trigger 
duplex (ΔGMFE) positively correlated with fluorescence in the SSW group and weakly in the 
WSS group. This is in contrast to RNA-based switches where correlation dropped as the 
number of A/T base-pairs near the top of the steam decreased (excluding the higher 
correlation in SSS switches). This suggests that by changing the switches from RNA-based 
to DNA-based, the thermodynamics of binding have altered, which affects the 
correlations. Lastly, no significant correlations were identified with ΔGtrigger. This was 
expected as the secondary structure of the trigger alone is minimal, unstable, and should 
not have a significant impact on the stem’s ability to unwind during trigger binding.  
Overall, a greater number of positive correlations between ΔG values and fluorescence 
were observed for network subgroups that contained at least one weak base pair in the 
triplet immediately preceding the RBS loop region. Of these parameters, ΔGRBS-Linker and 
ΔGStem appear the most appropriate to use as values for screening performance of novel 
networks. With this information, melting curve data can be reanalysed to see if this filter 
is able to more clearly group networks of similar performance.  
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6.4.4. Application of a Combined HRM-Thermodynamic Screening Framework to Toehold 
Switch Network Designs 
6.4.4.1. Application of Framework to Green et al. Designs 
Previous melting curve analysis of toehold switches was unable to provide a reliable or 
robust method of determining network performance based on melting temperature 
alone, but did show that generally performance increased as Tm and G/C content of the 
toehold switch decreased. This observation is consistent with the thermodynamic 
parameter screening work above that suggests the positioning of A-T bases at the top of 
the toehold hairpin stem is important, as A-T bases are weaker than G-C base pairs, which 
would lower Tm. By combining the two approaches, more information may be drawn from 
the melting curve than was previously possible. The melting data from the 14 successful 
positive control switches and switch-trigger duplexes (excluding design #12) were sorted 
into groups based on the number of A-T base pairs in the triplet codon at the top of the 
switch hairpin stem (Figure 6.13).  





Figure 6.13: Parameters of positive control toehold switch networks grouped by the number of A-T base pairs in the triplet codon at the top of the switch 
hairpin. All error bars represent the standard error of the mean. A) Average known performance of network groups in terms of on/off state fluorescence. B) 
Averaged Tm values for both switch and switch-trigger duplex structures. C) Averaged peak RFU from the melting profile using EvaGreen® dye. Number of 
switches with 3 A-T bps = 4, number of switches with 2 A-T bps = 7, number of switches with 1 A-T bp = 3. None of the networks tested contained 0 A-T base 
pairs in this region. 
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Grouping sequences by pre-RBS triplet identity shows that generally fluorescence 
decreases as number of G-C base pairs in the pre-RBS increase. This is consistent with 
previous thermodynamics data based on network unwinding. A two-tailed two sample t-
test between each group found that none of the means were significantly different, 
however the P-value between the 3 and 1 A/T base pair groups was just at the cusp of 
statistical significance (P = 0.0542) which indicates that pre-RBS triplet identity is 
important for high network performance. It would be expected that this could become 
clearer with a larger sample size to offset the effects of individual outliers. There is no 
clear correlation in the mean data between secondary structure Tm or peak EvaGreen® 
dye fluorescence and number of A-T base pairs preceding the RBS.  
To assess if melting temperature impacted ΔGRBS-Linker or ΔGStem (identified as the primary 
determiners of network performance) a series of linear regression analyses were 
performed. Again, networks were categorised by number of A-T base pairs at the top of 
the hairpin stem. Correlations between switch hairpin Tm and ΔGRBS-Linker were weak in all 
instances. This is expected as ΔGRBS-Linker is a measure of free energy of the switch in its 
unwound state, not the intact hairpin. Slope calculations and R2 values for switch-trigger 
duplexes appeared to contradict one another. While an increase in duplex Tm correlated 
negatively with ΔGRBS-Linker in switches with 3 A-T base pairs (R2 = 0.65), a positive 
correlation between the same parameters was identified for switches with 2 A-T base 
pairs (R2 = 0.99). These opposing values are likely a result of low sample size and more 
melting data on a greater number of switches in each A-T base pair category would be 
required to troubleshoot this experiment. It would be expected that duplexes of higher 
Tm would have an associated lower (more negative) ΔGRBS-Linker value, and thus a lower 
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performance due to the increased energy required to achieve this state upon trigger 
hybridisation.  
Increase of ΔGstem values correlated negatively with Tm of both switch and switch-trigger 
structures, with the strength of correlation increasing as the number of A/T base pairs at 
the top of the stem decreased (3 base-pairs: switch/switch-trigger duplex R2 = 
0.1132/0.0516, 2 base-pairs: switch/duplex R2 = 0.3615/0.3528, 1 base-pair: 
switch/duplex R2 = 0.0197/0.9934). Increasing of ΔGstem value is associated with a less 
stable toehold switch hairpin and would thus require less energy to break, being 
associated with a decrease in Tm. The variance in correlation strength is again thought to 
be due to small sample sizes. This provides some evidence that the ΔGstem metric could be 
predicted by melting temperature of the switch hairpin. This observation, combined with 
the evidence that ΔGstem correlates with fluorescence in DNA-based systems would enable 
melting temperature to be used as an indirect screen of network performance that can be 
carried out prior to wet laboratory validation.   
 
6.4.4.2. Application of Framework to Novel Forensic Toehold Switches 
Finally, screening of forensic biomarker toehold switches was performed by combining a 
melting curve approach with thermodynamic parameter analysis. Base-pair identity at the 
top of the switch stem along with ΔGRBS-Linker and ΔGStem values were calculated for the 
biomarker designs that had previously been subject to melting curve analysis (Figure 
6.11). From previous thermodynamic screening, it had been concluded that ΔGRBS-Linker 
correlated positively with performance in switch designs with WWW, WSW, and SSS base-
pairs at the top of the switch stem. Additionally, ΔGStem correlated positively with 
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performance in WWW, WSS and SSW groups. Six of the eleven biomarker designs (ALAS2 
#1, #3-5, HTN3 #1-2) belong to at least one of these groups. By inserting the ΔG values of 
these designs into the formulas of the linear regression calculations performed on the 
Green et al. data set (see section 6.4.3.2. Identification of Thermodynamic Parameters for 
DNA-Based Toehold Switch Performance Screening), it should be possible to predict 
output fluorescence (Table 6.6).  
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Table 6.6: Predicted performance in terms of ON/OFF fluorescence of biomarker designs calculated using linear regression formulas of ΔG parameter against 
log10 fluorescence derived from Green et al.’s data set. Calculations were only performed for network designs containing base pairs at the top of the switch 
stem that belonged to a group known to correlate with ΔGRBS-Linker or ΔGStem. 
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Four of the six designs were predicted as having on/off fluorescence ratios >2-fold (ALAS2 
#3-5, HTN3 #2), suggesting they may be useful candidates to validate experimentally. As 
the WWW group of positive control switches correlated with both thermodynamic 
parameters, two performance predictions could be calculated for HTN3 design #2 which 
belonged to this subgroup. The range between these outputs was large, with the ΔGRBS-
Linker formula predicting performance more than 10 times greater than the ΔGStem formula 
(61.10-fold vs 5.90-fold). This variance exemplifies the need for a more refined screen 
which can only be generated with additional validated toehold switch networks.  
Thermodynamic screening data generally correlated with previous interpretations of 
forensic biomarker network designs based off melting profiles (Figure 6.11). For instance, 
HTN3 design #1 was a design that had an unusual melting profile in that it appeared to 
conform to a typical switch-trigger duplex structure, but the switch hairpin itself 
appeared unstable which may lead to low performance. This network had a predicted 
fold-change in fluorescence of 0 and taken together these results would strongly indicate 
that a network should be discarded or redesigned. Conversely, the second design for 
HTN3 had clear separation of melting profiles between structures both in terms of peak 
melting temperature and dye fluorescence which had the greatest predicted fluorescence 
here. Although there is discrepancy in predicted performances based on the different 
linear regressions used, it indicates that the network would function correctly to an 
adequate degree. All of the ALAS2 designs when assessed by melting curve analysis had 
relatively low dye fluorescence compared to other biomarkers, this is reflected in the 
thermodynamic screen which predicts relatively low performance in all designs examined 
except #4, which had the clearest melting profile. This combined screening method 
having both methods concord with one another provides evidence for its utility as a 
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screening tool. As the AMEL-Y design used in this series of experiments did not belong to 
a subset of designs that correlated well with ΔGRBS-Linker/ΔGStem, it would be inappropriate 
to apply the thermodynamic portion of the combined screening framework to it to 
predict performance. Following on from this study, the AMEL-Y toehold switch should be 
redesigned to belong to one of these groups and re-analysed by both screening methods. 
This should be prioritised as it is this marker which fulfils the sex identification aspect of 
the novel toehold switches. 
Examining the melting temperatures, once again the switch hairpin melting temperature 
generally increases as the number of A/T base-pairs at the top of the switch stem 
decrease, reflecting increased energy requirements to melt. Designs containing two A/T 
base-pairs had poor predicted performance, but those containing only one or three base-
pairs had higher predictions. This discrepancy should be focussed on in further study in 
order to determine other factors present in the switch stem which may be affecting the 
final unwinding of the switch stem to linearise the ribosome binding site. While the 
results listed here are estimates, inclusion of the thermodynamic parameters has enabled 
a basic screen of a set of in-house de novo generated network designs for forensic 
detection and if refined further may allow for more accurate predictions to be made and 








6.5.1. Assessment of Coupled HRM-Thermodynamic Analysis as a Toehold Switch 
Screening Framework 
High-resolution melting curve analysis alone was not deemed suitable as a screening 
framework as although it was capable of differentiating between switches and switch-
trigger duplexes (the off and on states of the gene network, respectively), networks could 
not be grouped by characteristic melting temperature or profile appearance. There was 
some indication that network performance was linked with hairpin structure melting 
temperature but there was not a large enough data set to properly assess this.  
Troubleshooting of this approach was difficult given the generalised data set that was 
produced, making contributions from individual aspects of the switch and switch-trigger 
structures problematic to identify without drastically increasing cost and labour to 
characterise individual network regions. Thermodynamic analysis is then well suited to 
supplement experimental melting curve data as it allows for the nature of secondary 
structure formation and inter-strand interaction to be determined and data collected 
without introducing any additional wet laboratory work or costs.  
Data from thermodynamic analysis demonstrated that conversion of RNA sequences of 
known performance to DNA did not significantly impact ΔG values of various regions and 
maintained correlations between ΔG and performance at the same ionic concentrations 
that were deemed optimal for melting curve analysis. This is an important result as a key 
design aspect of the envisioned forensic biomarker assay is the use of DNA over RNA for 
the network structures. Use of ssDNA over RNA will reduce costs associated with the 
system and can be generated through an asymmetric PCR approach. After identification 
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of ΔG values that were linked with network performance (ΔGRBS-Linker, ΔGStem) the 
thermodynamic screening step was retroactively fitted onto melting curve data. Although 
this combined approach did reiterate the relation of ΔGRBS-Linker with network 
performance, it was not able to fully elaborate on the relationship between structure 
melting temperature and ΔGRBS-Linker. As such, predicted performances of novel forensic 
toehold switches made using this framework varied greatly and did not have a great 
degree of confidence. Again, this was due to a small data set, which was further 
subdivided in order to make like-for-like comparisons between data points. Although 
results were not conclusive, there is sufficient evidence that melting temperatures are 
related to switch unwinding and thus reporter gene expression. To fully characterise this 
relationship, a much larger set of networks (>100) would be necessary, with melting data 
acquired for each along with free energy thermodynamic calculations performed in silico. 
By applying the same linear regression analysis method used above, correlations between 
melting points and ΔG values could be identified without outliers skewing trends. While 
this initial characterisation step would be resource and time-intensive and outside of the 
scope of this chapter, the results obtained could be used to devise a design protocol that 
reduces or eliminates the need for wet laboratory HRM melt curve analysis. NUPACK 
analysis software has a feature that predicts input sequence melting temperature which 
would enable the entire design process to be performed in silico, greatly increasing its 
applicability to synthetic biologists.  Any observed relationship between delta G and 
network performance that is obtained by in silico simulation is unlikely to be 1:1. This is due 
to extraneous factors surrounding gene expression not taken into consideration that 
might impact performance. For instance, mutations in the 5’ flanking regions of genes 
expressed in E. coli have been demonstrated to significantly affect mRNA production 
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levels [362]. It stands to reason then that certain nucleotide sequences within the toehold 
switch itself may also cause such a phenomenon and presents a further avenue of 
optimisation to ensure a balance between ready linearisation of the toehold switch and 
high reporter gene expression levels.  
Despite the inconclusive screening results, high-resolution melting curve analysis has 
presented a simple and rapid means of clearly differentiating between toehold switches 
in their repressed and activated states. This could be a practical method to troubleshoot 
the network in cell-free protein synthesis reactions by ensuring that the correct switch-
trigger duplex structure is being formed and repression of gene expression removed 
instead of relying solely on in silico predicted folding data. The proposed link between 
toehold switch melting temperature and network performance could be investigated by 
taking validated toehold switch networks and varying designs by a single base pair at a 
time, then re-assessing performance. In doing so, it would be expected that performance 
would either increase or decrease as a result and this would be accurately captured by 
HRM analysis, as only a single base-pair differs between the two sequences, making HRM 
a powerful tool for screening. Again, this would require a start-up set of switches and 
designs which is outside of the scope of this chapter.  
 
6.5.2. Comparison of In-House Methods with Contemporary Network Design Protocols 
Since the original publication of toehold switch structure and demonstration of its high 
performance, specificity, and sensitivity in Nature in 2014 [17, 38], toehold switches have 
become a popular bio-detection tool for synthetic biologists. In particular, biosensing and 
molecular diagnostics have been key points of application, with several reviews detailing 
the ways in which this has been achieved with both DNA and RNA-based switches [171, 
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363]. Designs of toehold switches have also been altered to enable more complex sample 
processing [364] or the detection of RNA sequences outside of the bacterial/cell-free 
environments [365]. Many of these switch networks are RNA-based, though DNA toehold 
switches have been experimentally verified, lending confidence that the methodology 
used in this chapter is appropriate [363]. A common thread of discussion throughout the 
literature in the years following the original publication is the difficulties faced in design 
of high-performance toehold switch networks and the need for reliable design 
frameworks [363, 366, 367]. In response to this, several laboratories have independently 
devised and published in silico rational design strategies for toehold switches that take 
advantage of the high processing power offered by these techniques. One such strategy 
was the development a web tool for toehold switch design that was itself based on the 
same performance data of ~180 switches validated by Green et al. used in this chapter 
[368]. This tool partway automates toehold switch design by generating putative switches 
given an input trigger sequence of ~30 nucleotides in length and allows user 
customisation of RBS, promoter sequences and experimental conditions. The network 
performance of the switch in terms of its on/off fluorescence ratio (“efficacy”) is also 
predicted. Predicted performance is based on a multivariate calculation that includes ΔGs 
of the RBS-Linker, intact switch, and difference in free energies during switch-trigger 
binding, factors that were also deemed important in Green et al.’s work and the DNA free 
energies calculated in-house. The number of paired bases in the toehold stem is also 
taken into account, providing further evidence that position and identity of bases is an 
important metric for toehold switch design which would tie into melting curve analysis. 
One drawback of this tool outlined by the authors is that the reliability of the efficacy 
Chapter Six – Melting Curve Analysis Screening Framework 
317 
 
prediction cannot be improved with changes to the calculations without a subsequent 
increase in the number of samples being drawn from.  
More sophisticated in silico toehold switch design packages have been produced that use 
deep learning algorithms to redesign input sequences, with performance predicted by 
computationally analysing the difference in performance between the input sequence 
and a set of experimentally-validated switches [369, 370].  Nucleotide regions over-
represented in high-performance networks are identified, and then the input is 
redesigned to fit these factors. Although the adaptive nature of the neural networking 
algorithms present a powerful tool for overcoming design bottlenecks common to 
toehold switch development, this was only possible after the in vivo validation of 91,534 
toehold switches which highlights the sheer input requirements in developing a robust 
screening framework.  
These published frameworks appear more robust in their predictions than the in-house 
melting curve framework as a result of far greater sample sizes and processing power. 
However, the function of these frameworks to redesign input sequences may be at odds 
with the application of toehold switches to bio-detection. Redesigning an input sequence 
that was based around a biomarker’s mRNA sequence may shift its specificity away from 
this marker as nucleotide bases are altered. The melting curve analysis approach 
developed here does not do that, rather it triages input sequences to recommend further 
analysis in vitro/vivo or to redesign using a different region of the same marker. While this 
approach requires manual work to perform the melting curve analysis, it may be more 
practical to apply to bio-detection as a result. Furthermore, the use of free software tools 
to predict toehold switch melting temperatures could remove the need for manual 
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analysis if predicted and observed melting temperatures could be demonstrated to 
reliably align. None of the published frameworks have included melting curve analyses or 




The combined melting curve-thermodynamic screening framework outlined above is the 
first of its kind that employs melting curve analysis to predict toehold switch performance 
in terms of reporter gene expression, and preliminary data demonstrates the clear 
discrimination of switch and switch-trigger duplex melting profiles. Melting curve analysis 
alone is able to fulfil some of the criteria outlined earlier for an ideal screening 
framework, namely that it is a simple, cheap protocol requiring minimal instrumentation 
that does not require much hands-on laboratory validation time or training. Combining 
this method with a more robust in silico screening procedure could produce an ideal 
screening framework for DNA-based toehold switches. Despite the inconclusive 
predictions from in-house screening of toehold switch networks with melting curve and 
thermodynamic analysis, both experimental data and independently published data 
provide evidence that positioning of bases in the switch hairpin is a significant metric in 
predicting switch performance. High-resolution melting curve analysis is theoretically 
capable of distinguishing between single base-pair differences in a network, and these 
differences should have a quantifiable effect of network performance, providing the basis 
for a screening framework. As a recommendation for further work, melting curve analysis 
should be performed on a far greater number of validated switches (at least 180 to obtain 
the same amount of data as Green et al.), and differences in sequence between switches 
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should be minimised in order to maximise the information obtained from melting curves. 
After this, computational thermodynamic analysis screening for known parameters of 
interest should be re-performed to generate a complete data set that can be interpreted 
and assessed. Toehold switch networks that are predicted to have adequate performance 
at this stage should be validated in cell-free protein synthesis reactions to check 
concordance between predicted and observed performance before moving onto full 
validation of the toehold switch as a bio-detection tool for the biomarker of choice. 






The work presented throughout this thesis documents the development of DNA-based 
toehold switches for forensic sex identification at the crime scene, along with an E. coli-
derived cell lysate to facilitate in vitro protein synthesis outside of the equipped 
laboratory and an in silico screening framework to aid synthetic gene network design. The 
following sections discuss the major results and findings, how they relate to the original 
aims and objectives of the work, their implications, and a critique of the approaches used. 
Recommendations for future studies to expand upon this data and bring field-based 
forensic sex identification by DNA recognition to market are included. 
 
7.2. The Current State of Field-Based Nucleic Acid Bio-Detection 
7.2.1. Synthetic Biology as a Tool for Nucleic Acid Bio-Detection 
Before work on designing a synthetic gene network for forensic sex identification could 
begin in earnest, a scan of the literature was required to see if similar assays were in 
development or already in use in some fields (Chapter One). The major finding of this 
chapter was that synthetic biology applications to nucleic acid bio-detection had seen 
increased research interest in recent years, most notably in the field of healthcare. 
Reviews of these techniques irrespective of field of origin predicted a large increase in the 
use of synthetic approaches for nucleic acid detection in the future, citing improved 
specificity, sensitivity, time-to-result, and field-based workflow as key factors. While 
already considered a field of interest, research into synthetic gene networks as bio-
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detectors has drastically increased since the emergence of SARS-CoV-2, the viral human 
pathogen that causes COVID-19, which was declared a global pandemic by the World 
Health Organisation (WHO) on March 11th, 2020 [371] and reached an estimated 
20,000,000 cases worldwide as of August 10th, 2020 [372]. The common symptoms of 
COVID-19 (fever/high temperature, consistent dry cough, shortness of breath, loss of 
taste/smell) are non-specific and present upwards of 11 days after infection, making 
diagnosis by clinical presentation inaccurate outside of severe cases [373]. This positions 
molecular biology techniques as uniquely useful in the accurate and reliable diagnosis of 
COVID-19. Currently, the standard practice for confirmation of SARS-CoV-2 infection is via 
benchtop RT-PCR (Reverse Transcriptase PCR) of a throat swab taken from the patient, 
but there are concerns that this method that takes several hours and requires extensive 
labour is not sufficient to be scaled up by the orders of magnitude necessary to combat a 
pandemic in densely populated areas [96]. Research into alternative detection methods 
with shorter workflows and capacity for use at the point of care have identified 
isothermal amplification, RT-RPA, and indeed paper-based toehold switches as prime 
candidates [374-376]. As molecular bio-detection assays miniaturise and simplify with 
advancements in microfluidics, it facilitates the transfer of these assays from the confines 
of the laboratory into the field. This shift has been pre-empted by bodies such as the 
WHO, who have created the ASSURED guidelines (Affordable, Sensitive, Specific, User-
friendly, Rapid and Robust, Equipment-free and Deliverable to end users) as a framework 
for development of novel field-based assays [131]. While initially devised to aid 
development of point-of-care healthcare assays, the outlined criteria are all applicable to 
forensic investigation being conducted at a crime scene or other remote area. Toehold 
switch networks can fulfil all of these criteria in a forensic setting, justifying the research 
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into applying toehold switches to crime scene investigation which is in need of simple, 
rapid workflows. This rapid and ongoing development of synthetic and conventional 
molecular biology tools demonstrates that the field is still in need of reliable, accurate, 
and fast bio-detection tools. A lack of such synthetic tools specifically aimed at forensic 
body fluid and sex identification highlights the novelty and practical applicability of the 
toehold switch designs outlined here.  
 
7.2.2. Identification of Market Trends 
The literature scan above revealed a shortcoming in the market for a rapid, field-based, 
forensic sex identification assay targeting genetic sequences. This provided a 
developmental opportunity to combine knowledge surrounding synthetic gene network 
design and forensic sex identification to produce a toehold switch network for forensic 
use that could be validated experimentally and brought forward to market. However, the 
assumption could not be made that professionals working in forensics would have a need 
or use for such an assay provided one existed. Furthermore, forensic sex identification 
encompasses a variety of techniques with different applications, specifications, and 
weight of evidence produced. This made it difficult to answer basic questions regarding a 
novel toehold switch assay’s design, namely ‘what genetic target should the assay 
detect?’ and ‘how should the test aim to function?’. Without this information, assay 
development could not proceed efficiently.  
To address these issues, a market research study was conducted using a self-reported 
questionnaire. The primary objectives of this study were to determine if representative 
end-users had any need for novel assays in their routine detection work, and the 
Chapter Seven – General Discussion 
323 
 
specifications to which any novel assay should function. While the primary stakeholders 
of the market research were aligned with forensic investigation (e.g. forensic scientists, 
forensic-aware police), questionnaire participants also included end-users from 
healthcare and environmental monitoring fields, who also engage with field-based 
testing, to determine if any needs were overlooked in the decision to focus on toehold 
switches for forensic use. To supplement questionnaire participant numbers from 
professional respondents, a secondary survey was produced aimed at students in the 
above fields being surveyed that were either postgraduates or final-year undergraduates. 
As several of the questions regarding routine use of field-based detection platforms 
would not be appropriate here, a shortened survey of relevant questions was used. While 
the market research that was performed was somewhat basic in its approach, the survey 
identified a desire amongst forensic and healthcare participants for novel field-based 
detection tools targeting human DNA and body fluids. This finding was considered 
adequate to justify the continued development of forensic toehold switch assays in-
house. Other key needs reported included low instrumentation and reagent costs. 
Questionnaire participants expressed a preference for any novel assay to be presumptive 
in nature. From a forensics standpoint, this would mean that the assay should exist as a 
complement to existing techniques and aid in sample screening rather than replacing 
them. This information, combined with the identification of body fluids and DNA as key 
analytes, provides a targeted application context and enables the comparison of any 
validation data generated using toehold switches against existing similar techniques 
fulfilling this purpose.  
The use of market research as a tool for forensic assay development is justified by the 
existence of similar approaches in the literature that use market research results in order 
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to aid assay development and avoid pitfalls during commercialisation. The results of this 
market research aligned with the key findings of several others in the fields of both 
forensics and healthcare, namely identifying low cost, rapid time-to-result, <100 target 
copy detection and ≥95% accuracy as key developmental drivers [148, 156, 157]. Past 
studies of the intersection of needs between forensic science end-users and service 
providers produced a list of technological drivers for development. These were low cost, 
rapid analysis, increased portability/ease of use, simple interpretation, and ease of 
integration of resulting information to forensic decision workflows [172]. All of these 
technological drivers can potentially be fulfilled using toehold switches, although further 
troubleshooting and optimisation is required with in-house forensic toehold switch 
networks to demonstrate this.  
There are unique difficulties in bringing forensic assays to market given the applied 
nature of forensic science to law enforcement. To ensure that a forensic assay can 
robustly fit into forensic workflows either as a screening or diagnostic tool, its underlying 
scientific principles and suitable applications must be rigorously defined. There are few 
instances of documented routes to market for assays specifically designed for forensic 
scientists and police, but useful information can be gleaned from those that do exist. The 
ParaDNA® Screening System is a portable device for sample collection and PCR using 
Hybeacon™ probes for the presumptive detection of DNA [335]. This assay was classed as 
a level 1 DNA Screening Solution under the Accelerated DNA Profiling Technology 
(ADAPT) Initiative by the UK National Policing Improvement Agency (NPIA) [377]. This 
categorisation was due to the assay fulfilling several requirements, including testing for 
DNA presence, rapid (<90 minute workflow), ease of use/interpretation and capability to 
increase the robustness and reliability of the forensic decision making process with 
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regards to screening samples. This is a category that toehold switches would likely be a 
part of as well as throughout the thesis toehold switch performance has been identified 
as being closer to presumptive tests for DNA detection. This makes the ParaDNA® 
Screening System a useful case study in how to bring a forensic assay to market. The 
route to market used by the authors consisted of initial assessment of the assay’s 
scientific principles, usability testing by end-users, validation studies, and wider pilot 
testing. Throughout, there was co-operation and collaboration with relevant end-users 
and bodies in the wider forensic community including private industry, governmental 
departments and law enforcement. The in-house forensic sex identification toehold 
switch assay should therefore look to emulate this framework after demonstration of 
reaction success to maximise chances of commercial success.    
The surveys that were produced during this period reflected the guidelines for 
questionnaire design outlined by the Market Research Society [378], therefore 
representing best practice in the field. Research questions were generated from research 
objectives, which were then used to prepare a list of survey questions that would provide 
suitable data to fulfil research objectives. Every question in each survey related back to at 
least one research objective which provides confidence that the survey fulfils the specific 
purpose of gauging potential end-user opinions on novel assay development and design. 
Furthermore, the surveys were structured so that questions were presented in a logical 
manner, with questions regarding similar topics grouped together which was also 
communicated to respondents. This made for a questionnaire that was both effective at 
obtaining appropriate research data that was also simple for respondents to understand 
and complete. The primary downside of the research was the relatively small number of 
respondents for the professional and student surveys.  
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If this research was to be repeated, the market survey would have been spread out across 
a longer timeframe, specifically aimed at forensic professional end-users in different 
contexts (R&D, lab personnel, office personnel, SOCOs, etc.). This would give a data set 
that was more representative of the intended end-user group and the inclusion of several 
different job types and descriptions (as in the documented survey) would help to identify 
research needs of field-based forensic technicians. Secondly, the scale of the market 
research should be vastly increased to at least 1000 respondents to ensure that the 
results of the survey have the appropriate weight to be seen as representative of field-
based forensic end-users as a whole. Furthermore, once a prototype toehold switch assay 
for sex identification has been experimentally validated in-house, a follow-up 
questionnaire can be produced. The purpose of this would be to highlight that the results 
of the first questionnaire have been implemented (i.e. high specificity/sensitivity, minimal 
sample preparation, fast time-to-result, etc.) and to receive feedback on if these factors 
make for a desired assay or if further optimisation is required. This iterative testing and 
response approach has been previously demonstrated to assist assay development and 
streamline the introduction of assays to the market [133]. 
  
7.2.3. Validation of Existing Standard Techniques and Novel Assays 
Development of any novel assay necessitates comparisons against existing techniques to 
determine if any improvement is offered by the novel approach and to aid in 
identification of potential areas of application. As the toehold switch under development 
was targeted at body fluid and sex identification, there were two primary techniques that 
performance metrics could be compared against: qPCR and immunoassays. Quantitative 
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PCR can be used as a confirmatory tool for sex identification as commercial qPCR kits 
contain primers for the amplification of sex-specific regions of DNA and the high 
sensitivity and specificity of these kits prevents amplification of non-targets [222, 379]. 
Conversely, immunoassays act as rapid presumptive screening tools for sex identification 
by targeting sex-specific proteins and antigens deposited in human body fluids, with a 
qualitative report of assay result. Immunoassays have traditionally been less sensitive or 
specific than qPCR [380-382], but RSID kits for semen targeting semenogelin have 
demonstrated high sensitivity and lack of cross-reactivity with similar proteins [228]. 
Results of the market research identified a preference for presumptive function amongst 
end-users, which would point to immunoassays as a commercial benchmark for toehold 
switch performance.  However, the potentially quantitative nature of toehold switch 
reporting, the target under consideration (DNA), and the existence of other presumptive 
DNA detection techniques (e.g. ParaDNA® Screening System) would suggest that qPCR 
would be the more relevant technique to compare against.  To this end, the Investigator® 
Quantiplex® Pro RGQ Kit (QIAGEN) qPCR kit was internally validated (Chapter Three), 
having already completed its developmental validation by the manufacturer prior to 
entering pre-release phase. This is consistent with validation guidelines outlined by the 
Scientific Working Group on DNA Analysis Methods (SWGDAM), which states that to 
implement any assay into forensic protocol it must first be developmentally and internally 
validated for use [383]. These validation procedures are held to defined standards as the 
goal of forensic validation is to demonstrate to a court of law that a method, when used 
for its specific purpose, obtains results that can be shown to be reliable and admissible as 
either evidence or intelligence supporting other methods [384]. Forensic validation has 
several objectives: to determine whether an assay procedure can obtain results that 
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further forensic investigation, the conditions under which those results are obtained (i.e. 
clear definition of usage contexts), and the limitations of the system. Internal validation 
studies following SWGDAM guidelines recommend a series of individual experiments with 
a minimum number of samples (~50).  
All recommended studies relevant to the kit’s function (reproducibility, precision, 
sensitivity, mixture analysis) were performed in dedicated DNA analysis laboratories with 
the required number of samples. Known samples and mock casework samples were 
analysed in most cases, with some live casework samples from ancient remains (approx. 
700 years old) analysed where appropriate to gauge degradation marker accuracy. This 
portion of experimental work was successful, as standardised forensic protocol was 
followed to obtain a data set that clearly demonstrates the performance and limitations 
of the kit, which also concurred with developmental validation data from the 
manufacturer. Sensitivity studies found that total DNA could be detected down to 4 pg 
template quantity, and that male contribution could be detected against majority female 
background at a ratio of 1:1000 in 500 pg/µL of template. Toehold switch networks have 
been demonstrated to detect mRNA at single picomolar level input in laboratory 
validation [385], which suggests that this approach would also have high sensitivity. 
However, the limit of detection of pDNA constitutively expressing a fluorescent reporter 
in the in-house cell lysate was around 300 – 450 pg quantity, suggesting more 
optimisation of the process is required. Copy numbers of mRNA per microlitre of sample 
should be taken into consideration though to ensure that toehold switch sensitivity 
performs to a level that is forensically relevant. It should be noted that the qPCR method 
was far more sensitive for male DNA than downstream STR profiling, where below 1:25 
male:female quantification ratios, mixed STR profiles appeared identical to single-source 
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female profiles. This suggests that a toehold switch would only need to be capable of 
detecting a male contribution down to this level to perform adequately in existing 
workflows. Interestingly, this ratio was also the limit of detection of the RSID-Semen™ 
assay briefly used during qPCR kit validation, detecting ~20 pg male DNA from seminal 
fluid in a 500 pg total sample which acts as a performance benchmark that toehold switch 
approaches should look to emulate. Accuracy of the Quantiplex® Pro RGQ kit was high, 
with average accuracies between 80 - 90% for autosomal DNA and between 70 – 80% for 
male DNA down to 4 pg of template. The accuracy of forensic sex identification by 
toehold switches currently represents an unknown in development as it will depend on 
the target gene, but these values represent a benchmark to act as developmental drivers.  
Two factors considered highly important to validate for practical forensic application of 
the Quantiplex® Pro RGQ qPCR kit were inhibitor tolerance and interaction with degraded 
DNA template. The results of the validation studies found that the kit had high tolerance 
to the contaminants humic acid and hematin relative to contemporary qPCR kits and 
could reliably flag samples during analysis that contained degraded DNA. These factors 
have not been considered during the development of toehold switches in the literature as 
these designs are primarily focused on detection of bacterial or viral nucleic acids in 
clinical samples taken directly from patients [16, 166]. These samples are typically tested 
under laboratory conditions immediately after sourcing, or can be stored long-term at 
sub-zero temperature, providing little opportunity for sample degradation or inclusion of 
contaminants. Conversely, forensic samples are encountered in non-sterile environments, 
can be embedded onto surfaces, and may not be collected until days, weeks, or even 
months after first deposition. The potential effects of contaminants or degraded DNA on 
a toehold switch’s capability to interact with target mRNAs are therefore unknown and 
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must be addressed during validation in order to implement toehold switches into forensic 
workflows.  
This work provided the opportunity to participate in larger scientific community efforts to 
validate a novel assay, as several other laboratories participated in the pre-release beta 
test of the kit. The collective studies from these individual laboratories and the 
manufacturer’s own validation data create a repository of information for end-users 
looking to implement the kit into routine practice. The inclusion of live casework samples 
such as ancient skeletal remains is an important factor of the validation that sets it apart 
from studies that only use mock samples as it provides data within the context of the kit’s 
intended usage parameters. While ancient remains are likely to be in much poorer 
condition than the DNA extracted from crime scene samples, it demonstrates a practical 
application of the kit to extremely degraded samples, which the kit itself is marketed as 
being suitable for use with.  Finally, processing quantified samples through downstream 
STR profiling further aids forensic investigators by correlating quantification results with 
downstream analysis and identifying limits of detection of quantification and male:female 
mixture detection, aiding integration of the kit within existing casework protocol. This 
series of validation studies was compiled, edited for submission, peer-reviewed, and 
published in the March 2020 issue of Science & Justice (Elsevier), demonstrating the 
relevance of this work to the wider forensic community (see Appendix II).  
It is recommended that the validation framework used for qPCR is applied to toehold 
switch-based assays for forensic sex identification once a functioning prototype has been 
produced. However, the specifics of experimental design would need to change, as 
forensic validation requires that assays fit the specific purpose to which they are 
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developed for, and that they work to required standards at the site of use [384]. 
Validation against existing tests should also expand to include immunoassay approaches 
given the similarities that the two approaches possess in performance. The intended 
usage case of toehold switches is as a rapid, on-site presumptive test for sex identification 
from samples by DNA recognition. As such, experiments involving toehold switch assays 
should be carried out with known/mock samples without the assistance of confirmatory 
laboratory-based techniques, with the inclusion of live casework samples to bolster data. 
Lastly, samples processed as positive or negative for male DNA by the toehold switch 
assay can be processed further with downstream quantification by PCR. This places the 
results of the validation studies into its intended forensic casework context as a sample 
triaging tool and allows for its reliability to be assessed, similarly to how qPCR results 
were compared to later STR profiles.  
 
7.3. Development of a Cell-Free Protein Synthesis System for Toehold Switch Expression 
Development of a CFPS system for toehold switch expression is not a novel concept, 
indeed CFPS has been used as a molecular biology tool for decades [386, 387]. The 
purpose of producing a CFPS system in-house was two-fold: 1) a requirement for the 
envisioned field-based sex identification assay is that it can only be performed in vitro to 
remove storage and handling requirements; and 2) commercial CFPS kits are prohibitively 
expensive to use for long term characterisation and optimisation of protein synthesis 
from toehold switch networks. This portion of work consisted of several objectives across 
different stages to be completed in linear sequence as the CFPS system became more 
complex. The first stage consisted of lysing a culture of E. coli cells to obtain a cell lysate 
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that could perform protein synthesis in in vitro solution-phase reactions. The second and 
third stages involved expression of toehold switch networks in solution-phase and freeze-
dried paper-based platforms, respectively. Finally, multiplex detection of forensic markers 
would be achieved by incorporating multiple toehold switch networks with different 
forensic triggers and reporter genes.  While these objectives were being fulfilled, metrics 
such as suitable template types, limits of detection and shelf-life could be obtained for 
later comparison to existing gold-standard techniques.  
In terms of fulfilling this set of objectives, this section of work had the least success, as 
experimental work did not progress past the second phase of successfully expressing 
toehold switch networks in solution-phase reactions. This was due in part to 
underestimating the length of time required to obtain a cell lysate of sufficient TX-TL 
machinery concentration to allow for successful protein synthesis. This process required 
many rounds of iteration and troubleshooting, and since preparation of a cell lysate 
starting from inoculation of E. coli cells onto agar plates takes approximately 1 week, this 
quickly consumed a lot of time. This was compounded further by the unusual method of 
preparing a lysate without mechanical disruption of cells as is often used. As such, the 
expertise for working with the method was not available in-house and required reaching 
out to the laboratory that first published the protocol to discuss troubleshooting options. 
As a result, a functional cell lysate was not achieved until well into the second year of 
work, greatly reducing hands-on time with the system to characterise toehold switch 
networks.  
Solution-phase experiments involving the in-house cell lysate faced numerous setbacks. 
Even when using toehold switch designs that have been experimentally validated in RNA-
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based systems, protein synthesis from the unwound switch was not observed when using 
PCR product, linear oligonucleotide, or plasmid DNA. This required simplification of the 
system to one that expressed reporter genes from constitutive plasmids to diagnose 
system issues, which further detracted from toehold switch experimentation. Although 
protein synthesis was successful across batches of E. coli cell lysate, the inordinate length 
of time this took to achieve left very little time for expression of forensic biomarker-
specific toehold switches in the system. Furthermore, batch variability led to significant 
differences in CFPS activity despite similar protein concentrations, and reduction in CFPS 
activity over time during storage at -80°C was observed within ~6 months of lysate 
production. The final experiment of this section of work (Chapter Five) did use a novel 
toehold switch design for forensic biomarker (TGM4) detection, but reporter gene 
expression was not detected. Early troubleshooting did reveal that a positive control 
plasmid was expressed, pointing to an issue with the toehold switch networks. However, 
allotted time for experimental work concluded before any further troubleshooting could 
take place. If more time was available, several ideas for troubleshooting the network 
were posited, which could all be tested simultaneously and would be expected to take a 
few months of extra work to complete. These methods would be to a) double-check the 
sequences of the TGM4 switch and trigger sequences and use in silico simulations to 
ensure correct interaction and switch unwinding and repeating the experiment; b) return 
to the use of validated arbitrary toehold switch designs; or c) remaking the TGM4 designs 
as RNA sequences. Of these options, the first is perhaps the least likely to succeed as in 
silico simulations were run prior to this experiment which showed correct unwinding of 
the TGM4 switch in the presence of its cognate trigger, and expression of the positive 
control plasmid eliminates experimental error as a factor of reaction failure. Use of 
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validated arbitrary designs would increase the chances of successful protein synthesis but 
this lacks of the novelty aspect of using toehold switches for forensic sex identification. 
This leaves changing the TGM4 switch and trigger to RNA as the most viable option as it 
retains the novelty but also would be much easier to troubleshoot and optimise as there 
is a far greater amount of literature surrounding RNA-based toehold switches. Although 
this is not in line with the design brief of a DNA-based assay, it is considered more 
important to simply have a functioning system that can be altered later once the protocol 
is set. Were this work to have been repeated, more time would have been allotted to in-
house cell lysate production as this only began around the beginning of the second year 
of work. The reason for this was that the first year of experimental work consisted of 
melting curve screening and analysis, and testing of commercial CFPS systems. The 
assumption had been made that transfer of the published protocol in-house would have 
been simple, taking only a few months maximum and so could have been put off until 
commercial lysates and plate reader measurements had been optimised. Instead, 
development of the in-house cell lysate should have been placed alongside the melt curve 
screening and commercial CFPS work to make the best use of time. This would have 
extended CFPS characterisation by upwards of a year and greatly increased the available 
data set while extending troubleshooting of expressing toehold switch networks.  
Other issues arose in in-house cell-free development due to poor planning or lack of 
preliminary research. Given the time constraints that began to appear in the second year 
of work, hands-on laboratory time was prioritised to generate data. However, in rushing 
to obtain reagents for cell-free protein expression, certain factors were overlooked. 
Primary amongst these was the choice of reporter gene used to measure network 
performance. Initially, GFPmut3b was used as a reporter to replicate the method from 
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Green et al. and would enable direct comparison of results to the literature assuming the 
system functioned as intended. The problem with this reporter that was not identified 
until after testing had begun was that the plate reader used (ClarioStar) cannot set 
excitation/emission filters close enough to reflect GFPmut3b’s optical maxima (501/513 
nm, respectively). This made data interpretation difficult, introducing large amounts of 
noise where excitation light is being read back as emitted fluorescence, and measuring at 
sub-optimal wavelengths. The reporter gene issue was exacerbated further by attempting 
to address it, by replacing GFPmut3b with wtGFP. The logic here was that a reporter gene 
of greater Stokes shift would be most preferable as excitation and emission wavelengths 
become easier to distinguish. However, wtGFP is an outdated reporter with weaker 
fluorescent intensity, slower fluorophore folding maturation rates (increasing the delay 
between synthesis and measured fluorescence) and has been superseded by the use of 
enhanced-GFP mutants [388]. Also, wtGFP lacks commercial dyes in its spectral region to 
act as positive controls. Had more research into fluorophores been done before returning 
to laboratory work, many of the difficulties in detection and quantification of 
fluorescence would have been circumvented. The reporter gene used in the final set of 
experiments with the forensic TGM4 toehold switch design (superfolder GFP) should have 
been used from the beginning. Superfolder GFP is a model reporter of high fluorescent 
intensity which would have made it far easier to integrate into standard protocol.  
The changing of reporter gene makes comparisons and assessment of assay performance 
more difficult as metrics such as sensitivity are a function of the reporter used. Sensitivity 
studies with wtGFP as the reporter found that the in-house system could detect the 
presence of as little as 300 pg/µL pDNA against a blank background. However, this would 
need to be re-established using sfGFP as a reporter with greater fluorescent intensity may 
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require a smaller input concentration of DNA to achieve the same relative fluorescence. 
The use of plasmid DNA to express toehold switch hairpins is a factor of assay design that 
can remain in place. Freeze-drying the toehold switch onto paper discs will allow for their 
stability to be retained when rehydrated, so use of plasmid DNA is preferable as this is the 
method of toehold switch design with the greatest stability and confidence in sequence 
accuracy. Once toehold switches have been demonstrated to function both in vitro and 
on paper using pDNA to express trigger sequences, work must be done to ensure the 
system is still capable of functioning using trigger sequence that has been extracted from 
biological samples or is a part of a crude mixture. This is vital for the assay to function in 
its intended forensic context, and is also needed to determine if switching from pDNA 
constructed trigger to “live” trigger has measurable impact on assay performance, and 
should be a priority in later development and validation.    
Another aspect of in-house CFPS performance that was unable to be characterised due to 
time constraints was the impact of inhibitors on protein expression. This is a critical factor 
to consider given the likelihood of co-collection with forensic samples, and the known 
impact of inhibitors on other forensic processes such as qPCR. There is some evidence in 
the literature that suggests that heme-containing compounds can inhibit protein 
synthesis in bacteria including Escherichia coli [389], which is the cell type from which in-
house system was prepared. As discussed in Chapter Three, humic acid binds template 
DNA and chelates magnesium ions. Magnesium is a key cofactor for enzymes and 
molecules involved in transcription/translation pathways [390-392], so the presence of 
humic acid in the reaction mixture may impede protein synthesis via a similar mechanism 
to PCR inhibition. Early studies that examined inhibition of protein synthesis in cell-free 
systems derived from E. coli have identified RNAses, and the antibiotics puromycin and 
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chloramphenicol as significant inhibitory molecules [387]. Puromycin is unlikely to be co-
collected with forensic samples in most contexts, but RNAses and chloramphenicol have 
both been identified in soil [393, 394], which is also a primary source of humic acid. It 
indicates then that in addition to inhibition from humic acid, additional molecules which 
are not inhibitory to qPCR will have to be considered when using forensic samples for 
detection in a genetic network.   
Choosing to stick to the defined linear progression schedule of increasing CFPS complexity 
may have been a hindrance as it prevented beginning work on later stages until earlier 
stages had been optimised.  As reporter gene expression had been detected from a 
constitutively expressing plasmid in both commercial and in-house lysates in solution-
phase, work could have begun on preparing paper-based reactions with the same 
template input. This would have been worth the time to set up during solution-phase 
reaction optimisation as although it does not reflect the final intended assay function, it 
would have demonstrated that paper-based detection was able to be transferred in-
house, while also reducing start-up and troubleshooting times for after the conclusion of 
solution-phase reaction work. In this time, supplementary data regarding shelf-life, 
sensitivity, time-to-result, etc. with paper-based reactions could have been obtained and 
compared to solution-phase reactions to identify if transferring CFPS to paper has any 
adverse effects on reaction kinetics. This information would be very useful for later 
planning of experiments. As with toehold switches, paper-based biodetection platforms 
have remained an area of interest for assay developers. The reduced cost, high shelf-life, 
wide application contexts and high performance are all highly beneficial aspects of the 
system that would facilitate their transfer to routine use. As mentioned previously, paper-
based toehold switch assays have been generated for COVID-19 [376], highlighting the 
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quick turn-around time in generating new networks as necessary. There have still not 
been any applications of this technology to forensic biodetection, which suggests that the 
research outlined here should be carried forward to development of a novel assay.  
 
7.4. Design and Screening of Toehold Switch Networks 
A key issue with synthetic gene networks, and indeed synthetic biology as a whole, is the 
poor correlation between network design and performance [10, 395, 396]. High 
performance variation is noted even within toehold switch groups that have been 
iteratively designed for higher performance [38]. For toehold switches to enter routine 
diagnostic use in any field they first require design strategies that are simple and 
predictable.  
Many toehold switch designs utilise RNA as a material as it is single-stranded and will 
immediately form a hairpin. Little work had been identified that used DNA as a toehold 
switch design material, which would be cheaper to use than RNA, and can also be 
produced in a single-stranded state using asymmetric PCR [397]. Melting curve analysis 
was proposed as a method for screening network designs due to the hypothesised link 
between melting temperature and ease of hairpin unwinding, the simple and rapid 
process to obtain a melt curve over full in vivo validation, and the resolution offered by 
HRM melting curves which can resolve between two sequences differing by a single base-
pair. The results from melting curve analysis of previously published toehold switch 
designs of known performance were intended to be used to reliably design toehold 
switches that were specific to forensic biomarkers of interest. However, these melting 
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curves were inconclusive from melting curve analysis alone and required a combined 
approach that also incorporated thermodynamic screening.  
If this work were to be taken further, which is recommended due to the ease and rapidity 
at which melting curve analysis can be carried out, a far greater number of toehold 
switches should be analysed, at least in the hundreds in order to more easily categorise 
switch designs and identify trends between design and performance. This would be 
simple and not take a particularly large amount of hands-on laboratory time either, given 
that in-house protocols for melting curve analysis are already in place, and there are 
much larger repositories of validated toehold switch designs compared to 4 years ago. 
Retroactively fitting the linear regression formulae onto in-house designs was able to 
estimate forensic biomarker-specific toehold switches of unknown performance but this 
estimate is likely inaccurate, evidenced by the relatively low R2 values of the regressions 
(≤~0.4) and the high variance of predicted network performance for networks that could 
be calculated using multiple regression formulae. This portion of the work was also not 
finished by the time that the in-house CFPS system was ready to test inducible forensic 
biomarker-based networks, meaning the toehold switch marker used in these 
experiments (TGM4) was designed solely to forward-engineered design parameters 
outlined by Green et al. rather than from the conclusions of the in-house screening work. 
That said, the results of the in-house screening framework generally backed up those of 
the more complex thermodynamic approach (lower temperatures were associated with 
greater numbers of A/T bonds and higher performance, base-pair identity in the switch 
hairpin stem is an important metric for determination of switch unwinding). This disunity 
between experimental timelines contributed to troubleshooting systems perhaps taking 
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longer than they would otherwise as work was performed using inefficient protocols or 
toehold switch designs.   
Toehold switches were an area of research interest almost immediately after the first 
publication that characterised them in 2014. The known issues of poor design-to-
performance predictability has led several independent research laboratories to devise 
screening methods in silico which have only recently been published. These methods are 
far more complex, utilizing deep learning algorithms and data sets containing many 
thousands of experimentally validated toehold switch designs to predict performance, 
and even recommend changes to input designs to increase performance further [368, 
369]. The existence of these screening frameworks makes justification of further 
development of the melting curve prediction strategy difficult. However, the lack of data 
linking melting temperature/melting curves with toehold switch performance may still be 
an area of interest to supplement these other methods, although not necessarily a 
priority.  
 
7.5. General Comments and Conclusions 
Overall, the results outlined in this thesis indicate that toehold switches are an emerging 
platform for bio-detection purposes but could not be successfully applied to forensic sex 
identification. This is an issue as both existing confirmatory and presumptive gold-
standard forensic techniques for sex identification face drawbacks that complicate 
forensic investigation. Quantitative PCR as a confirmatory tool for the presence of DNA is 
both labour and time intensive, and existing cheap, easy-to-use, and rapid immunoassays 
have comparatively poor accuracy, sensitivity, and specificity which limits the 
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interpretation of forensic evidence obtained with them.  Furthermore, there is a much 
smaller proportion of novel techniques being developed specifically for forensic end-users 
compared to fields like healthcare, which reduces the likelihood of these issues being 
addressed by private industry or governmental research and development.  
There is a market research position to suggest that forensic and forensically aligned fields 
(i.e. policing) would be receptive to an assay that is low-cost, presumptive in nature, high 
specificity/sensitivity, minimal handling, storage requirements and time-to-result – all 
qualities that toehold switch assays possess. In the years since toehold switches were first 
presented, their design protocols have rapidly advanced and recent efforts have 
demonstrated automation, which would rapidly enable designs of high performance to be 
generated. This would eliminate much if not all of the iterative design and optimization 
testing that is currently used for synthetic gene networks, and would allow for forensic 
biomarker toehold switches for various targets (e.g. sex identification, body fluid ID, etc.) 
to be created with short turnaround as needed.  
Cell lysates from E. coli prepared using only an incubator and ultracentrifuge for 
instrumentation requirements were demonstrated to synthesise protein in vitro from 
sub-nanogram quantities of plasmid DNA. The reduced instrumentation requirement 
opens the method to a wider array of laboratories. Toehold switch network circuit 
execution was not successful in this lysate but also in a commercial lysate, suggesting that 
additional work must be done to troubleshoot in-house toehold switch designs and 
ensure correct function. As both the novelty and commercial need/want for a toehold 
switch forensic sex identification assay has been retained during the course of this work, 
this thesis ends with the recommendation that troubleshooting work into expressing 
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toehold switches in cell-free systems continues. Much of the groundwork in transferring 
this method in-house has already been completed and results indicate that a few extra 
months of troubleshooting would yield a functioning bio-detection platform for forensic 
sex identification that can be later optimised and considered for bringing to market while 
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Table 1: Question list for the questionnaire distributed to professional participants. 
Question Number Question Type Question Answer Options (Options Separated by Commas)
1 Multiple Choice (Single Option) Which of the following options most closely describes your field of work?
Forensic investigation/policing, Healthcare Professional, Environmental Monitoring, Other 
(specified by respondent)
2 Multiple Choice (Choose all that apply) Which of the following options most closely describes your primary role within your work?
Laboratory-based personnel, administrative role, Non-laboratory-based personnel, research and 
development personnel, other (specified by respondent)
3 Multiple Choice (Choose all that apply) Which sample type is most commonly processed in your routine work?
Known human biological samples, known animal biological samples, known environmental 
samples, samples of unknown origin, other (specified by respondent)
4 Multiple Choice (Single Option)
What proportion of time spent by you/your team is spent outside of the laboratory environment (not 
including routine office work)
<10%, 10-<20%, 20-<30%, 30-<40%, 40-<50%, ≥50%
5 Multiple Choice (Single Option) How often are non-laboratory-based tests used in your routine sample detection and analysis work? Daily, Weekly, Monthly, Greater than monthly, Never, Don't know
6 Percentage Scoring
Assign a percentage score based on the test descriptions below based on how often they are used in your 
routine work (Presumptive tests)
Rating scale between 0-100% across 3 test types (protein, chemical, and DNA-based)
7 Multiple Choice (Single Option)
When considering your last month's work, how many samples does this combined percentage in question 6 
represent?
<5, 5-<10, 10-<20, 20-<50, 50-<100, ≥100, Don't know
8 Percentage Scoring
Assign a percentage score based on the test descriptions below based on how often they are used in your 
routine work (Confirmatory tests)
Rating scale between 0-100% across 3 test types (protein, chemical, and DNA-based)
9 Multiple Choice (Single Option)
When considering your last month's work, how many samples does this combined percentage in question 8 
represent?
<5, 5 - <10, 10 - <20, 20 - <50, 50 - <100, ≥100, Don't know
10 Multiple Choice (Single Option)
Do the confirmatory tests you use require sample pre-treatment (e.g. heating of sample, extraction of DNA, 
mixing with other reagents, etc. prior to testing)?









Question Number Question Type Question Answer Options (Options Separated by Commas)
11 Multiple Choice (Single Option)
How long does it take from the point of sample collection outside of the laboratory to obtaining a 
confirmatory result?
<1 day, 1-3 days, 3 days - <1 week, 1-<2 weeks, 2 weeks-<1 month, 1-<2 months, ≥2 months
12 Multiple Choice (Choose all that apply) How do these confirmatory tests report their results?
Visual identifier, manual interpretation of data, automatic interpreation by instrument, raw data 
exported to specialised software, other (specified by respondent)
13 Multiple Choice (Single Option)
Do you agree with the fllowing statement: "I am familiar with the range of both presumptive and 
confirmatory non-laboratory-based tests available in my field?"
Strongly agree, agree, neither agree nor disagree, disagree, strongly disagree
14 Ranking of Options
Rank which of the following issues you think represents the greatest hurdle to adopting a new detection 
technique as standard practice
Cost of new equipment/instrumentation, per-test cost of reagents, time taken to obtain a result, 
size of instrumentation, training required to operate instrumentation or interpret results, poor 
accuracy of assay/instrument, poor sensitivity of assay/instrument, poor flexibility of assay, lack of 
quality control, difficult storage of reagents, no issues with the current process
15 Multiple Choice (Single Option)
Do you agree with the following statement: "My routine testing needs are adequately met by existing 
(laboratory and non-laboratory) practices"?
Strongly agree, agree, neither agree nor disagree, disagree, strongly disagree
16 Multiple Choice (Single Option) Would a hypothetical non-laboratory-based confirmatory test be useful to you in your routine work?
Very useful, somehwat useful, slightly useful, no noticeable effect, slightly unhelpful, somewhat 
unhelpful, very unhelpful
17 Multiple Choice (Single Option)
Is there a non-laboratory-based confirmatory test currently available that you do not use that would fit 
your requirements?
Yes, No - non-laboratory based tests do exist but are of inferior quality to our laboratory-based 
alternatives, No - non-laboratory-based tests do exist but are too expensive for routine use, No - 
non-laboratory-based tests do not currently exist for my use, Don't know
18 Multiple Choice (Single Option) Should a novel non-laboratory-based test be confirmatory or presumptive in function? Confirmatory, Presumptive, No Preference
19 Multiple Choice (Single Option)
What is the maximum amount you would be willing to spend on a field-based confirmatory instrument that 
performed according to your needs?
<£100, £100-<£500, £500-<£1000, £1000-<£5000, ≥£5000
20 Multiple Choice (Single Option)
What is the maximum amount you would be willing to spend per-test on a field-based assay that performed 
according to your needs?












Question Number Question Type Question Answer Options (Options Separated by Commas)
21 Multiple Choice (Single Option)
Should a novel non-laboratory-based confirmatory test be specific towards detecting a single target or 
detect a range of different sample types?
Single Target, Multiplex
22 Multiple Choice (Choose all that apply)
Which sample type(s) in particular do you feel a novel field-based confirmatory test should be designed to 
detect?
Human body fluids (neat), human body fluids (mixed), human tissues, human DNA, human DNA 
(male-specific), Human DNA mixtures, degraded human DNA, pathogens/parasites in human body 
fluids, unprocessed animal tissues, animal body fluids, processed animal tissues, animal DNA, 
degraded animal DNA, pathogens/parasites in animal body fluids, soil-born pathogens/parasites, 
environmental soil sample chemistry, water-borne pathogens/parasites, environmental water 
sample chemistry, unprocessed plant tissues, processed plant tissues, plant DNA, plant pathogen, 
other (specified by respondent)
23 Multiple Choice (Single Option) What is the lowest level of accuracy that would accept in a field-based confirmatory test? 80%, 85%, 90%, 95%, 99%, 100%
24 Multiple Choice (Single Option) What level of sensitivity do you think is most appropriate for a novel field-based confirmatory test?
Very low input (e.g. single target copy detection), Low input (e.g. <100 target copy detection), 
Medium input (e.g. <1000 target copy detection), High input (e.g. <10,000 target copy detection), 
Very high input (e.g. <100,000 target copy detection)
25 Multiple Choice (Single Option)
What is the maximum length of time that a field-based confirmatory test should take to generate a result 
following sample input?
5-<10 minutes, 10-<30 minutes, 30-<60 minutes, 1-2 hours
26 Multiple Choice (Single Option) How should the test result be detected and interpreted?
Visual detection with end-user interpretation, visual detection with automatic interpretation by 
software, instrument detection with raw data analysis by end-user, instrument detection with 





Table 2: Question list for the questionnaire distributed to student participants. 
Question Number Question Type Question Answer Options (Options Separated by Commas)
1 Multiple Choice (Single Option) Which of the following most closely describes your field of study? Forensics, Healthcare, Environmental Sciences, Policing, Other (Specified by Respondent)
2 Multiple Choice (Single Option)
How much do you agree with the following statement: "I am familiar with the 
range of detection techniques that are used in my field"?
Strongly agree, agree, neither agree nor disagree, disagree, strongly disagree (Laboratory-Based and 
Field-Based)
3 Ranking of Options
Rank which of the following issues you think represents the greatest hurdle to 
adopting a new detection technique as standard practice
Cost of new equipment/instrumentation, per-test cost of reagents, time taken to obtain a result, size of 
instrumentation, training required to operate instrumentation or interpret results, poor accuracy of 
assay/instrument, poor sensitivity of assay/instrument, poor flexibility of assay, lack of quality control, 
difficult storage of reagents, no issues with the current process
4 Multiple Choice (Single Option)
Do you think that a novel field-based confirmatory test would be particularly 
useful in your area of study?
Extremely helpful, somewhat helpful, don't know, not very helpful, not at all helpful
5 Multiple Choice (Single Option)
Should a novel field-based test function to replace existing laboratory-based 
methods (confirmatory) or inform further sample processing (presumptive)?
Confirmatory, presumptive, no preference
6 Multiple Choice (Single Option)
Should a novel field-based test be specific to detecting a single target or a range 
of targets (multiplex)?
Single target, multiplex, no preference
7 Multiple Choice (Choose all that apply)
Which sample type(s) should a novel field-based test in your area of study be 
designed to detect?
Human body fluids (neat), human body fluids (mixed), human tissues, human DNA, human DNA (male-
specific), Human DNA mixtures, degraded human DNA, pathogens/parasites in human body fluids, 
unprocessed animal tissues, animal body fluids, processed animal tissues, animal DNA, degraded animal 
DNA, pathogens/parasites in animal body fluids, soil-born pathogens/parasites, environmental soil 
sample chemistry, water-borne pathogens/parasites, environmental water sample chemistry, 
unprocessed plant tissues, processed plant tissues, plant DNA, plant pathogen, other (specified by 
respondent)
8 Multiple Choice (Single Option)
How quickly should the workflow of a novel field-based test be carried out (i.e. 
how quickly should a result be obtained after sample input)?
5 - <10 minutes, 10 - <30 minutes, 30 - <60 minutes, 1 - 2 hours, 2+ hours
9 Multiple Choice (Choose all that apply) How should the results from a novel field-based test be detected/interpreted?
Visual detection with manual interpreation of result by end user, visual detection with automatic 
interpretation of result by software, detection of target by instrumentation w/ manual interpreation of 
raw data by end user, detection of target by instrumentation w/ automatic interpreation of results by 
software, other (specified by respondent)
10 Multiple Choice (Single Option)
Should a hypothetical field-based confirmatory test perform to the same 
standards of specificity and sensitivity as an equivalent laboratory-based test 
that takes longer to reach a result?
Yes - both tests should perform to the same standards, No - the field-based test should not be as 
specific/sensitive as the laboratory-based equivalent, No - the laboratory test should not be as 










Green et al. Toehold Switch Number ON/OFF Fluorescence Switch DNA Sequence (Excluding Linker) Trigger DNA Sequence
1 292.0 ± 19.5 GGGTGAATGAATTGTAGGCTTGTTATAGTTATGAACAGAGGAGACATAACATGAACAAGCCT AACTATAACAAGCCTACAATTCATTCAAAC
2 279.6 ± 17.6 GGGTATAAGTAAATCGCTTGCTGTATGTCGTTAAACAGAGGAGATAACGAATGACAGCAAGC TAACGACATACAGCAAGCGATTTACTTATACTA
3 265.3 ± 28.2 GGGTGATGGAATAAGGCTGTGTATATGATGTTAGACAGAGGAGATAACATATGATACACAGC TAACATCATATACACAGCCTTATTCCATCACAC
4 264.6 ± 19.9 GGGAATTGATATTGTGATTATGTGATGATTGTAAACAGAGGAGATACAATATGCACATAATC TACAATCATCACATAATCACAATATCAATTACT
5 253.0 ± 12.5 GGGTAGATATTGAATGCTGCTGTTATGTCGTTAAACAGAGGAGATAACGAATGAACAGCAGC TAACGACATAACAGCAGCATTCAATATCTAAAC
45 41.4 ± 5.1 GGGATAGAGACGAAAGCTAAGTGTATGTGTCGGGACAGAGGAGACCGACAATGACACTTAGC CCGACACATACACTTAGCTTTCGTCTCTATTAG
46 40.5 ± 2.7 GGGAATTGATATTGTGCTGTTTATGTGCGTTCGGACAGAGGAGACGAACGATGATAAACAGC CGAACGCACATAAACAGCACAATATCAATTCAC
47 39.6 ± 3.0 GGGAGTATGATATGAGAGTGTGCGATGATTCTGAACAGAGGAGACAGAATATGCGCACACTC CAGAATCATCGCACACTCTCATATCATACTAAC
48 39.1 ± 6.7 GGGCTCATTATCTATAGTTCGTCGAGGGTCTTAAGCAGAGGAGATAAGACATGCGACGAACT TAAGACCCTCGACGAACTATAGATAATGAGCAC
49 38.7 ± 4.7 GGGATGATGAGATGAGAGTGTAGGATGAGTTAGAACAGAGGAGACTAACTATGCCTACACTC CTAACTCATCCTACACTCTCATCTCATCATAAC
144 2.0 ± 1.2 GGGCGAGAATTGATGCGTTGATTTAGGGATTTGGACAGAGGAGACAAATCATGAAATCAACG CAAATCCCTAAATCAACGCATCAATTCTCGCAA
145 2.0 ± 1.3 GGGAATTGATATTGTGAAGTTAGGATGGTAGTGAACAGAGGAGACACTACATGCCTAACTTC CACTACCATCCTAACTTCACAATATCAATTCAC
146 1.9 ± 0.3 GGGATTGATTTACTGAGGTGATTGATGTCTATGGACAGAGGAGACATAGAATGCAATCACCT CATAGACATCAATCACCTCAGTAAATCAATAAG
147 1.9 ± 0.5 GGGCGAAATGAAATGAGTGAGTGGATGGTATGAGACAGAGGAGATCATACATGCCACTCACT TCATACCATCCACTCACTCATTTCATTTCGTTA




















Green et al. Switch Universal Forward Primer GAAGTCTAACGCTGCTCTGGGCTAACTGTCGCGCTAATACGACTCACTATAGGG
Green et al. Switch Universal Reverse Primer TTTACGCATCTTTTGCGCTGC
Green et al. Trigger Universal Forward Primer AACGTGTACGGGCTATCTGGCTTTCGTTGCGCTAATACGACTCACTATAGGG





























































Figure 1: Formation of oligonucleotide hairpins and free energies of ALAS2 designs at 29°C (top) and 37°C (bottom) as calculated by NUPACK software at 








Figure 2: Formation of oligonucleotide hairpins and free energies of HTN3 designs at 29°C (top) and 37°C (bottom) as calculated by NUPACK software at 






Figure 3: Formation of oligonucleotide hairpins and free energies of the AMEL-Y toehold switch at 
29°C (left) and 37°C (right) as calculated by NUPACK software at 0.0125 mM Mg2+and 0.05 mM 
Na+.  
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